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The Gram positive, cluster forming bacteria Staphylococcus aureus belongs to the 
family of opportunistic pathogens that may cause blood stream infections when the 
integrity of skin is broken and the immune system can no longer fight the infection.  S. 
aureus has become one of the most frequent causes of infections in newborns, surgical 
patients, trauma and burn patients, patients receiving an implant, and dialysis patients 
with high mortality rates. As a matter of fact, S. aureus has become one of the largest 
public health and economic impacts amongst all bacterial infectious diseases worldwide. 
This situation is further complicated by the rapid increase in anti-microbial drug 
resistance. Since the S. aureus bacterial cell is surrounded by a polysaccharide capsule, 
preventive vaccination based on polysaccharide or saccharide-protein conjugates is a 
suitable tool against the bacterial invasion. Serotyping has revealed that the majority of S. 
aureus strains express either capsular polysaccharides type 5 (CP5) or type 8 (CP8). 
Previous studies at Pfizer Inc. involved the preparation of conjugates of the 
purified native CPs derived from fermentation with protein carriers. Characterization of 
the activated products derived from purified native CPs by spectroscopic methods proved 
to be difficult owing to their large size. It was also noted that over activation and side 
reactions taking place during the conjugation process could lead to a loss of the epitopes 
required to achieve high immunogenicity of CP conjugate vaccines. This, in turn, can 
lead to the failure of the vaccine candidates in clinical trials.  
This thesis details the total syntheses of oligosaccharides structurally related to the 
repeating units of capsular polysaccharides S. aureus type 5 and 8. Our targets including 
two disaccharides, two trisaccharides and a hexasaccharide that will be studied by our 
collaborators at Pfizer Inc. to understand chemical activation for conjugation to the 
experimental carrier proteins. The improved understanding of the conjugation process 
will, in turn, lead to a more controlled, predictable, and reproducible outcome of 
polysaccharide conjugations. The additional potential outcome of this synthetic study is 
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1.1 Introduction 
An opportunistic gram-positive bacteria Staphylococcus aureus normally 
colonizes on the human skin.
1
 It can cause blood stream infections when the immune 
system gets weakened and can no longer fight the infection.  S. aureus is one of the most 
frequent causes of infections in newborns, surgical patients, and immunocompromised 
patients with high mortality rates. As a matter of fact, S. aureus has become one of the 
largest public health and economic impacts amongst all bacterial infectious diseases 
worldwide. This situation is further complicated by the rapid increase in anti-microbial 
drug resistance. One of the greatest concerns is antibiotic (methicillin)-resistant strains 
(MRSA), which have limited treatment options.
2
 The development of new antibiotics is 
not sustainable due to the continuous increase in antibiotic-resistance of MRSA. Passive 
or active immunizations of patients may be promising alternatives to the prophylactics of 
infections caused by MRSAs. In particular, immunotherapies based on the conjugates of 




1.2 Biosynthesis of S. aureus capsular polysaccharides 
Encapsulation of pathogenic bacteria allows for evasion of host immune systems.
4
 
The capsule is an extracellular component that can extend hundreds of microns from the 
cellular surface and is predominantly made up of long chains of capsular polysaccharides 
(CPs).  This results in the masking of surface proteins, the typical antigens that trigger an 
adaptive immune response in a host.  Many bacterial species have been shown to produce 
CPs, and a single species can produce numerous, structurally distinct CPs, forming a 
basis for serotyping isolates. There have been 13 distinct S. aureus serotypes identified so 
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far with type 5 (CP5) and type 8 (CP8) being the most prevalent in clinical isolates.
5
 
Expression of both CP5 and CP8 was shown to be important for S. aureus to evade 
opsonophagocytic killing, and furthermore MRSA and Methicillin-sensitive 
Staphylococcus aureus (MSSA) strains were killed by anti-CP antibodies.  While CPs are 
poorly immunogenic both in the young and elderly, CP-protein conjugates have been 
shown to elicit robust, T-cell dependent immune responses across all age groups.  Several 
vaccines against S. aureus containing CP5- and CP8-protein conjugates have been 
developed as clinical candidates.  Thus, the study of S. aureus CPs has been an active 
area of research for academic and industrial scientists. 
The biosyntheses of both CP5 and CP8 have been recently reviewed by 
Grundling
6
 and are proposed to follow the typical Gram positive Wzy-dependent 
mechanism. In accordance with this mechanism, membrane-linked trisaccharide 
repeating units are assembled in a non-processive polymerization. However, literature 
reports of experimental evidence for the entire biosynthetic pathway is incomplete.  
Production of both CP5 and CP8 requires 16 genes.  Of these genes, 12 were reported to 
code for enzymes with high sequence homology between CP5 and CP8 and were 
proposed to play common roles in production of the CPSs. This leaves 4 genes that were 
proposed to produce proteins playing serotype-specific biosynthetic functions.   
The common precursor for all three of the requisite monosaccharide building 
blocks of both CP5 and CP8 has been proposed to be UDP-D-GlcNAc.
6
 Conversion to 
UDP-D-ManNAcA requires epimerization of the C-2 position and oxidation of the 
primary hydroxyl at C-6. These steps have been reported to be catalyzed by the 
epimerase CapP and the dehydrogenase CapO, respectively. Conversion of UDP-D-
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GlcNAc to UDP-D-FucNAc requires epimerization of C-4 and reduction of the C-6 
primary alcohol. These transformations have been proposed to occur by the action of 
dehydrogenase CapD and the reductase CapN.  UDP-L-FucNAc has been reported to be 
derived from UDP-D-GlcNAc by the sequential action of bifunctional dehydrogenase 
epimerase CapE, reductase CapF, and epimerase CapG.  CP5 requires O-acetylation of 
the C-3 hydroxyl of UDP-L-FucNAc, and this has been proposed to be accomplished by 
the action of Cap5H.  Likewise, Cap8J is thought to acetylate the C-4 hydroxyl of UDP-
D-ManNAcA for production of CP8.  
Assembly of the CPs is thought to begin with transfer of UDP-D-FucNAc to 
membrane-bound undecaprenyl phosphate by glycotransferase CapM in the cytoplasm.  
Then UDP-L-FucNAc and UDP-D-ManNAcA are transferred respectively by CapM and 
Cap5I (for CP5) or Cap8H (for CP8) to generate a membrane-bound trisaccharide repeat 
unit.  Cap K has been proposed to translocate membrane-bound repeat unit to the outer 
leaflet of the membrane.  Trisaccharide repeating units are then proposed to be assembled 
by the action of either Cap5J (for CP5) or Cap8I (for CP8), with CapA and CapB 
believed to be regulators of the polysaccharide chain length.  The completed 
polysaccharides were shown to be transferred from the undecaprenyl-linked intermediate 




1.3 Characterization of Staphylococcus aureus capsular polysaccharides 
In 1982, Karakawa and Vann have developed the system to classify S. aureus 
capsular polysaccharides based on the immunological specificity.
8
 Based on the typing 
studies, 11 different serotypes have been identified
9
 and nowadays 13 serotypes have 




 According to the colony morphology, these capsular polysaccharides 
can be divided into two main groups. CPs serotype 1 and 2 that belong to the first main 
group are classified as mucoid-type capsules due to heavily encapsulated capsules and 
mucoid colonies. CPs of the second main group, serotypes 3-11, are classified as 




1.3.1 Capsular polysaccharide Type 1  
The polysaccharide capsule of type 1 prototype strain (strain D) was found to 
have the following trisaccharide repeating unit: 4)-α-2-acetamido-2-deoxy-D-
galactopyranosyl uronic acid-(14)-α-2-acetamido-2-deoxy-D-galactopyranosyl uronic 
acid-(13)-α-2-acetamido-2-deoxy-D-fucopyranosyl(1.
8, 12
 The strain M S. aureus 
capsular polysaccharide was initially isolated by Smith in 1962.
13
 The character of a 
capsulate S. aureus was reported by Scott in 1969.
13
 In 1974, Liau et.al. have analyzed 
the chemical components of polysaccharide from Staphylococcus aureus M strain.
14
 They 
have found the components of surface antigen which comprises Taurine, D-
galactosamine uronic acid, and D-fucosamine. After that, the ratio of the chemical 
composition was reported by Liau et.al. in 1977 which found to be hexasaccharide 
comprises N-acetyl-D-galactosamine uronic acid, N-acetyl-D-fucosamine and taurine in 
molar ratios of 4:2:1.
15
 Furthermore, the isolated disaccharide was characterized as N-
acetyl-D-galactosamine uronic acid-(13)-N-acetyl-D-fucosamine. Taurine was found to 
be connected with N-acetyl-D-galactosamine uronic acid by forming amide bond with 
carboxylic group. The complete chemical structure of strain M was reported by Murthy 
et.al. in 1983.
16
 The M strain polysaccharide comprises repeating unit of 4)-O-2-
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acetamido-2-deoxy-α-D-galactopyranosyl uronic acid-(14)-O-2-acetamido-2-deoxy-α-
D-galactopyranosyl uronic acid-(13)-O-2-acetamido-2-deoxy-α-D-fucopyranosyl(1. 
Taurine is linked to every fourth 2-acetamido-2-deoxy-D-galactopyranosyl uronic acid 
residue by amide bond. However, taurine residue was not found in strain D but it could 





Table 1.1.  The serotypes and chemical structures of S. aureus CPs. 








*Taurine is linked to every fourth α-D-





















3 Mardi unknown NA NA 











6 C unknown NA NA 




9 91 unknown NA NA 
10 537 unknown NA NA 
11 191 unknown NA NA 
12 NA unknown NA NA 
13 NA unknown NA NA 
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1.3.2 Capsular polysaccharide Type 2 
The capsular polysaccharide of type 2 prototype strain (11127-var) was reported 
by Karakawa et. al. in 1982.
8
 It is similar to the polysaccharide of strain K-93M, which 
was reported previously in 1972 by the same group.
20
 It was also found to be the same as 
the polysaccharide from strain Smith which was reported in 1962.
21
 The strain Smith was 
found to contain an aminosugar by Perkin in 1963.
22
 The complete chemical structure of 
type 2 capsular polysaccharide was reported by Hanessian in 1964.
23
 This staphylococcal 
polysaccharide has been shown to consist of equimolar portion of 2-acetamido-2-deoxy-
D-glucuronic acid and 2-[(N-acetylalanyl)amino]-2-deoxy-D-glucuronic acid linked by 
β-(14) linkages. 
 
1.3.3 Capsular polysaccharide Type 3 
The type 3 capsular polysaccharide was identified by Karakawa in 1982
9
 by 
immunological method using prototype strain Mardi which was described in 1979.
24
 The 




1.3.4 Capsular polysaccharide Type 4 
The capsular polysaccharide type 4 (prototype strain: 7007)
9
 was reported in 1974 by 
Karakawa et.al.
26
 It was shown to contain the following sequence: 2-acetamido-2-deoxy-
mannopyranosyl uronic acid-(13)-O-2-acetamido-2-deoxy-fucopyranose. It also has 
been found to be cross reactive with strain T described by Wu et. al. in 1971.
27
 That is 
because both polysaccharides contain similar residues, N-acetylmannosamine uronic acid 
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and N-acetylfucosamine. Nevertheless, no complete chemical structures have yet been 
reported.  
 
1.3.5 Capsular polysaccharide Type 5 
The type 5 capsular polysaccharide was isolated from strain Reynold by Fournier 
in 1987.
28
 Initially, its chemical structure was described by Van in 1988.
29
 It was found to 
consist of repeating units containing two molecules of N-acetylfucosamine and one 
molecule of N-acetylmannosamine uronic acid. The complete preliminary chemical 
structure of type 5 capsular polysaccharide was reported by Moreau et. al. in 1990.
30
 It 
was initially assumed that the polysaccharide has the following repeating unit: 4)-2-
acetamido-3-O-acetyl-2-deoxyl-β-D-mannopyranosyl uronic acid-(14)-2-acetamido-2-
deoxy-α-L-fucopyranosyl-(13)-2-acetamido-2-deoxy-β-D-fucopyranosyl-(1. In 
2005, Jones has reported the revised chemical structure of capsular polysaccharide type 5. 




 It should be 





1.3.6 Capsular polysaccharide Type 6 
The capsular polysaccharide type 6 prototype strain (strain C) was reported in 
1982.
9
 However, there no structural study of this polysaccharide has been reported yet. 
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The type 6 capsule has been found to be cross-reactive with anti-type 8 monoclonal 




1.3.7 Capsular polysaccharide Type 7 
The type 7 capsular polysaccharide prototype strain (strain 207) was described in 
1982,
9
 although no structural study of this capsular polysaccharide has yet emerged.  
 
1.3.8 Capsular polysaccharide Type 8 
The capsular polysaccharide type 8 was isolated from the prototype strain Becker 
in 1984 by Fournier.
33
 Its repeating unit was originally thought to contain O-acetyl 
groups, N-acetylfucosamine and an aminouronic acid, possibly N-acetylgalactosamine 
uronic acid. In 1988, a preliminary study of its chemical structure showing the same 
composition as that of type 5 repeating unit was reported. It was noted, however, that 
both substitution and the anomeric configuration of the N-acetylfucosamine residues are 
different.
29
 The revised chemical structure of capsular polysaccharide type 8 was 






1.3.9 Capsular polysaccharide Types 9 – 13 
In 1985, Sompolinsky et. al. reported three other types of S. aureus capsular 
polysaccharide which are type 9 (prototype 91), type 10 (prototype 537) and type 11 




 After that, serotypes 12 and 13 have been described.
12
 However, no 
further characterization of these serotypes is yet available.  
 
1.4 The chemical syntheses of Staphylococcus aureus related oligosaccharides 
The native S. aureus CPs acquired by bacterial fermentation have been conjugated 
to carrier protein such as, Pseudomonas aeruginosa recombinant exoprotein A (rEPA), 
Pseudomonas aeruginosa endotoxin A (ETA) or non-toxic variant of diphtheria toxin 
(CRM 197).
34-38
 The resulting conjugate vaccines can provide the different immune 
response due to the variation of the ratio between polysaccharides and carrier proteins. 
Moreover, the characterization of the activated products derived from purified native 
polysaccharides by spectroscopic methods proved to be very difficult owing to their large 
size (MW > 50 kDa).
38
 The over-activation and side reactions taking place during the 




The chemical synthesis could be used to overcome these problems. It would allow 
us to modify chemical structures. For instance, the introduction of spacer molecules 
would reduce the steric hindrance between polysaccharides and carrier protein and 
facilitate the conjugation process.
40
 Furthermore, the synthetic compounds can be used 
for structure-activity relationship (SAR) study, and the determination of required minimal 
epitope for immune response. Also, the synthetic compounds will allow us to understand 
the sites of activation, reactivity profile of different functional groups involved in the 
conjugation reactions, and to learn controlling side reactions. 
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There are three serotypes of S. aureus capsular polysaccharide which are type 1, 5 




1.4.1 The synthesis of Staphylococcus aureus capsular polysaccharide type 1 (CP1) 
The chemical synthesis of S. aureus type 1 strain M disaccharide was recently 
reported by the Codee group.
45
 In 2017, they presented the synthesis of protected 
disaccharide 1.3 (Scheme 1.1). The synthesis involved glycosylation between D-fucosyl 
donor 1.1 bearing the selenophenyl leaving group at the anomeric center and D-
galactosamine uronate acceptor 1.2 using donor preactivation strategy with diphenyl 
sulfoxide (Ph2SO), 2,4,6-tri-tert-butylpyrimidine (TTBP) and Tf2O in CH2Cl2 to yield 
disaccharide 1.3 with α-linkage exclusively. 
Scheme 1.1. Synthesis of fully protected CP1 disaccharide 1.3. 
 
 
Subsequently, the same group has reported the chemical synthesis of a trisaccharide 
representing the S. aureus strain M capsular polysaccharide repeating unit.
44
 As shown in 
Scheme 1.2, the synthesis started from the glycosylation of di-tert-butylsilylidene 
(DTBS)-functionalized galactopyranosyl donor 1.4 and the N-substituted 5-
aminopentanol derivative in the presence of NIS and TMSOTf as the promoter system in 
CH2Cl2. As a result, glycoside 1.5 was obtained with complete α-selectivity. 
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Scheme 1.2. Synthesis of trisaccharide repeating unit CP1 1.12. 
 
 
After that, silyl ether of 1.5 was removed with hydrogen fluoride in pyridine (HF-
Py) in THF to provide 4,6-diol 1.6. The latter was then subjected to selective oxidation of 
the primary hydroxyl with TEMPO and BAIB in AcOH and wet CH2Cl2. Subsequent 
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esterification was affected with iodomethane (CH3I) in the presence of potassium 
carbonate (K2CO3) in DMF to afford glycosyl acceptor 1.2. The latter was glycosylated 
with galactosyl donor 1.4 in the presence of NIS and TMSOTf in CH2Cl2 to form 1,2-cis-
linked disaccharide 1.7. Then, selective silyl ether removal of 1.7 was achieved by the 
treatment with HF-Py in THF to obtain diol 1.8. The 6’-OH of 1.8 was then selectively 
oxidized using the Pinnick oxidation sequence (TEMPO/BAIB) to obtain carboxylic acid 
which was esterified with CH3I in the presence of K2CO3 in DMF to provide disaccharide 
1.9. After that, 4’-OH was glycosylated with D-fucosamine donor 1.1 preactivated with 
Ph2SO, TTBP and Tf2O in CH2Cl2 to afford trisaccharide 1.10. The functionalization of 
trisaccharide was initiated by the reaction with thioacetic acid (AcSH) to form 
triacetamido derivative 1.11. Then, the TBS ether was removed with HF-Py, followed by 
saponification of the methyl ester with potassium hydroxide and hydrogen peroxide in 
THF and wet tert-butanol to yield dicarboxylated trisaccharide. Finally, all benzylic 
substituents were removed by hydrogenation using Pd(OH)2/C in AcOH, THF and wet t-
BuOH to afford the target compound 1.12.  
 
1.4.2 The synthesis of Staphylococcus aureus capsular polysaccharide type 5 (CP5) 
The first chemical synthesis of the repeating unit of S. aureus type 5 capsular 
polysaccharide (CP5) was achieved by Adamo in 2012.
43
 They decided to synthesize CP5 
trisaccharide repeating unit containing aminopropyl spacer at the reducing end which can 
be conjugated to carrier protein. The following key steps were employed in their 
synthetic strategy. They pursued the C-2’ epimerization strategy according to which a β-
glucosyl residue in introduced followed by epimerization to β-mannosyl residue. Then, 
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disaccharide product was glycosylated with D-fucosamine acceptor to construct the 
trisaccharide repeating unit.  
The D-glucuronic acid donor was prepared by glycosylation of allyl alcohol with 
orthoester 1.13 using TMSOTf as a promoter (Scheme 1.3). This reaction was 
accompanied with concomitant partial deacetylation. Therefore, the crude reaction 
mixture was acetylated to afford allyl 2-O-acetyl derivative 1.14. Then, acetolysis of the 
6-O-benzyl ether was conducted in the presence of ZnCl2 in acetic acid to acquire 6-O-
acetyl compound 1.15. The removal of acetyl groups was affected with sodium 
methoxide in methanol gave diol compound 1.16, followed by selective protection of the 
primary alcohol of 1.16 with t-butyldimethylsilyl chloride and imidazole to obtain 
compound 1.17. Afterward, 2-OH was esterified with levulinic acid in the presence of 
N,N’-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) to obtain 
compound 1.18. Then, one-pot desilylation and oxidation at C-6 was performed by Jones 
oxidation, followed by benzyl ester formation at C-6 using benzyl bromide (BnBr) and 
sodium bicarbonate (NaHCO3) to afford benzyl carboxylate derivative 1.19. In order to 
obtain trichloroacetimidate donor 1.20, selective deallylation was performed with 
palladium chloride (PdCl2), followed by trichloroacetimidate introduction with 
trichloroacetonitrile in the presence of and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).  
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Scheme 1.3. Synthesis of D-glucosyl donor 1.20. 
 
The L-fucosamine acceptor was prepared by sequential di-epimerization of a L-
rhamnose precursor at C-4 and C-2. Thus, allyl 2,3-O-isopropylidene-α-L-
rhamnopyranoside 1.21 was epimerized at C-4 via Swern oxidation followed by the 
reduction with sodium borohydride (NaBH4) to give L-talose derivative 1.22 (Scheme 
1.4). Then, the 2,3-O-isopropylidene group of 1.22 was cleaved with aqueous acetic acid, 
followed by the 3,4-O-isopropylidene introduction using dimethoxypropane in the 
presence p-toluenesulfonic acid (p-TsOH) to afford compound 1.23. The latter was 2-O-
sulfonated with trifluoromethanesulfonic anhydride (Tf2O) in the presence of pyridine, 
followed by epimerization in the presence of freshly prepared tetrabutylammonium azide 
to yield 2-azido-L-fucoside 1.24. At last, the isopropylidene group was removed by 
acidic hydrolysis to yield diol compound 1.25, followed by regioselective acetylation at 
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C-3 with acetyl chloride in the presence of pyridine in dichloromethane to obtain L-
fucosamine acceptor 1.26.  
Scheme 1.4. Synthesis of L-fucosyl acceptor 1.26. 
 
The preparation of D-fucosamine acceptor 1.35 began from glycosylation of 
benzyl N-(3-hydroxypropyl)carbamate with tetra-O-acetyl-D-fucopyranose 1.27 in the 
presence of boron trifluoride diethyl etherate (BF3-Et2O) to yield compound 1.28 
(Scheme 1.5). After that, deacetylation with NaOMe, followed by isopropylidene 
introduction at C-3 and C-4 hydroxyl groups in the presence of dimethoxypropane and p-
toluenesulfonic acid produced compound 1.29. The hydroxyl group of 1.29 was then 
subjected to the Swern oxidation followed by the reduction with NaBH4 to yield talose 
derivative 1.30. Then, 2-O-triflate was introduced, followed by epimerization with 
sodium azide (NaN3) in dimethyl formamide (DMF) to provide 2-azido D-fucoside 1.31. 
The latter was subjected to isopropylidene removal with 90% aq. acetic acid to give diol 
1.32. The temporary selective p-methoxybenzyl ether (PMB) introduction at 3-OH of 
1.32 was affected by dibutyl tin (IV) oxide (Bu2SnO), p-methoxy benzyl bromide 
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(PMBBr) and tetrabutylammonium iodide (TBAI) in toluene to give compound 1.33. 
Then, C-4 of 1.33 was benzylated with BnBr in the presence of NaOH and crown ether in 
THF to yield compound 1.34. Finally, the PMB group removal was achieved by 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in wet CH2Cl2 to acquire the desired D-
fucosamine acceptor 1.35.  
Scheme 1.5. Synthesis of D-fucosyl acceptor 1.35. 
 
As shown in Scheme 1.6, the desired sequence was achieved with glucuronate 
1.20, L-fucosamine 1.26, and D-fucose 1.35 building blocks. Thus, in order to obtain 
disaccharide 1.36, trichloroacetimidate 1.20 was glycosidated with fucosyl acceptor 1.26 
in the presence of TMSOTf in CH2Cl2 at -10 
o
C. Then, the 2-O-levulinoyl group of 
disaccharide 1.36 was selectively removed with hydrazine acetate (H2NNH2-AcOH) to 
yield 2-OH derivative 1.37. The inversion of configuration at C-2’ was achieved by 
sulfonation with Tf2O followed by the nucleophilic substitution with 
tetrabutylammonium azide to obtain β-manno-configured disaccharide 1.38. The 
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anomeric allyl group of disaccharide 1.38 was removed with PdCl2, and the 
trichloroacetimidoyl leaving group was introduced with trichloroacetonitrile in the 
presence of DBU to yield trichloroacetimidate 1.40 as a mixture of α,β-anomers. The 
glycosidation of disaccharide donor 1.40 with D-fucosyl acceptor 1.35 was performed in 
the presence of TMSOTf in CH2Cl2 at -10 
o
C to yield trisaccharide 1.41 as a mixture of 
α,β-anomers. The desired α-linked trisaccharide was separated and subjected to 
hydrogenation with a 10% Pd/C cartridge to reduce the azide groups and remove benzylic 
protecting groups. Subsequent N-acetylation with acetic anhydride in MeOH afforded the 
target compound 1.42.  
Scheme 1.6. Synthesis of CP5 trisaccharide 1.42. 
 
Another chemical synthesis of S. aureus type 5 trisaccharide repeating unit was 
reported by Boons in 2015.
42
 They decided to apply a [1 + 2] strategy to synthesize the 
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trisaccharide repeating unit that was equipped with the aminopentyl spacer at the 
reducing end. In according to their design, L-fucosamine donor was first coupled with D-
fucosamine acceptor and the β-mannosidic linkage was introduced last using direct 
mannosylation with a S-phenyl D-ManpN3 donor via the intermediacy of the α-anomeric 
triflate at low temperature. 
The trisaccharide synthesis was initiated with the glycosylation of L-fucosamine 
donor 1.43 and D-fucosamine acceptor 1.44 using various reaction conditions to form 
disaccharide 1.45 (Table 1.1). It was found that the glycosylation in the presence of 1-
benzene sulfinyl piperidine (BSP) and Tf2O with TTBP as a base in CH2Cl2 at -60 
o
C 
afforded only α-fucosidic linkage, albeit with a low yield. A similar result was achieved 
with diphenylsulfoxide (DSP) and Tf2O, which is more powerful system. Glycosylations 
in the presence of NIS and TMSOTf or silver trifluoromethanesulfonate (AgOTf) at -60 
o
C produced disaccharide 1.45 in a much higher yield, albeit lower stereoselectivity.  
Table 1.2. Glycosylation optimization of 1.43 and 1.44. 
 
promoter/conditions yield β/α 
BSP, Tf2O, TTBP, CH2Cl2, -60 
o
C 30% α 
DPS, Tf2O, TTBP, CH2Cl2, -60 
o
C 30% α 
NIS, TMSOTf, CH2Cl2, -60 
o
C 73% 1/4 
NIS, AgOTf, CH2Cl2, -60 
o
C 70% 1/4 
NIS, TMSOTf, CH2Cl2/Et2O (4/1), -60 
o
C 72% 1/4 
 
The disaccharide 1.45 was then deacetylated in the presence of NaOMe in MeOH 
to acquire disaccharide acceptor 1.46. (Scheme 1.7) Next, glycosidation of D-
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mannosamine donor 1.47 with disaccharide acceptor 1.46 using DSP and Tf2O as the 
promoter system gave trisaccharide 1.48 with exclusive β-manno stereoselectivity. The 
functionalization of trisaccharide 1.48 was initiated by the PMB ether removal in the 
presence of DDQ, followed by acetylation with Ac2O in the presence of 4-dimethylamino 
pyridine (DMAP) in pyridine to give trisaccharide 1.49. Then, selective removal of the 
anomeric TDS group in the presence of hydrogen fluoride – pyridine complex afforded 
hemiacetal 1.50. The latter was converted to N-phenyl trifluoroacetimidate with 2,2,2-
trifluoro-N-phenylacetamidoyl chloride in the presence of cesium carbonate (CsCO3) in 
CH2Cl2. The glycosidation of the imidate donor with 5-
(benzyloxycarbonyl)aminopentanol was achieved in the presence of TMSOTf as the 
promoter in CH2Cl2/ CH3CN at -78 
o
C to obtain trisaccharide 1.51. The latter was the 
subjected to the concomitant Troc group removal and the azide group reduction with Zn, 
AcOH and Ac2O in THF to yield triacetamido derivative 1.52. Then, benzylidene group 
of 1.52 was cleaved with 80% aq. AcOH at 90 
o
C, and the resulting diol was selectively 
oxidized at the primary position using a modified Huang’s one-pot procedure involving 
(2,2,6,6-tetramethyl-piperidin-1-yl)oxyl (TEMPO)/NaOCl-NaClO2 to yield carboxylic 
acid 1.53. Finally, the hydrogenation in the presence of palladium hydroxide (PdOH)2 to 
remove benzyl ethers and benzyloxycarbamate gave the target compound 1.54.  
In 2016, our group developed another approach for the synthesis of S. aureus type 
5 trisaccharide repeating unit bearing capping methyl groups at the points of propagation 
of the polysaccharide sequences.
39
 In order to acquire the β-mannosidic linkage, 
glucosylation was performed, followed by the inversion of the stereocenter at C-2’ post-
Satsawat Visansirikul | UMSL 2018 | Page  21 
 
glycosylationally. Disaccharide was then glycosylated to form trisaccharide subunit. The 
detailed description of this synthesis in presented in Chapter 3. 
Scheme 1.7. Synthesis of CP5 trisaccharide 1.54. 
 
In 2017, Codee reported the synthesis of S. aureus type 5 trisaccharide repeating 
unit equipped with the same spacer as that in the study by Boons.
45
 The synthesis of the 
trisaccharide repeating unit was initiated by the glycosidation of selenoglycoside donor 
1.55 with aminopentanol in the presence of Ph2SO, TTBP and Tf2O in CH2Cl2 and Et2O. 
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This reaction proceeded via the intermediate anomeric triflate to afford spacer-containing 
fucosamine derivative 1.56 as a mixture of anomers (α/β = 1/7, Scheme 1.8).  
Scheme 1.8. The synthetic approach of CP5 trisaccharide 1.54 by Codee. 
 
 
Then, the 3-OBz group of D-fucosamine 1.56 was removed by reaction with 
NaOMe in MeOH to give compound 1.57. The latter was subjected to glycosylation with 
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the L-fucosyl donor 1.58 in the presence of Ph2SO, TTBP, Tf2O in CH2Cl2 to provide 
disaccaride 1.59 as a single anomer. After that, all silyl ethers of disaccahride 1.59 were 
removed with tetrbutylammonium fluoride (TBAF) in THF, followed by selective 
benzoylation at 3’-OH with Taylor’s diphenylborinate catalyst 1.60, benzoyl chloride, 
N,N-diisopropylethylamine (DIPEA) in CH3CN to afford disaccharide 1.61. The 
glycosylation of disaccharide acceptor 1.61 with mannosyl donor 1.62 was performed 
with tert-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf) as a promoter in 
CH2Cl2 to form trisaccharide 1.63 with exclusive β-manno stereoselectivity. The ester 
groups of trisaccharide 1.63 were removed by the treatment with potassium hydroxide 
(KOH) and hydrogen peroxide (H2O2) in water and THF to provide trisaccharide 1.64. 
The C-3’ hydroxyl group of 1.64 was acetylated with Ac2O in pyridine, followed by the 
treatment with thioacetic acid (AcSH) in pyridine to yield the triacetamide derivarive 
1.65. The final compound 1.54 was obtained by hydrogenation of 1.65 with palladium 
hydroxide on carbon (Pd(OH)2/C).  
 
1.4.3 The chemical synthesis of Staphylococcus aureus capsular polysaccharide type 
8 (CP8) 
The first chemical synthesis of the repeating unit of capsular polysaccharide S. 
aureus type 8 (CP8) was reported by our group in 2015.
41
 The synthesized trisaccharide 
subunit contains methyl group as capping groups at the propagating point of the 
polysaccharide sequence. The synthetic strategy was similar to CP5 synthesis described 
previously, which was the β-glucosylation with neighboring group participation, followed 
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by epimerization to yield β-mannosidic linkage. The detailed description of this synthesis 
is presented in Chapter 2. 
In 2017, the Codee group has also reported the chemical synthesis of CP8 derived 
disaccharide containing L-fucosamine, D-fucosamine and the aminopentyl spacer. The 
synthesis of the disaccharide target began with the glycosidation of D-fucosamine donor 
1.66 with aminopentanol acceptor in the presence of Ph2SO, TTBP and Tf2O in CH2Cl2 
and 1,4-dioxane. This reaction proceeding via the intermediacy of the anomeric triflate 
afforded spacer-containing fucosamine derivative 1.67 as a mixture of anomers (α/β = 
7/1, Scheme 1.9). After that, the TBS group of 1.67 was removed selectively with TBAF 
in THF to yield D-fucosyl acceptor 1.68. The glycosylation of the latter with L-
fucosamine donor 1.69 was performed in the presence of Ph2SO, TTBP and Tf2O in 
CH2Cl2 to acquire disaccharide 1.70 as a mixture of diastereomers (α/β = 7/1). Finally, 
the silyl ether of 1.70 was removed with TBAF in THF to obtain disaccharide 1.71. 
Scheme 1.9. Synthesis of the CP8-derived disaccharide 1.71. 
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1.5 Conclusions and Outlook 
 The S. aureus bacterium is surrounded by capsular polysaccharides. These 
capsular polysaccharides are important in the pathogenesis of staphylococcal infection. 
The majority strains express capsular polysaccharides type 5 (CP5) or 8 (CP8). There are 
11 serotypes of capsular polysaccharides that have been identified, and up to 13 serotypes 
have been described. Some effort has been made to establish chemical structures of CPs 
and the structures of repeating units of CP1, CP2, CP5 and CP8 have been fully 
elucidated. In addition, the chemical structure of CP4 has been partially established. The 
chemical syntheses of CP1, CP5 and CP8 derived oligosaccharides have been 
successfully achieved by a number of groups. The chemical syntheses provide analogs or 
structural motifs of native CPs, which are of high demand for a number of purposes. 
Chemically synthesized molecules can help to confirm the elucidated structures of native 
CPs. Synthetic analogues are useful for establishing the structure-activity relationship or 
could be used to determine the minimal epitope required for prophylactic immune 
response. Also, the synthetic small molecule models based on the repeat unit can be used 
for the study of activation and protein conjugation process. This would offer a means to 
fully characterize the structure of activated CP, identify and quantify the activation site 
and understand the side reaction occurring during activation process.  
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2.1 Introduction 
The Gram positive, cluster forming bacteria Staphylococcus aureus normally 
colonizes in the human nose and skin.
1
 It belongs to the family of opportunistic 
pathogens that may cause blood stream infections when the integrity of skin is broken 
and the immune system can no longer fight the infection.  S. aureus has become one of 
the most frequent causes of infections in surgical patients, trauma and burn patients, 
patients receiving an implant, newborns, dialysis patients with high mortality rates. 
Immunocompromised individuals and patients with prosthetic devices or long-term 
intravascular catheters are particularly vulnerable.
2
 The S. aureus bacterium is 
surrounded by a polysaccharide capsule, preventive vaccination based on polysaccharide 
or saccharide-protein conjugates is a suitable tool against the bacterial invasion.
3
  
Serotyping has revealed that the majority of S. aureus strains express either 
capsular polysaccharide type 5 (CP5) or type 8 (CP8).  The structures of CP5 and CP8 
have been established
4
 and chemical syntheses of the repeating unit of CP5 have been 
reported.
5-6
 Herein, we report the first synthesis of trisaccharide repeating unit of CP8. 
The CP8 repeating unit consists of a trisaccharide, but it is an unusual sequence of three 
uncommon monosaccharide residues (Figure 2.1). The trisaccharide bears a terminal 
ManNAcA (D-mannosamine uronic acid) residue, which is 4-O-acetylated. ManNAcA is 
then β-(1,2-cis) glycosidically linked to the L-FucNAc (L-fucosamine) unit via 3-OH. L-
FucNAc is in turn linked via the 1,2-cis-glycosidic bond to the C-3 of D-FucNAc. In the 
natural polysaccharide sequence, D-FucNAc is then linked to another D-ManNAcA via 
α-(1-3) linkage, etc. The synthetic target T1 was designed as a tool compound to study 
activation and conjugation of full length CP8 derived from fermentation of S. aureus as 




 Hence, in order to preserve the conjugation sites the synthetic 
trisaccharide T1 (Scheme 2.1) needs to be equipped with capping groups (methyl) at the 
points of propagation of the polysaccharide sequence. 




From a synthetic perspective, one could anticipate a number of challenges and 
hurdles. For instance, the introduction of 1,2-cis glycosidic linkages
8
 often proceeds with 
low selectivity, and our synthetic target T1 has three such linkages. In addition, all three 
monosaccharide components of the repeat unit are uncommon and hence one could 
anticipate the necessity to perform the total synthesis of each monosaccharide. Our initial 
goal was to perform the direct synthesis of the β-mannosidic linkage,
9
 an approach that 
was successfully used for other targets containing ManNAcA.
6,10
 However, the direct 
mannosylation failed presumably due to a very low reactivity profile for the benzylidene-
protected mannosamine donors. After extended experimentation with thioglycoside and 
S-benzoxazolyl (SBox) donors, we abandoned the mannosylation route and chose to 
proceed via a glucosylation route instead, followed by inversion of the stereocenter at C-2 
post-glycosylationally. 
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2.2   Results and Discussion 
According to this revised plan, the 2-OH of known thioglycoside 2.1
11
 was 
protected as levulinoyl (Lev) ester by 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) and 4-dimethylaminopyridine (DMAP)-mediated coupling with LevOH to give 
2.2 in 98% (Scheme 2.2). Reaction of 2.2 with bromine followed by the introduction of 
S-benzoxazolyl (SBox) leaving group with KSBox
12
 in the presence of 18-crown-6 
allowed glucosyl donor 2.3 in 67% yield over two steps. 
The synthesis of L-fucosyl acceptor for the introduction of the middle unit in the 
trisaccharide sequence was originated from known L-fucal 2.4
13
 as follows. 
Azidonitration of 2.4 with sodium azide in the presence of ceric ammonium nitrate 
(CAN) in MeCN at -15 
o
C followed by the reaction with sodium 4-penten-1-oxide gave 
β-pentenyl glycoside 2.5b in 65% yield over two steps. Diol 2.5b was then protected as 
3,4-O-benzylidene acetal using dimethoxytoluene (DMT) in the presence of 
camphorsulfonic acid (CSA) in MeCN to afford compound 2.6 in 87% yield. The 
reductive benzylidene ring opening in 2.6 with NaCNBH3 in 2 M HCl in diethyl ether 
afforded L-fucosyl acceptor 2.7 in 94% yield. 
With glucosyl donor 2.3 and fucosyl acceptor 2.7 in hand, we conducted selective 
activation of the SBox leaving group in the donor in the presence of O-pentenyl anomeric 
group in the acceptor. This was affected in the presence of silver 
trifluoromethanesulfonate (AgOTf) in 1,2-dichloroethane. As a result, disaccharide 2.8 
was isolated in 73% yield. In this context, thioglycoside donor 2.2 could also be activated 
over O-pentenyl acceptor 2.7. This activation requires MeOTf,
14
 a relatively mild 
activator, which in this particular application gave modest results due to a highly 
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disarmed reactivity profile of donor 2.2. Selective levulinoyl group removal in 2.8 with 
hydrazine acetate in methanol and dichloromethane (1/20, v/v) gave disaccharide 2.9 in 
72% yield. The latter was then subjected to sequential treatment with Tf2O and sodium 
azide to obtain the C-2’ epimerized
15
 D-mannosyl disaccharide 2.10 in 90% yield over 
two steps. 
The synthesis of D-fucosyl acceptor for the introduction of the reducing end unit 
in the trisaccharide sequence was initiated from D-galactose via known D-fucal 2.11
16-17
 
as follows. Azidonitration of 2.11 with NaN3 and CAN followed by methyl glycoside 
formation with NaOMe gave α-fucoside 2.12a in 72% yield over two steps. Benzylidene 
acetal protection of diol 2.12a with DMT in the presence of CSA gave 3,4-O-benzylidene 
fucoside 2.13 in 78% yield. The reductive benzylidene ring opening in 2.13 with 
NaCNBH3 in 2 M HCl in diethyl ether and THF afforded the desired D-fucosyl acceptor 
2.14 in 90% yield. The latter was glycosylated with disaccharide donor 2.10. O-Pentenyl 
leaving group was then activated with N-iodosuccinimide (NIS) and TfOH to afford 
trisaccharide 2.15 with exclusive 1,2-cis stereoselectivity in 87% yield. 
With the backbone sequence constructed, and after thorough experimentation, we 
settled on the following sequence for the conversion of 2.15 into the target trisaccharide 
T1. First, the three azide groups were reduced with propane-1,3-dithiol in the presence of 
triethylamine
18
 (TEA) in wet pyridine followed by acetylation with Ac2O in methanol to 
obtain trisaccharide 2.16 in 94% yield over 2 steps. Second, the benzylidene acetal 
removal was performed with trifluoroacetic acid (TFA) in wet CH2Cl2 to acquire diol 
trisaccharide 2.17 in 92% yield.   
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Scheme 2.2. Synthesis of CP8 repeating unit T1. 
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The oxidation of the primary alcohol in 2.17 was effected with (2,2,6,6-
tetramethyl-piperidin-1-yl)oxyl (TEMPO) and (diacetoxyiodo)benzene (BAIB) in wet 
CH2Cl2.
19
 The resulting carboxyl group was esterified with BnBr in the presence of 
NaHCO3 in DMF to afford trisaccharide 2.18 in 58% yield over two steps. The 4-OH of 
the mannosamine subunit was then acetylated with Ac2O in pyridine to afford 
trisaccharide 2.19 in 99% yield. Finally, all benzylic protecting groups in 2.19 were 
removed by hydrogenation in the presence of palladium on charcoal in wet ethanol to 
acquire the final compound T1 in 97% yield. 
 
2.3 Conclusions and Outlook 
We report the synthesis of a trisaccharide repeating unit of S. aureus CP8 bearing 
terminal methyl groups to preserve the activation sites. Characterization of the activation 
products derived from natural polysaccharides is very difficult owing to their large 
molecular size (MW = 100-2000 kDa). The study of small model compound T1 based on 
the structure of the repeat unit offers a means to fully characterize the structure of the 
activated polysaccharides, quantify the level of activation and begin to understand side 
reactions occurring after polysaccharide activation for conjugation. Over-activation and 
side reactions can lead to a loss of the epitopes required for immunogenicity of 
polysaccharide conjugate vaccines, leading to product failure. The improved 
understanding of the conjugation process will, in turn, lead to a more controlled, 
predictable, and reproducible outcome of polysaccharide conjugations. 
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2.4 Experimental 
2.4.1 General Methods  
The reactions were performed using commercial reagents (Aldrich or Acros) and 
the ACS grade solvents were purified and dried according to standard procedures.  
Column chromatography was performed on silica gel 60 (EM Science, 70-230 mesh), 
reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). The compounds 
were detected by examination under UV light and by charring with 10% sulfuric acid in 
methanol. Solvents were removed under reduced pressure at <40 
o
C. CH2Cl2 and 
ClCH2CH2Cl were distilled from CaH2 directly prior to application. Molecular sieves 
(3Å), used for reactions, were crushed and activated in vacuo at 390 °C during 8 h in the 
first instance and then for 2-3 h at 390 °C directly prior to application. AgOTf was co-
evaporated with toluene (3 x 10 mL) and dried in vacuo for 2-3 h directly prior to 
application. Optical rotations were measured at ‘Jasco P-1020’ polarimeter. 
1
H NMR 
spectra were recorded at 300 MHz (Bruker Avance) or 500 MHz (Bruker ARX-500) or 
600 MHz (Agilent), 
13
C-NMR spectra were recorded at 75 MHz (Bruker Avance) or 125 
MHz (Bruker ARX-500) or 150 MHz (Agilent). The 
1
H chemical shifts are referenced to 
the signal of the residual CHCl3 (δH = 7.27 ppm) for solutions in CDCl3 or the signal of 
the residual CH3OH (δH = 3.31 ppm) for solutions in CD3OD. The 
13
C chemical shifts are 
referenced to the central signal of CDCl3 (δC = 77.23 ppm) for solutions in CDCl3 or the 
central signal of CD3OD (δC = 49.24 ppm) for solutions in CD3OD. HRMS 
determinations were made with the use of JEOL MStation (JMS-700) mass spectrometer. 
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2.4.2 Preparation of monosaccharide building blocks 2.3, 2.7, and 2.14. 
Ethyl 4,6-O-benzylidene-2-O-levulinoyl-3-O-methyl-1-thio-β-D-glucopyranoside 
(2.2). Levulinic acid (1.08 g, 9.25 mmol), EDC (2.73 g, 14.24 mmol) and DMAP (174 
mg, 1.42 mmol) were added to a stirring solution of ethyl 4,6-O-benzylidene-3-O-methyl-
1-thio-β-D-glucopyranoside
11
 (2.1, 2.41 g, 7.38 mmol) in CH2Cl2 (60 mL) and the 
resulting mixture was stirred for 1 h at rt. After that, the reaction mixture was diluted with 
CH2Cl2 (~200 mL) and washed with sat. aq. NaHCO3 (50 mL) and water (2 x 50 mL). 
The organic phase was separated, dried over MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to afford the title compound as a white amorphous solid (3.07 g, 98%). 
Analytical data for 2.2: Rf = 0.30 (ethyl acetate/hexane, 3/7, v/v); []D
20
 28.5 (c = 1, 
CHCl3); 
1
H NMR (600 MHz, CDCl3): δ, 1.25 (t, 3H, CH2CH3), 2.19 (s, 3H, COCH3), 
2.60-2.78 (m, 4H, COCH2CH2CO), 2.82 (q, 2H, CH2CH3), 3.45-3.53 (m, 2H, H-3, 5), 
3.57 (s, 3H, OCH3), 3.65 (dd, 1H, J4,5 = 9.6 Hz, H-4), 3.76 (dd, 1H, J6a,6b = 10.3 Hz, H-
6a), 4.35 (dd, 1H, J5,6a = 4.9 Hz, H-6b), 4.47 (d, 1H, J1,2 = 10.1 Hz, H-1), 4.97 (dd, 1H, 
J2,3 = 8.4 Hz, H-2), 5.54 (s, 1H, CHPh), 7.35-7.48 (m, 5H, aromatic) ppm; 
13
C NMR (150 
MHz, CDCl3): δ, 15.0, 24.1, 28.2, 30.0, 38.0, 60.9, 68.7, 70.8, 71.8, 81.3, 82.1, 84.3, 
101.4, 126.2 (x 2), 128.4 (x 2), 129.2, 137.3, 171.7, 206.4 ppm; HR-FAB MS [M+Na]
+
 
calcd for C21H28NaO7S 447.1453, found 447.1450. 
 
Benzoxazolyl 4,6-O-benzylidene-2-O-levulinoyl-3-O-methyl-1-thio-β-D-
glucopyranoside (2.3). A solution of 2.2 (1.75 g, 4.13 mmol) and activated molecular 
sieves (3Å, 2.1 g) in CH2Cl2 (60 mL) was stirred under argon for 1 h at rt. The mixture 
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was cooled to 0 
o
C, freshly prepared solution of Br2 in CH2Cl2 (40 mL, 1/165, v/v) was 
added, and the resulting mixture was stirred for 15 min at 0 
o
C. After that, the solid was 
filtered off, rinsed successively with CH2Cl2 and the combined filtrate (~200 mL) was 
concentrated under reduced pressure at rt and dried in vacuo for 2 h. The crude residue 
was dissolved in dry acetone (20 mL), KSBox
12
 (2.35 g, 12.4 mmol) and 18-crown-6 
(0.334 g, 1.24 mmol) were added and the reaction mixture was stirred under argon for 1 h 
at rt. After that, the reaction mixture was concentrated in vacuo. The residue was 
dissolved in CH2Cl2 (~250 mL), washed with 1% aq. NaOH (50 mL) and water (3x 50 
mL). The organic phase was separated, over MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
graduate elution) to afford the title compound in 67% yield (1.43 g, 2.79 mmol) as a 
white amorphous solid. Analytical data for 2.3: Rf = 0.52 (ethyl acetate/hexane, 1/1, v/v); 
[]D
21
 16.6 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 2.17 (s, 3H, COCH3), 2.57-
2.66 (m, 2H, COCH2), 2.69-2.87 (m, 2H, COCH2), 3.61 (s, 3H, OCH3), 3.63-3.83 (m, 
4H, H-3, 4, 5, 6a), 4.41 (m, 1H, J5,6a = 3.9 Hz, J6a,6b = 8.6 Hz, H-6b), 5.21 (dd, 1H, J2,3 = 
8.4 Hz, H-2), 5.60 (s, 1H, CHPh), 5.73 (d, 1H, J1,2 = 10.4 Hz, H-1), 7.28-7.53 (m, 8H, 
aromatic), 7.68 (m, 1H, aromatic); 
13
C NMR (75 MHz, CDCl3): δ, 28.0, 29.9, 37.9, 61.1, 
68.5, 71.1, 71.5, 81.0, 82.0, 84.2, 101.5, 110.3, 119.1, 124.7, 124.7, 126.2, 128.4, 128.5, 
129.2, 137.1, 141.7, 152.1, 161.3, 171.7, 206.1 ppm; HR-FAB MS [M+Na]
+
 calcd for 
C26H27NNaO8S 536.1355, found 536.1357. 
 
4-Pentenyl 2-azido-2,6-dideoxy-α-galactopyranoside (2.5a) and 4-Pentenyl 2-azido-
2,6-dideoxy-β-L-galactopyranoside (2.5b). Ceric ammonium nitrate (16.4 g, 29.9 
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mmol) and sodium azide (1.46 g, 22.4 mmol) were added to a solution of 3,4-di-O-acetyl-
1,5-anhydro-L-lyxo-hex-1-enitol
13
 (2.4, 2.0 g, 9.3 mmol) in anhydrous acetonitrile (50 
mL) and the resulting mixture was stirred for 3 h at -15 
o
C. After that, the volatiles were 
evaporated under reduced pressure at rt. The residue was dissolved in a mixture of diethyl 
ether and ethyl acetate (1/1, v/v, ~120 mL) and washed with water (30 mL). The organic 
phase was separated and the aqueous layer was extracted with a mixture of diethyl ether 
and ethyl acetate (1/1, v/v, 3 x 50 mL). The combined organic phase was dried with 
MgSO4 and concentrated in vacuo and the residue was dried in vacuo for 3 h. The crude 
residue was dissolved in 4-penten-1-ol (10.0 mL), cooled to 0 
o
C, sodium (240 mg, 10.4 





) was added till pH ~ 7, the resin was filtered off, and washed 
successively with MeOH. The combined filtrate (~80 mL) was concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
graduate elution) to yield 2.5a (1.11 g, 46%) and 2.5b (445 mg, 19%) as a pale-yellow 
foam. Analytical data for 2.5a: Rf = 0.51 (ethyl acetate/hexane, 7/3, v/v); []D
32
 -118.0 (c 
= 1, CH3OH);  
1
H NMR (500 MHz, CD3OD): δ, 1.23 (d, 3H, J5,6 = 6.6 Hz, C-6), 1.71-
1.75 (m, 2H, CH2), 2.18-2.23 (m, 2H, CH2), 3.36 (dd, 1H, J2,3 = 10.8 Hz, H-2), 3.46-3.49 
(m, 1H, CH2
a
), 3.70-3.75 (m, 2H, H-4, CH2
b
), 3.97-4.02 (m, 2H, H-3, 5), 4.84 (d, 1H, J1,2 
= 3.6 Hz, H-1), 4.98-5.08 (m, 2H, CH=CH2), 5.80-5.90 (m, 1H, CH=CH2) ppm; 
13
C 
NMR (125 MHz, CD3OD): δ, 14.8, 28.1, 29.6, 59.2, 65.9, 66.5, 67.3, 71.6, 98.0, 113.5, 
137.5 ppm; HR-FAB MS [M+H]
+
 calcd for C11H20O4N3 258.1454, found 258.1444.  
Analytical data for 2.5b: Rf = 0.47 (ethyl acetate/hexane, 7/3, v/v); []D
26
 -7.86 (c = 1, 
CH3OH);  
1
H NMR (600 MHz, CD3OD): δ, 1.26 (d, 3H, J5,6 = 6.5 Hz, C-6), 1.68-1.73 
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(m, 2H, CH2), 2.16-2.19 (m, 2H, CH2), 3.37-3.41 (m, 2H, H-2, 3), 3.52-3.60 (m, 3H, H-4, 
5, CH2
b
), 3.88-3.92 (m, 1H, CH2
a
), 4.23 (d, 1H, J1,2 = 7.3 Hz, H-1),  4.95-5.05 (m, 2H, 
CH=CH2), 5.80-5.85 (m, 1H, CH=CH2)
 13
C NMR (150 MHz, CD3OD): δ, 16.8, 30.3, 
31.4, 65.8, 70.1, 72.1, 72.5, 73.6, 103.7, 115.5, 139.5 ppm; HR-FAB MS [M+Na]
+
 calcd 
for C11H19O4NaN3 280.1273, found 280.1277. 
 
4-Pentenyl 2-azido-3,4-O-benzylidene-2,6-dideoxy-β-L-galactopyranoside (2.6). 
Dimethoxytoulene (1.9 mL, 12.6 mmol) and camphorsulfonic acid (74 mg, 0.32 mmol) 
we added to a solution of 2.5b (1.62 g, 6.3 mmol) in acetonitrile (20 mL) and the 
resulting mixture was stirred under argon for 1 h at rt. After that, triethylamine (~0.3 mL) 
was added and the volatiles were removed in vacuo. The residue was diluted with CH2Cl2 
(~200 mL) and washed with water (40 mL), sat. aq. NaHCO3 (40 mL), and water (2 x 40 
mL). The organic phase was separated, dried with MgSO4, and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to yield the title compound as a white amorphous solid (1.89 g, 87%). 
Analytical data for 2.6: Rf = 0.58 (ethyl acetate/hexane, 3/7, v/v); []D
21
 85.2 (c = 1, 
CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.49 (d, 3H, C-6), 1.71-1.78 (m, 2H, CH2), 2.13-
2.21 (m, 2H, CH2), 3.38-3.43 (m, 1H, H-2), 3.51-3.56 (m, 1H, OCH2
a
), 3.85-3.97 (m, 2H, 
H-5, OCH2
b
), 3.98-4.06 (m, 2H, C-3, 4), 4.24 (d, 1H, J1,2 = 8.6 Hz, H-1), 4.95-5.10 (m, 
2H, CH=CH2), 5.77 (m, 1H, CH=CH2), 5.94 (s, 1H, CHPh), 7.39-7.41 (m, 3H, aromatic), 
7.42-7.54 (m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.6, 28.7, 30.1, 65.5, 
68.8, 69.3, 76.8, 78.0, 101.8, 104.5, 115.1, 126.6 (x 2), 128.5 (x 2), 129.5, 137.1, 138.0 
ppm; HR-FAB MS [M+Na]
+
 calcd for C18H23O4Na N3 368.1586, found 368.1582. 
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4-Pentenyl 2-azido-4-O-benzyl-2,6-dideoxy-β-L-galactopyranoside (2.7). A solution 
of compound 2.6 (400 mg, 1.16 mmol) and activated molecular sieves (3Å, 800 mg) in 
THF (10 mL) was stirred under argon for 1 h at rt. NaCNBH3 (876 mg, 13.9 mmol) was 
added in one portion, 2M HCl in diethyl ether (17 mL, 17.4 mmol) was added dropwise, 
and the resulting mixture was kept for 1 h at rt. After that, the solids were filtered off and 
rinsed successively with CH2Cl2. The combined filtrate (~100 mL) was washed with 
water (20 mL), sat. aq. NaHCO3 (20 mL), and water (2 x 20 mL). The organic phase was 
separated, dried with MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield the 
title compound as a clear syrup (376 mg, 94%). Analytical data for 2.7: Rf = 0.48 (ethyl 
acetate/hexane, 3/7, v/v); []D
21
 48.7 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 
1.22 (d, 3H, C-6), 1.65 (m, 2H, CH2), 2.17 (m, 2H, CH2), 2.55 (d, 1H, J3,OH = 7.0 Hz, 
OH), 3.40-3.60 (m, 5H, H-2, 3, 4, 5, OCH2
a
), 3.94-4.00 (m, 1H, OCH2
b
), 4.21 (d, 1H, J1,2 
= 7.6 Hz, H-1), 4.79 (dd, 2H, 
2
J = 11.6 Hz, CH2Ph), 4.87-4.99 (m, 2H, CH=CH2), 5.85 
(m, 1H, CH=CH2), 7.30-7.50 (m, 5H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 
16.9, 28.8, 30.1, 64.7, 69.3, 70.8, 72.9, 75.8, 78.4, 102.3, 115.0, 128.0, 128.2 (x 2), 128.5 
(x 2), 138.0, 138.1 ppm; HR-FAB MS [M+Na]
+
 calcd for C18H25O4NaN3 370.1743, 
found 370.1750. 
 
Methyl 2-azido-2,6-dideoxy-α-D-galactopyranoside (2.12a) and Methyl 2-azido-2,6-
dideoxy-β-D-galactopyranoside (2.12b). Ceric ammonium nitrate (7.72 g, 14.08 mmol) 
and sodium azide (686 mg, 10.61 mmol) were added to a solution of 3,4-di-O-acetyl-1,5-




 (2.11, 942 mg, 4.4 mmol) in anhydrous acetonitrile (30 
mL) and the resulting mixture was stirred for 3 h at -15 
o
C. After that, the volatiles were 
removed under the reduced pressure at rt. The residue was dissolved in a mixture of 
diethyl ether and ethyl acetate (1/1, v/v, 120 mL) and washed with water (30 mL). The 
organic phase was separated and the aqueous layer was extracted with a mixture of 
diethyl ether and ethyl acetate (1/1, v/v, 3 x 50 mL). The combined organic extract was 
dried with MgSO4, concentrated in vacuo, and the residue was dried in vacuo for 3 h. The 
crude residue was dissolved in methanol (~10 mL), sodium (194 mg, 8.42 mmol) was 
added portionwise, and the resulting mixture was kept for 30 min at 0 
o
C. After that, the 
reaction mixture was neutralized with Dowex (H
+
), the resin was filtered off, rinsed 
successively with MeOH, and the combined filtrate (~60 mL) was concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
graduate elution) to yield 2.12a (328 mg, 37%) and 2.12b (315 mg, 35%) as white 
amorphous solids. Analytical data for 2.12a: Rf = 0.48 (ethyl acetate/hexane, 7/3, v/v); 
[]D
30
 146.0 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.27 (d, 3H, C-6), 3.39 (s, 
3H, OCH3), 3.48-3.53 (m, 2H, J2,3 = 10.4 Hz, H-2, OH), 3.78 (br. s, 1H, H-4), 3.85 (br. s, 
1H, OH), 3.94 (m, 1H, H-5), 3.98 (m, 1H, H-3), 4.77 (d, 1H, J1,2 = 3.4 Hz, H-1) ppm; 
13
C 
NMR (75 MHz, CDCl3): δ, 16.2, 55.5, 60.2, 65.8, 69.0, 72.1, 99.1 ppm; HR-FAB MS 
[M+Na]
+
 calcd for C7H13NaO4N3 226.0804, found 226.0810. Analytical data for 2.12b: 
Rf = 0.46 (ethyl acetate/hexane, 7/3, v/v); []D
30
 27.3 (c = 1, CHCl3); 
1
H NMR (300 
MHz, CDCl3): δ, 1.32 (d, 3H, C-6), 3.40-3.59 (m, 4H, H-2, 3, 5, OH), 3.54 (s, 3H, 
OCH3), 3.68-3.72 (m, 1H, H-4), 3.88 (d, 1H, J3,OH = 6.2 Hz, OH), 4.13 (d, 1H, J1,2 = 7.4 
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Hz, H-1) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.3, 57.2, 65.8, 70.7, 71.1, 72.8, 103.3 
ppm; HR-FAB MS [M+Na]
+
 calcd for C7H13NaO4N3 226.0804, found 226.0819.  
 
Methyl 2-azido-3,4-O-benzylidene-2,6-deoxy-α-D-galactopyranoside (2.13). 
Dimethoxytoluene (0.45 mL, 2.96 mmol) and camphorsulfonic acid (17 mg, 0.07 mmol) 
were added to a solution of compound 2.12a (300 mg, 1.48 mmol) in acetonitrile (20 mL) 
and the resulting mixture was stirred under argon for 1 h at rt. After that, triethylamine 
(~0.3 mL) was added and the volatiles were removed in vacuo. The residue was diluted 
with CH2Cl2 (~200 mL) and washed with water (40 mL), sat. aq. NaHCO3 (40 mL), and 
water (2 x 40 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) to yield the title compound as a clear syrup (336 
mg, 78%). Analytical data for 2.13: Rf = 0.61 (ethyl acetate/hexane, 2/3, v/v); []D
26
 
225.9 (c = 1, CHCl3); 
1
H NMR (600 MHz, CDCl3): δ, 1.47 (d, 3H, C-6), 3.41 (dd, 1H, 
J2,3 = 8.4 Hz, H-2), 3.45 (s, 3H, OCH3), 4.17 (dd, 1H, J4,5 = 2.5 Hz, H-4), 4.19-4.22 (m, 
1H, J5,6 = 6.6 Hz, H-5), 4.51 (dd, 1H, J3,4 = 5.6 Hz, H-3), 4.73 (d, 1H, J1,2 = 3.3 Hz, H-1), 
6.00 (s, 1H, CHPh), 7.40-7.55 (m, 5H, aromatic) ppm; 
13
C NMR (150 MHz, CDCl3): δ, 
18.9, 58.2, 64.3, 65.8, 76.2,  80.7, 101.5, 106.6, 128.9 (x 2), 131.1 (x 2), 131.9, 140.2 
ppm; HR-FAB MS [M+Na]
+
 calcd for C14H17O4NaN3 314.1117, found 314.1119. 
 
Methyl 2-azido-4-O-benzyl-2,6-dideoxy-α-D-galactopyranoside (2.14).  A solution of 
compound 2.13 (114 mg, 0.33 mmol) and activated molecular sieves (3Å, 500 mg) in 
THF (10 mL) was stirred under argon for 1 h at rt. NaCNBH3 (328 mg, 5.2 mmol) was 
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added in one portion, then 2M HCl in diethyl ether (2.6 mL, 5.2 mmol) was added 
dropwise and the resulting mixture was stirred under argon for 1 h at rt. After that, the 
solids were filtered off and rinsed successively with CH2Cl2. The combined filtrate (~100 
mL) was washed with water (20 mL), sat. aq. NaHCO3 (20 mL), and water (2 x 20 mL). 
The organic phase was separated, dried with MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to yield the title compound as a white amorphous solid (103 mg, 90%). 
Analytical data for 2.14: Rf = 0.53 (ethyl acetate/hexane, 2/3, v/v); []D
26
 226.1 (c = 1, 
CHCl3); 
1
H NMR (600 MHz, CDCl3): δ, 1.29 (d, 3H, C-6), 2.16 (dd, 1H, J3,OH = 6.2 Hz, 
OH), 3.39 (s, 3H, OCH3), 3.49 (dd, 1H, J2,3 = 10.6 Hz, H-2), 3.65 (d, 1H, J4,5 = 3.1 Hz,  
H-4), 3.94 (dd, 1H, J5,6 = 6.7 Hz, H-5), 4.03 (dd, 1H, J3,4 = 3.2 Hz, H-3), 4.75 (dd, 2H, 
2
J 
= 11.5 Hz, CH2Ph), 4.76 (d, 1H, J1,2 = 3.5 Hz, H-1), 7.31-7.37 (m, 5H, aromatic), ppm; 
13
C NMR (150 MHz, CDCl3): δ, 19.4, 58.1, 63.9, 68.9, 71.7, 78.8, 82.7, 101.7, 130.8 (x 
2),130.9, 131.3 (x 2), 140.4 ppm; HR-FAB MS [M+Na]
+
 calcd for C14H19O4NaN3 
316.1273, found 316.1271. 
 
2.4.3 Synthesis and modification of oligosaccharides 
4-Pentenyl O-(4,6-O-benzylidene-2-O-levulinoyl-3-O-methyl-β-D-glucopyranosyl)-
(13)-2-azido-4-O-benzyl-2,6-dideoxy-β-L-galactopyranoside (2.8).  A mixture of 
donor 2.3 (1.76 g, 3.43 mmol), acceptor 2.7 (1.08 g, 3.12 mmol), and freshly activated 
molecular sieves (3Å, 6.0 g) in ClCH2CH2Cl (70 mL) was stirred under argon for 2 h at 
rt. Freshly conditioned AgOTf (1.6 g, 6.24 mmol) was added and the resulting mixture 
was stirred under argon for 1 h at rt. After that, the solids were filtered-off and rinsed 
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successively with CH2Cl2. The combined filtrate (~150 mL) was washed with sat. aq. 
NaHCO3 (40 mL) and water (2 x 40 mL). The organic phase was separated, dried with 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - hexane gradient elution) to afford the title compound as a 
white foam (1.29 g,73%). The yield calculation is based on acceptor 2.7 recovered (218 
mg, 0.63 mmol). Analytical data for 2.8: Rf = 0.50 (ethyl acetate/hexane, 2/3, v/v); []D
20
 
-104.2 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.18 (d, 3H, J5,6 = 6.3 Hz, C-6), 
1.76 (m, 2H, CH2), 2.11 (s, 3H, COCH3), 2.16 (m, 2H, CH2), 2.50-2.66 (m, 4H, 
COCH2CH2CO), 3.47-3.56 (m, 4H, H-3’, 5, 5’, OCH2
a
), 3.58 (s, 3H, OCH3), 3.65-3.92 
(m, 6H, H-2, 3, 4, 4’, 6a’, OCH2
b
), 4.17 (d, 1H, J1,2 = 7.7 Hz, H-1), 4.45 (dd, 1H, J5’,6b’ = 
4.9 Hz, J6a’,6b’ = 10.5 Hz, H-6b’), 4.75 (dd, 2H, 
2
J = 11.6 Hz, CH2Ph), 4.86 (d, 1H, J1’,2’ = 
7.4 Hz, H-1’), 4.97-5.07 (m, 3H, H-2’, CH=CH2), 5.59 (s, 1H, CHPh), 5.84 (m, 1H, 
CH=CH2), 7.25-7.60 (m, 10H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.8, 27.9, 
28.9, 30.0, 30.2, 37.8, 60.5, 63.4, 66.5, 68.8, 69.5, 70.5, 73.9, 74.9, 75.6, 80.6, 80.9, 81.2, 
100.3, 101.4, 102.4, 115.0, 126.2 (x 2), 127.7, 128.2 (x 2), 128.3 (x 2), 128.4 (x 2), 128.6, 
129.2, 138.4, 138.6, 171.4, 206.5 ppm; HR-FAB MS [M+Na]
+
 calcd for C37H47NaO11N3 
732.3108, found 732.3104. 
 
4-Pentenyl O-(4,6-O-benzylidene-3-O-methyl-β-D-glucopyranosyl)-(13)-2-azido-4-
O-benzyl-2,6-dideoxy-β-L-galactopyranoside (2.9).  Hydrazine acetate (214 mg, 2.37 
mmol) was added to a solution of disaccharide 2.8 (874 mg, 1.23 mmol) in 
CH2Cl2/methanol (40 mL, 20/1, v/v) and the resulting mixture was stirred for 3 h at rt. 
After that, the reaction mixture was diluted with CH2Cl2 (~100 mL) and washed with sat. 
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aq. NaHCO3 (20 mL) and water (2 x 20 mL). The organic phase was separated, dried 
with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam (528 mg, 72%). Analytical data for 2.9: Rf = 0.58 (ethyl 
acetate/hexane, 2/3, v/v); []D
20
 -94.4 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 
1.19 (d, 3H, J5,6 = 6.4 Hz, C-6), 1.73 (m, 2H, CH2), 2.15 (m, 2H, CH2), 2.97 (d, 1H, J2,OH  
= 2.6 Hz, OH), 3.40-3.51 (m, 4H, H-3’, 5, 5’, OCH2
a
), 3.58-3.65 (m, 4H, H-2’, 3, 4, 4’), 
3.68 (s, 3H, OCH3), 3.79 (dd, 1H, J2,3 = 7.8 Hz, H-2), 3.82 (dd, 1H, J5’,6a’ = 4.9 Hz, J6a’,6b’ 
= 10.5 Hz, H-6a’), 3.93 (m, 1H, OCH2
b
), 4.22 (d, 1H, J1,2 = 7.8 Hz, H-1), 4.37 (dd, 1H, 
J5’,6b’ = 4.9 Hz, H-6b’), 4.64 (d, 1H, J1’,2’ =7.8 Hz, H-1’), 4.90 (dd, 2H, 
2
J = 11.7 Hz, 
CH2Ph), 5.01-5.10 (m, 2H, CH=CH2), 5.57 (s, 1H, CHPh), 5.80-5.90 (m, 1H, CH=CH2), 
7.26-7.50 (m, 10H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.9, 28.9, 30.3, 61.2, 
62.1, 67.0, 68.8, 69.5, 70.6, 72.9, 74.9, 75.8, 81.4, 82.4, 101.3, 101.5, 102.3, 115.0, 126.2 
(x 2), 127.9, 128.4, 128.5 (x 4), 128.6 (x 2), 129.3, 137.3, 138.3, 138.4 ppm; HR-FAB 
MS [M+Na]
+




(2.10).  Pyridine (0.5 mL) was added to a solution of disaccharide 2.9 (150 mg, 0.23 
mmol) in CH2Cl2 (5.0 mL) and the resulting mixture was cooled to 0 
o
C. 
Trifluoromethanesulfonic anhydride (100 µL, 0.59 mmol) was added dropwise and the 
reaction mixture was kept for 3 h at 0 
o
C. After that, the reaction was quenched with ice-
cold water (~5 mL), diluted with CH2Cl2 (~100 mL), and washed with cold sat. aq. 
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NaHCO3 (20 mL) and cold water (2 x 20 mL). The organic phase was separated, dried 
over MgSO4, and concentrated in vacuo. The crude residue was dissolved in DMF (2.0 
mL), NaN3 (96 mg, 1.47 mmol) was added, and the resulting suspension was stirred for 
16 h at 60 
o
C. Upon completion, ethyl acetate (~50 mL) and water (~50 mL) were added. 
Organic layer was separated and washed with sat. aq. NaCl (2 x 15 mL). The combined 
aqueous phase was extracted with ethyl acetate (3 x 30 mL). The combined organic 
extract was dried with MgSO4 and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate-hexane gradient elution) to afford the 
title compound as a white foam (135 mg, 90% over 2 steps). Analytical data for 2.10: Rf 
= 0.3 (ethyl acetate/hexane, 3/7, v/v); []D
20
 -90.9 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.36 (d, 3H, J5,6 = 6.4 Hz, C-6), 1.75 (m, 2H, CH2), 2.16 (m, 2H, CH2), 3.22 
(m, 1H, H-5’), 3.29 (dd, 1H, J3’,4’ = 3.7 Hz, H-3’), 3.47-3.62 (m, 4H, J2’,3’ = 9.6 Hz, H-2’, 
4, 5, OCH2
a
), 3.53 (s, 3H, OCH3), 3.66-3.77 (m, 2H, H-2, 3), 3.85-3.99 (m, 3H, H-4’, 6a’, 
OCH2
b
), 4.21 (d, 1H, J1,2 = 7.2 Hz, H-1), 4.29 (dd, 1H, J5’,6b’ = 4.9 Hz, J6a’,6b’ = 10.5 Hz, 
H-6b’), 4.45 (s, 1H, H-1’), 4.77 (dd, 2H, 
2
J = 12.2 Hz, CH2Ph), 4.95-5.07 (m, 2H, 
CH=CH2), 5.55 (s, 1H, CHPh), 5.83 (m, 1H, CH=CH2), 7.33-7.48 (m, 10H, aromatic) 
ppm; 
13
C NMR (75 MHz, CDCl3): δ, 17.2, 28.7, 30.1, 59.1, 62.2, 67.6, 68.3, 69.4, 70.4, 
75.3, 75.7, 77.1, 77.2, 78.3, 78.7, 97.0, 101.7, 102.3, 115.0, 126.1 (x 2), 128.2, 128.4 (x 
2), 128.5 (x 2), 128.6 (x 2), 129.2, 137.2, 138.2, 138.3 ppm; HR-FAB MS [M+Na]
+
 calcd 
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O-benzyl-2,6-dideoxy-α-D-galactopyranoside (2.15).  A mixture of donor 2.10 (336 g, 
0.53 mmol), acceptor 2.14 (186 mg, 0.63 mmol), and freshly activated molecular sieves 
(4Å, 1.0 g) in ClCH2CH2Cl (20 mL) was stirred under argon for 2 h at rt. The resulting 
mixture was cooled to 0 
o
C, N-iodosuccinimide (237 mg, 1.05 mmol) and 
trifluoromethanesulfonic acid (17 mg, 0.11 mmol) were added, and the resulting mixture 
was stirred under argon for 2 h at 0 
o
C. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~100 mL) was washed with sat. aq. 
NaHCO3 (40 mL) and water (2 x 40 mL). The organic phase was separated, dried with 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - hexane gradient elution) to afford the title compound as a 
white amorphous solid (282 mg, 87%). The yield calculation is based on acceptor 2.14 
recovered (73 mg, 0.25 mmol). Analytical data for 2.15: Rf = 0.47 (ethyl acetate/hexane, 
2/3, v/v); []D
26
 -86.6 (c = 1, CHCl3);  
1
H NMR (600 MHz, CDCl3): δ, 1.25 (2d, 6H, C-6, 
6’), 3.25 (m, 1H, H-5”), 3.38 (dd, 1H, J3”,4” = 9.6 Hz, H-3”), 3.40, 3.55 (2s, 6H, 2 x 
OCH3), 3.58 (dd, 1H, J4,5= 1.0 Hz, H-4), 3.64 (dd, 1H, J4’,5’ = 1.0 Hz, H-4’), 3.72 (dd, 1H, 
J2”,3” = 3.2 Hz, H-2”), 3.75 (dd, 1H, J2’,3’ = 10.7 Hz, H-2’), 3.81 (dd, 1H, J5”,6a” = 4.8 Hz, 
J6a”,6b” = 9.6 Hz, H-6a”), 3.91-3.99 (m, 4H, H-2, 4”, 5, 5’), 4.07 (dd, 1H, J3,4 = 2.4 Hz, H-
3), 4.15 (dd, 1H, J5”,6b” = 4.9 Hz, H-6b”), 4.22 (dd, 1H, J3’,4’ = 2.7 Hz, H-3’), 4.61 (br. s, 
1H, H-1”), 4.74 (dd, 2H, 
2
J = 14.8 Hz, CH2Ph), 4.76 (dd, 2H, 
2
J = 11.3 Hz, CH2Ph), 4.83-
4.86 (m, 2H, J1,2 = 3.5 Hz, H-1), 5.26 (d, 1H, J1’,2’ = 3.5 Hz, H-1’), 5.54 (s, 1H, CHPh), 
7.31-7.51 (m, 15H, aromatic) ppm; 
13
C NMR (150 MHz, CDCl3): δ, 16.8, 16.9, 55.5, 
58.5, 59.3, 60.8, 62.6, 66.8, 67.6, 67.8, 68.4, 74.9, 75.4, 76.0, 76.8, 77.0, 78.4, 78.9, 79.8, 
98.1, 99.1, 99.9, 101.7, 126.2 (x 2), 127.9 (x 2), 128.0, 128.3, 128.4 (x 2), 128.5 (x 2), 
Satsawat Visansirikul | UMSL 2018 | Page  53 
 
128.6 (x 2), 128.7 (x 2), 129.2, 137.3, 138.0, 138.4 ppm; HR-FAB MS [M+Na]
+
 calcd for 





galactopyranoside (2.16).  Water (9.0 mL), triethylamine (2.0 mL, 14.2 mmol) and 1.3-
propanedithiol (20 mL, 19.2 mmol) were added to a solution of trisaccharide 2.15 (270 
mg, 0.32 mmol) in pyridine (35.0 mL) and the resulting mixture was kept for 6 h at rt. 
After that, the reaction mixture was concentrated and dried in vacuo. The crude residue 
was dissolved in MeOH (3.0 mL), Ac2O (0.4 mL, 3.84 mmol) was added, and the 
resulting suspension was stirred under argon for 16 h at rt. Upon completion, the reaction 
mixture was concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (methanol - dichloromethane gradient elution) to afford the title compound 
as a white foam (268 mg, 94% over 2 steps). Analytical data for 2.16: Rf = 0.77 
(methanol/dichloromethane, 1/4, v/v); []D
26
 -20.1 (c = 1, CHCl3);  
1
H NMR (600 MHz, 
CDCl3): δ, 1.19 (d, 3H, J5,6 = 6.5 Hz, C-6), 1.29 (d, 3H, J5’,6’ = 6.5 Hz, C-6’), 1.95, 1.99, 
2.10 (3s, 9H, 3 x COCH3), 3.27 (m, 1H, H-5”), 3.36 (s, 3H, OCH3), 3.41 (dd, 1H, J2”,3” = 
4.6 Hz, H-3”), 3.46-3.48 (m, 2H, H-4, 4’), 3.49 (s, 3H, OCH3), 3.59 (dd, 1H, J3”,4” = 9.7 
Hz, H-4”), 3.63 (dd, 1H, J2,3 = 10.7 Hz, J3,4 = 2.3 Hz, H-3), 3.68 (dd, 1H, J6a”,6b” = 10.3 
Hz, H-6a”), 3.82 (m, 1H, C-5), 3.86 (dd, 1H, J2’,3’ = 10.8 Hz, J3’,4’ = 2.5 Hz, C-3’), 3.93 
(m, 1H, C-5’), 4.20 (dd, 1H, J5”,6b” = 4.9 Hz, H-6b”), , 4.54 (d, 1H, J1”,2” = 1.6 Hz, H-1”), 
4.61 (dd, 1H, J1’,2’ = 3.7 Hz, H-2’), 4.62 (dd, 1H, J1,2 = 3.6 Hz, H-1), 4.66 (dd, 2H,
 2
J = 
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J = 11.7 Hz, H-1’, 2, CH2Ph), 
5.52 (s, 1H, CHPh), 5.74 (d, 1H, J2,NH = 9.6 Hz, 2-NH), 5.90 (d, 1H, J2”,NH = 8.6 Hz, 2”-
NH), 6.03 (d, 1H, J2’,NH = 9.6 Hz, 2’-NH), 7.25-7.51 (m, 15H, aromatic) ppm; 
13
C NMR 
(150 MHz, CDCl3): δ, 16.9, 17.1, 23.4, 23.8, 24.2, 47.8, 48.9, 50.6, 55.3, 58.5, 67.0, 67.1, 
67.8, 68.8, 75.2, 75.5, 76.4, 77.4, 78.7, 78.8, 79.3, 80.1, 98.8, 99.1, 100.6, 102.0, 126.3 (x 
2), 127.3 (x 2), 127.7, 128.0, 128.1 (x 2), 128.4 (x 2), 128.5 (x 2), 128.7 (x 2), 129.3, 
170.9, 171.2, 172.0 ppm; HR-FAB MS [M+Na]
+





benzyl-2,6-dideoxy-α-D-galactopyranoside (2.17).  Trifluoroacetic acid (2.0 mL) was 
added to a solution of trisaccharide 2.16 (203.0 mg, 0.2 mmol) in CH2Cl2 (20.0 mL) and 
water (50 μL) and the resulting mixture was stirred for 16 h at rt. After that, the reaction 
mixture was neutralized with triethylamine (~5.0 mL) and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (methanol - 
dichloromethane gradient elution) to afford the title compound as a white amorphous 
solid (169 mg, 92%). Analytical data for 2.17: Rf = 0.54 (methanol/CH2Cl2, 1/4, v/v); 
[]D
26
 -13.9 (c = 1, CHCl3); 
1
H NMR (600 MHz, CD3OD): δ, 1.21-1.24 (2d, 6H, C-6,6’), 
1.92 (2s, 6H, 2 x COCH3), 2.04 (s, H, COCH3), 3.16 (dd, 1H, J5”,6a” = 6.6 Hz, J5”,6b” = 3.1 
Hz, H-5”), 3.23 (dd, 1H, J2”,3” = 4.2 Hz, H-3”), 3.30, 3.34, 3.42 (3s, 9H, 3 x OCH3), 3.53, 
(dd, 1H, J3”,4” = 9.7 Hz, H-4”), 3.62 (dd, 1H, H-4), 3.67 (dd, 1H, J6a”,6b” = 11.4 Hz, H-
6a”), 3.78 (dd, 1H, H-6b”), 3.81 (dd, 1H, H-4’), 3.95-4.03 (m, 4H, H-3, 3’, 5, 5’), 4.41 
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(dd, 1H, , J2’,3’ = 11.3 Hz, H-2’), 4.53 (d, 1H, J1,2 = 3.8 Hz, H-1), 4.62 (dd, 1H, J2,3 = 11.1 
Hz, H-2), 4.71 (dd, 1H, H-2”), 4.73 (d, 1H, J1”,2” = 2.7 Hz, H-1”), 4.75 (dd, 2H,
 2
J = 11.0 
Hz, CH2Ph), 4.86 (dd, 2H,
 2
J = 11.7 Hz, CH2Ph), 5.02 (d, 1H, J1’,2’ = 3.7 Hz, H-1’), 7.25-
7.47 (m, 10H, aromatic) ppm; 
13
C NMR (150 MHz, CD3OD): δ, 17.2, 17.3, 22.8, 23.0, 
23.6, 49.3, 49.8, 50.7, 50.8, 55.7, 58.0, 61.5, 66.8, 68.2, 68.9, 75.4, 76.4, 76.6, 78.1, 78.2, 
78.6, 81.0, 83.7, 99.8, 100.4, 100.7, 128.7, 128.9, 129.0 (x 2), 129.3 (x 2), 129.5 (x 2), 
129.6 (x 2), 140.4, 173.7, 173.8, 173.9 ppm; HR-FAB MS [M+Na]
+
 calcd for 
C40H57NaO14N3 826.3738, found 826.3706. 
 
Methyl O-(benzyl 2-acetamido-2-deoxy-3-O-methyl-β-D-mannopyranosyl uronate)-
(13)-O-(2-acetamido-4-O-benzyl-2,6-dideoxy-α-L-galactopyranosyl)-(13)-2-
acetamido-4-O-benzyl-2,6-dideoxy-α-D-galactopyranoside (2.18). Water (0.5 mL), 
2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO, 0.7 mg, 0.01 mmol) and diacetoxy 
iodobenzene (16.1 mg, 0.05 mmol) were added to a solution of trisaccharide 2.17 (18 mg, 
0.02 mmol) in CH2Cl2 (1.0 mL) and the resulting mixture was stirred for 4 h at rt.  After 
that, the reaction mixture was passed through a pad of silica gel, concentrated in vacuo, 
and dried. The crude residue was dissolved in DMF (2.0 mL), benzyl bromide (0.01 mL, 
0.15 mmol) and NaHCO3 (7.6 mg, 0.09 mmol) were added, and the resulting suspension 
was stirred under argon for 16 h at rt. After that, the reaction was the reaction was 
quenched with ice-cold water (~5 mL) and extracted with ethyl acetate (3 x 10 mL). The 
organic extract was washed with brine (2 x 10 mL). The organic extract was dried with 
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (methanol - dichloromethane gradient elution) to afford the title compound 
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as a white amorphous solid (10.1 mg, 58% over 2 steps). Analytical data for 2.18: Rf = 
0.71 (methanol/dichloromethane, 1/4, v/v); []D
27
 -27.3 (c = 1, CHCl3);
 1
H NMR (600 
MHz, CDCl3): δ, 1.18 (d, 3H, J5’,6’ = 6.5 Hz,  H-6’), 1.30 (d, 3H, J5,6 = 6.5 Hz, H-6), 1.96, 
1.97, 2.04 (3s, 9H, 3 x COCH3), 3.09 (d, 1H, J4”,OH = 5.8 Hz, 4”-OH), 3.20 (dd, 1H, J2”,3” 
= 4.1 Hz, H-3”), 3.37 (s, 3H, OCH3), 3.42 (dd, 1H, H-4’), 3.46 (dd, 1H, H-4) 3.47 (s, 3H, 
OCH3), 3.71-3.75 (m, 2H, H-3’, 5’), 3.80 (d, 1H, J4”,5” = 9.2 Hz, H-5”), 3.81-3.87 (m ,2H, 
J3”,4” = 8.9 Hz, H-3, 4”), 3.92 (dd, 1H, H-5), 4.58 (d, 1H, J1”,2” = 1.8 Hz H-1”), 4.59 (dd, 
1H, J2’,3’ = 10.2 Hz, H-2’), 4.63 (dd, 2H,
 2
J = 11.4 Hz, CH2Ph), 4.65 (d, 1H, J1,2 = 3.6 Hz, 
H-1), 4.67 (dd, 1H, H-2”), 4.75 (br. s., 2H, CH2Ph), 4.77 (dd, 1H, J2,3 = 10.3 Hz, H-2), 
4.85 (d, 1H, J1’,2’ = 3.7 Hz, H-1’), 5.33 (dd, 2H, 
2
J = 12.0 Hz, CH2Ph), 5.77 (d, 1H, J2,NH 
= 9.7 Hz, 2-NH), 6.09 (d, 1H, J2”,NH = 8.4 Hz, 2”-NH), 6.19 (d, 1H, J2’,NH = 9.5 Hz, 2’-
NH), 7.21-7.45 (m, 15H, aromatic) ppm; 
13
C NMR (150 MHz, CDCl3): δ, 16.9, 17.3, 
23.3, 23.7, 23.8, 47.9, 48.9, 49.0, 55.3, 58.2, 67.2, 67.6, 67.9, 68.1, 74.9, 75.2, 75.3, 76.8, 
77.3, 78.7, 80.6, 81.4, 98.1, 99.2, 100.7, 127.5 (x 2),127.6, 127.7, 128.1 (x 2), 128.4 (x 2), 
128.6 (x 2), 128.8, 128.9 (x 2), 129.2 (x2), 135.2, 138.5, 138.9, 168.7, 170.7, 171.9, 172.0 
ppm; HR-FAB MS [M+Na]
+
 calcd for C47H61NaO15N3 930.4000, found 930.4014. 
 
Methyl O-(benzyl 2-acetamido-4-O-acetyl-2-deoxy-3-O-methyl-β-D-mannopyranosyl 
uronate)-(13)-O-(2-acetamido-4-O-benzyl-2,6-dideoxy-α-L-galactopyranosyl)-
(13)-2-acetamido-4-O-benzyl-2,6-dideoxy-α-D-galactopyranoside (2.19). Ac2O (0.3 
mL) was added to a solution of trisaccharide 2.18 (10 mg, 0.01 mmol) in pyridine (2.0 
mL) and the resulting mixture was stirred under argon for 16 h. After that, the reaction 
was quenched with MeOH (~3.0 mL), the volatiles were removed in vacuo, and the 
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residue was co-evaporated with toluene (3 x 3 mL) The residue was purified by column 
chromatography on silica gel (methanol - dichloromethane gradient elution) to afford the 
title compound as a white amorphous solid (12 mg, 99%). Analytical data for 2.19: Rf = 
0.61 (methanol/dichloromethane, 3/17, v/v); []D
25
 -27.9 (c = 1, CHCl3);
 1
H NMR (300 
MHz, CDCl3): δ, 1.14-1.21 (2d, 6H, H-6, 6’), 1.73, 1.90, 1.92, 1.97 (4s, 12H, 4 x 
CH3CO), 3.18 (s, 3H, OCH3), 3.27 (dd, 1H, H-3”), 3.28 (s, 3H, OCH3), 3.43 (dd, 1H, H-
4), 3.65 (dd, 1H, H-4’), 3.82-3.87 (m, 3H, H-3, 5, 5’), 4.03 (d, 1H, J4”,5” = 4.7 Hz, H-5”), 
4.32 (dd, 1H, J3’,4’ = 9.4 Hz, H-3’), 4.56-4.69 (m, 3H, H-1, 2’, 2”), 4.67 (dd, 2H,
 2
J = 12.0 
Hz, CH2Ph), 4.87 (dd, 1H, J1,2 = 3.6 Hz, H-2), 4.89 (dd, 2H, 
2
J = 12.1 Hz, CH2Ph), 4.95-
4.98 (2d, 2H, H-1’, 1”), 5.01 (br. s., 2H, CH2Ph), 5.35 (dd, 1H, J3”,4” = 5.7 Hz, H-4”), 
5.67 (d, 1H, J2,NH = 9.7 Hz, 2-NH), 6.28 (d, 1H, J2”,NH = 9.3 Hz, 2”-NH), 6.47 (d, 1H, 
J2’,NH = 9.3 Hz, 2’-NH), 7.22-7.38 (m, 15H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): 
δ, 17.2, 17.5, 21.1, 23.1, 23.7, 23.8, 46.2, 47.9, 49.0, 55.3, 58.9, 67.3, 67.5, 67.7, 68.1, 
71.7, 74.4, 74.6, 75.5, 76.6, 76.8, 77.2, 77.4, 79.6, 93.2, 99.3, 100.3, 127.3 (x 2), 127.5, 
127.6 (x 2), 128.4 (x 2), 128.5 (x 2), 128.7, 128.8 (x 2), 129.0 (x 2), 135.1, 138.4, 139.2, 
167.8, 170.0, 170.6, 171.1, 172.0 ppm; HR-FAB MS [M+Na]
+
 calcd for C49H63NaO16N3 




2,6-dideoxy-α-D-galactopyranoside (T1). 10% Pd on activated charcoal (200 mg) was 
added to a solution of trisaccharide 2.19 (50 mg, 0.044 mmol) in 90% aq. ethanol (5.0 
mL) and the resulting suspension was vigorously stirred under H2 atmosphere for 24 h at 
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rt. After that, the solids were filtered off and rinsed successively with methanol. The 
combined filtrate (~35 mL) was concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (dichloromethane - methanol gradient elution) to 
afford the title compound as a white amorphous solid (35 mg, 98% yield). Analytical data 
for 1: Rf = 0.18 (methanol/dichloromethane, 3/7, v/v); []D
27
 -40.0 (c = 1, CH3OH); 
1
H 
NMR (300 MHz, CD3OD): δ, 1.21-1.24 (2d, 6H, H-6, 6’), 1.91, 2.00, 2.04, 2.05 (4s, 12H, 
4 x CH3CO), 3.33 (s, 3H, OCH3), 3.36 (s, 3H, OCH3), 3.51 (dd, 1H, J3”,4” = 9.8 Hz, H-
3”), 3.64 (dd, 1H, H-4), 3.70 (d, 1H, H-5”), 3.83 (dd, 1H, J3,4 = 2.9 Hz, H-3), 3.88 (dd, 
1H J3’,4’ = 2.7 Hz, H-4’), 3.92 (dd, 1H, J5,6 = 6.6 Hz, H-5), 4.02 (dd, 1H, J5’,6’ = 6.5 Hz, 
H-5’), 4.07 (dd, 1H, J2’,3’ = 11.2 Hz, H-3’), 4.27 (dd, 1H, J1’,2’ = 3.9 Hz, H-2’), 4.46 (dd, 
1H, J2,3 = 11.0 Hz, H-2), 4.53 (d, 1H, J1,2 = 3.6 Hz, H-1), 4.69 (d, 1H, J2”,3” = 3.9 Hz, H-
2”), 4.81 (s, 1H, H-1”), 4.96 (d, 1H, H-1’), 5.12 (dd, 1H, J4”,5” = 10.1 Hz, H-4’’) ppm; 
13
C 
NMR (150 MHz, CD3OD): δ, 16.8, 17.0, 21.1, 22.8, 22.9, 23.5, 49.3, 50.0, 50.7, 55.7, 
57.7, 67.5, 67.8, 69.1, 70.3, 72.8, 74.6, 75.8, 76.5, 81.0, 96.3, 100.4, 100.7, 171.9, 173.4, 
173.8, 174.7, 175.9 ppm; HR-FAB MS [M-H+2Na]
+
 calcd for C28H44O16N3Na2 
724.2517, found 724.2524. 
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 is one of the most frequent causes of infections in 
newborns, surgical patients, and immunocompromised individuals.
2
 The majority of S. 
aureus strains express either capsular polysaccharide type 5 (CP5) or type 8 (CP8), which 
coat the cell for the purpose of immune evasion and define its serotype.
3
 These 
polysaccharides are comprised of many repeats of a unique arrangement of 
monosaccharides (the repeat unit) specific to a given bacterial serotype.  The chemical 
composition of both types has been established
4
 and chemical syntheses of trisaccharides 
related to CP5
5-6
 and CP8 have been reported.
7
 The trisaccharide repeating unit of CP5 
consists of the terminal D-mannosamine uronic acid (ManNAcA) that is β-(14)-linked 
to 2,3-di-N,O-acetylated L-fucosamine (3Ac-L-FucNAc, Figure 3.1). The latter is α-
(13)-linked to D-fucosamine (D-FucNAc). In the bacterial polysaccharide, D-FucNAc 
is then linked to another D-ManNAcA via β-(14) linkage, etc.
4
 Though this is a natural 
product, chemical syntheses of CP5 have been achieved by targeting a trisaccharide 
repeating unit equipped with the conjugation amenable spacer group at the reducing end 
(Scheme 3.1).
5,6
  Each building block required total synthesis from common sugars as the 
monosaccharide components are not available commercially. 
Conjugates of the purified native S. aureus capsular polysaccharides (CPs) 
derived from fermentation with two different protein carriers have been tested in human 
clinical trials.
8-9
 Fattom, et al. reported on the preparation of conjugates of CP5 and CP8 
with Pseudomonas aeruginosa endotoxin A (ETA).
10
  Freese et al. reported the 
preparation of conjugates of CP5 and CP8 with cross-reacting material 197 (CRM197).
11
 
Covalent bond formation between native CPs and protein carriers requires chemically 
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mediated activation of the CPs, and in some instances the protein carrier. The reagents 
used to activate the polysaccharides in the aforementioned CP5 and CP8 conjugates 
included 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), carbonyldiimidazole 
(CDI), and carbonylditriazole (CDT). 




Characterization of activation products derived from purified native CPs by 
spectroscopic methods is very difficult owing to their large size (MW > 50 kDa). Over 
activation and side reactions can lead to a loss of the epitopes required for 
immunogenicity of CP conjugate vaccines leading to product failure. The study of small 
model compounds based on the structure of the repeat unit offers a means to fully 
characterize the structure of the activated CP, identify and quantify sites of activation, 
and understand side reactions occurring after CP activation. Reported herein is the 
synthesis of the trisaccharide T2 that on one hand mimics the repeat unit of CP5, and on 
the other hand preserves the potential conjugation sites as in the native polysaccharide. 
For this purpose, trisaccharide T2 will be equipped with capping methyl groups at the 
points of propagation of the polysaccharide sequence, C-1 and C-4” (Scheme 3.2).   
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Scheme 3.2. Retrosynthetic analysis of S. aureus type 5 for the CDT activation 
studies. 
 
It should be noted that although the direct introduction of the β-manno linkage 
was proven feasible by Boons et al.,
6
 it was rather ineffective in our hands. We relate this 
disappointing result to a fairly low reactivity profile of 4,6-acetalated mannosyl donors 
tested and 3-O-acetylated L-fucosyl acceptor 3.4. Instead, β-glycosylation with S-
benzoxazolyl (SBox) glycosyl donor 3.3 followed by the C-2 epimerization, an approach 
executed in our previous synthesis of CP8, was adopted instead.
7
  
The SBox leaving group
12-13
 gave us far superior results in activation over O-
pentenyl moiety of acceptor 3.4 than SEt. The activation of the SEt group over the O-
pentenyl moiety is also feasible, but it requires the use of MeOTf as promoter,
14
 which in 
this case was ineffective due to the disarming protecting group pattern of the donor. 
Protecting groups in building blocks 3.3, 3.4 and 3.9 were selected to ensure both 
selective deprotection for site-specific functionalization and the survival of the base-
labile O-acetyl group that needs to be retained throughout the entire synthesis. The 
levulinoyl group was selected at C-2 of donor 3.3 for two reasons: first, to assist in β-
glucosylation, and second, to give access to selective deprotection followed by 
epimerization at the disaccharide level. p-Methoxybenzylidene was found suitable for 
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gaining the ready access to the 4”-O-methylation position via the reductive opening at the 
trisaccharide level. The resulting 6”-O-p-methoxybenzyl group would then provide 
straightforward access to 6”-OH to be oxidized at the later stage of the synthesis. Finally, 
benzyl and azide protecting groups were found suitable for temporary protection of the 
remaining O- and N-positions because their removal would not affect 3’-O-acetyl group. 
 
3.2 Results and Discussion 
In accordance with our strategic plan the synthesis of glucosyl donor 3.3 began 
from known thioglycoside 3.1.
15
 (Scheme 3.3) Accordingly, the 2-hydroxyl derivative 3.1 
was reacted with levulinic acid (LevOH), dicyclohexycarbodiimide (DCC) and 4-
dimethylaminopyridine (DMAP) to afford 2-levulinoyl derivative 3.2 in 94% yield 
(Scheme 3.3). Reaction of thioglycoside 3.2 with bromine followed by the introduction of 
the SBox leaving group with KSBox
12,16
 in the presence of 18-crown-6 in acetone yielded 
the first key building block, glycosyl donor 3.3 in 78% yield over two steps. The 
synthesis of L-fucosyl acceptor 3.4 was originated from the previously described O-
pentenyl glycoside 2.5a.
7
 Regioselective acetylation of the equatorial 3-hydroxyl in 3,4-
diol 2.5a with acetyl chloride in the presence of pyridine in CH2Cl2 at 0 °C gave the 
desired L-fucosyl acceptor 3.4 in 91% yield. Selective activation of the SBox leaving 
group in glycosyl donor 2 over the O-pentenyl anomeric moiety of glycosyl acceptor 3 
was achieved in the presence of silver trifluoromethanesulfonate (AgOTf). This 
glycosylation afforded the desired β-linked disaccharide 3.5 in 78% yield. 
Disaccharide 3.5 was then subjected to a three-step synthetic sequence to 
epimerize the C-2’ stereocenter of the non-reducing end monosaccharide in order to 
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create the desired D-manno configuration. As previously refined for the synthesis of CP8 
(Chapter 2), 2’-O-levulinoyl group in 3.5 was removed with NH2NH2-AcOH in methanol 
and dichloromethane (1/20, v/v) to afford intermediate 3.6 in 86% yield.  Sulfonation of 
2’-OH in compound 3.6 was affected with triflic anhydride in the presence of pyridine in 
dichloromethane at 0 °C. The resulting 2’-O-triflate was directly subjected to the 
nucleophilic displacement by reaction with sodium azide in DMF at 60 °C. As a result, 
disaccharide glycosyl donor 3.7 was isolated in 81% yield over two steps. The synthesis 
of the D-fucosyl acceptor 3.9 was originated from the previously described methyl 
fucoside 2.12b.
7
  The 3,4-diol in compound 2.12b was first protected as the benzylidene 
acetal upon treatment with dimethoxytoluene (DMT) in the presence of catalytic amount 
of camphorsulfonic acid (CSA) to afford compound 3.8 in 79% yield. Regioselective 
benzylidene ring opening in 3.8 was conducted with NaCNBH3 in the presence of 2M 
HCl in diethyl ether and THF and led to the desired D-fucosyl acceptor 3.9 in 87% yield. 
Glycosylation of acceptor 3.9 with disaccharide donor 3.7 involved activation of the O-
pentenyl leaving group with N-iodosuccinimide (NIS) and TfOH in the presence of 
molecular sieves (4 Å) in 1,2-dichloroethane at 0 °C. This approach allowed us to obtain 
the desired trisaccharide 3.10 as a pure α-anomer in 79% yield.  
With the key trisaccharide intermediate 3.10 in hand, we then endeavored to 
identify a series of protecting and functional group modifications to obtain the target 
trisaccharide T2. After thorough experimentation, the following reaction sequence was 
developed with the main goal to avoid a spontaneous C-2”,6” lactamization that was 
encountered when the carboxyl (or carboxylate) and amine functional groups were 
present concomitantly.  
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Scheme 3.3. Synthesis of CP5 repeating unit T2. 
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First, the 3”,4”-p-methoxybenzylidine acetal in 3.10 was regioselectively opened 
with NaCNBH3 in the presence of 2 M HCl in diethyl ether and THF. As a result, 6”-p-
methoxybenzyl protected trisaccharide 3.11 was obtained in 94% yield. The 4”-OH group 
in 3.11 was then methylated with MeI in the presence of silver(I) oxide in CH2Cl2 to 
yield compound 3.12 in 79% yield. The neutral reaction conditions for the methylation 
step were essential for the survivability of the 3’-O-acetyl group.  
After that, all three azide groups in trisaccharide 3.12 were reduced with propane-
1,3-dithiol and trimethylamine in wet pyridine.
17
 The resulting triamine was acetylated 
with Ac2O in methanol to afford trisaccharide 3.13 in 91% yield over two steps. The 6”-
O-PMB protecting group in 3.13 was then removed with DDQ in wet CH2Cl2 to give 
trisaccharide 3.14 in 84% yield. The primary alcohol in 3.14 was oxidized to the 
carboxylic acid with (2,2,6,6-tetramethyl-piperidin-1-yl)oxyl (TEMPO) and 
(diacetoxyiodo)benzene (BAIB) in wet dichloromethane
18
 and the remaining 3”- and 4-
O-benzyl groups were removed by hydrogenation in the presence of 10% palladium on 
charcoal in wet ethanol to obtain the target trisaccharide T2 in 73% yield over two steps. 
 
3.3 Conclusions and Outlook 
As a result of the elaborated synthetic strategy, we accomplished an efficient 
synthesis of CP5, trisaccharide T2. The developed strategy allowed assembly of the key 
trisaccharide intermediate 3.10 from building blocks 3.3, 3.4 and 3.9 with an overall 43% 
yield. It should be noted that this yield presents a notable improvement over the assembly 
stage of the synthesis reported by Adamo and co-workers (28%) employing a similar 
concept of the indirect ManNAc introduction via β-glycosylation-epimerization. Our 
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assembly was at least as efficient as the assembly stage reported by Boons and co-
workers, who employed a direct mannosylation approach (total yield for the assembly 
stage 42%). The protecting group strategy for selective functionalization employed in our 
synthesis allowed for an efficient modification of the key intermediate 3.10 into the target 
compound T2. This sequence was accomplished in an overall 41% yield, which surpasses 
the yields of the deprotection-functionalization sequences achieved by Adamo (26%) and 
Boons (21%). This synthesis provided tool compounds useful for understanding chemical 
activation of native CP5 and the propensity for side reactions.  This research represents a 
novel approach to the synthesis of conjugation amenable repeating units designed to 
increasing process and product understanding of conjugate vaccines. 
 
3.4 Experimental 
3.4.1 General Methods  
The reactions were performed using commercial reagents and the ACS grade solvents 
were purified and dried according to standard procedures.  Column chromatography was 
performed on silica gel 60 (70-230 mesh), reactions were monitored by TLC on Kieselgel 
60 F254. The compounds were detected by examination under UV light and by charring 
with 10% sulfuric acid in methanol. Solvents were removed under reduced pressure at 
<40 
o
C. CH2Cl2 and ClCH2CH2Cl were distilled from CaH2 directly prior to application. 
Molecular sieves (3Å), used for reactions, were crushed and activated in vacuo at 390 °C 
during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to application. 
AgOTf was co-evaporated with toluene (3 x 10 mL) and dried in vacuo for 2-3 h directly 
prior to application. Optical rotations were measured at polarimeter. 
1
H NMR spectra 
Satsawat Visansirikul | UMSL 2018 | Page  71 
 
were recorded at 300 MHz or 600 MHz, 
13
C-NMR spectra were recorded at 75 MHz or 
150 MHz. The 
1
H chemical shifts are referenced to the signal of the residual CHCl3 (δH = 
7.24 ppm) for solutions in CDCl3 or the signal of the residual CH3OH (δH = 4.78 ppm) for 
solutions in CD3OD. The 
13
C chemical shifts are referenced to the central signal of 
CDCl3 (δC = 77.23 ppm) for solutions in CDCl3 or the central signal of CD3OD (δC = 
49.24 ppm) for solutions in CD3OD. HRMS determinations were made with the use of 
JEOL MStation (JMS-700) mass spectrometer. 
 
3.4.2 Preparation of monosaccharide building blocks 3.3, 3.4 and 3.9. 
Ethyl 3-O-benzyl-2-O-levulinoyl-4,6-O-(p-methoxybenzylidene)-1-thio-β-D-
glucopyranoside (3.2).  Levulinic acid (1.10 g, 9.23 mmol), DCC (1.77 g, 8.58 mmol) 
and DMAP (0.11 g, 0.92 mmol) were added to a stirring solution of ethyl 3-O-benzyl-
4,6-O-(p-methoxybenzylidene)-1-thio-β-D-glucopyranoside
15
 (3.1, 2.0 g, 4.62 mmol) in 
CH2Cl2 (60 mL) and the resulting mixture was stirred for 1 h at rt. After that, the reaction 
mixture was diluted with CH2Cl2 (~200 mL) and washed with sat. aq. NaHCO3 (50 mL) 
and water (2 x 50 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) to afford the title compound as a white 
amorphous solid in 94% yield (2.31 g, 4.35 mmol). Analytical data for 3.2: Rf = 0.43 
(ethyl acetate/hexane, 2/3, v/v); []D
24
 -46.1 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.24 (t, 3H, J = 7.5 Hz, CH2CH3), 2.15 (s, 3H, COCH3), 2.45-2.55 (m, 2H, 
COCH2), 2.55-2.80 (m, 4H, SCH2CH3,  COCH2), 3.46 (m, 1H, H-5), 3.65-3.75 (m, 3H, 
H-3, 4, 6a), 3.79 (s, 3H, OCH3), 4.32 (dd, 1H, J5,6b = 4.9 Hz, J6a,6b = 10.4 Hz, H-6b), 4.44 
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(d, 1H, J1,2 = 10.1 Hz, H-1), 4.78 (dd, 2H, 
2
J = 12.0 Hz, CH2Ph), 5.04 (dd, 1H, J2,3 = 8.9 
Hz, H-2), 5.52 (s, 1H, >CHPh), 6.80-7.50 (m, 9H, aromatic) ppm; 
13
C NMR (75 MHz, 
CDCl3): δ, 14.9, 24.0, 28.0, 29.9, 37.9, 55.3, 68.5, 70.7, 71.7, 74.3, 79.6, 81.4, 84.2, 
101.2, 113.7 (x 2), 127.4 (x 2), 127.7, 128.0 (x 2), 128.3 (x 2), 129.7, 138.3, 160.1, 171.5, 
206.2 ppm; HR-FAB MS [M+Na]
+
 calcd for C28H34NaO8S 553.1872, found 553.1875. 
 
Benzoxazolyl 3-O-benzyl-2-O-levulinoyl-4,6-O-(p-methoxybenzylidene)-1-thio-β-D-
glucopyranoside (3.3).  A mixture of 3.2 (2.30 g, 4.34 mmol) and activated molecular 
sieves (3Å, 2.1 g) in CH2Cl2 (70 mL) was stirred under argon for 1 h. Freshly prepared 
solution of Br2 in CH2Cl2 (45 mL, 1/165, v/v) was then added and the reaction mixture 
was kept for 10 min at rt. After that, the solid was filtered-off and the filtrate was 
concentrated under reduced pressure at rt and then dried in vacuo for 2 h. The crude 
residue was then dissolved in dry acetone (30 mL), KSBox
19
 (1.64 g, 8.67 mmol) and 18-
crown-6 (0.23 g, 0.87 mmol) were added and the resulting mixture was stirred for 1 h 
under argon at rt. After that, the reaction mixture was concentrated under reduced 
pressure. The residue was redissolved in CH2Cl2 (250 mL), washed with 1% aq. NaOH 
(50 mL) and water (3x 50 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane graduate elution) to afford the title compound in 78% yield (2.10 
g, 3.39 mmol) as a white foam. Analytical data for 3.3: Rf = 0.46 (ethyl acetate/hexane, 
2/3, v/v); []D
24
 +54.3 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 2.11 (s, 3H, 
COCH3), 2.35-2.58 (m, 2H, COCH2), 2.60-2.80 (m, 2H, COCH2), 3.60-3.90 (m, 7H, H-3, 
4, 5, 6a, OCH3), 4.37 (dd, 1H, J5,6a = 3.8 Hz, J6a,6b = 9.4 Hz, H-6b), 4.81 (dd, 2H, 
2
J = 
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11.9 Hz, CH2Ph), 5.24 (dd, 1H, J2,3 = 8.2 Hz, H-2), 5.55 (s, 1H, >CHPh), 5.67 (d, 1H, J1,2 
= 10.4 Hz, H-1), 7.80-7.70 (m, 13H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ 28.0, 
30.0, 37.9, 55.5, 68.5, 71.1, 71.5, 74.6, 79.5, 81.2, 84.3, 101.5, 110.3, 113.8 (x 2), 119.1, 
124.7 (x 2), 127.5 (x 2), 127.9, 128.2 (x 2), 128.5 (x 2), 129.7, 138.1, 141.7, 152.1, 160.3, 
161.4, 171.7, 206.0 ppm; HR-FAB MS [M+Na]
+
 calcd for C33H33NaNO9S 642.1774, 
found 642.1781. 
 
4-Pentenyl 3-O-acetyl-2-azido-2,6-dideoxy-α-L-galactopyranoside (3.4). 4-Pentenyl 2-
azido-2-deoxy-α-L-fucopyranoside
7
 (2.5a, 1.50 g, 5.83 mmol) in pyridine (23 mL) was 
stirred under argon at -40 
o
C. A solution of acetyl chloride (0.43 ml, 6.07 mmol) in dry 
toluene (6.3 mL) was then added dropwise and the resulting mixture was stirred at -40 
o
C 
for 30 min. Then, the temperature was gradually increased to 0 
o
C and the reaction 
mixture was stirred for additional 4 h. The reaction mixture was diluted with CH2Cl2 (250 
mL) and the organic layer was washed with water (50 mL), saturated aq. NaHCO3 (50 
mL), and water (2 x 50 mL). The organic phase was separated, dried and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (acetone - 
dichloromethane gradient elution) to yield the title compound as a white amorphous solid 
in 91% yield (1.59 g, 5.31 mmol). Analytical data for 3.4: Rf  = 0.51 (acetone/ 
dichloromethane, 1/9, v/v); []D
30
 -134.3 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 
1.20 (d, 3H, CH3), 1.63-1.72 (m, 2H, CH2), 2.07-2.15 (m, 2H, CH2), 2.12 (s, 3H, 
COCH3), 2.53 (s, 1H, OH), 3.39-3.46 (m, 1H, CH2), 3.57 (dd, 1H, J2,3 = 11.1 Hz, H-2), 
3.62-3.70 (m, 1H, CH2), 3.88 (br. s, 1H, H-4), 3.97-4.04 (dd, 1H, J5,6 = 6.6 Hz, H-5), 4.86 
(d, 1H, J1,2 = 3.6 Hz, H-1), 4.90-5.02 (m, 2H, CH=CH2), 5.22 (dd, 1H, J3,4 = 3.0 Hz, H-
Satsawat Visansirikul | UMSL 2018 | Page  74 
 
3), 5.69-5.78 (m, 1H, CH=CH2) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.0, 21.0, 28.6, 
30.2, 57.1, 65.7, 67.8, 70.0, 71.2, 98.2, 115.1, 137.9, 170.3 ppm; HR-FAB MS [M+Na]
+
 
calcd for C13H21O5NaN3 322.1379, found 322.1375. 
 
Methyl 2-azido-3,4-O-benzylidene-2,6-dideoxy-β-D-galactopyranoside (3.8).  
Dimethoxytoluene (1.38 mL, 9.15 mmol) and camphorsulfonic acid (58 mg, 0.031 mmol) 
were added to a solution of methyl 2-azido-2-deoxy-β-D-fucopyranoside
7
 (2.12b, 0.62 g, 
3.05 mmol) in THF (20 mL) and the resulting mixture was stirred under argon for 1 h at 
rt. After that, triethylamine (~0.3 mL) was added and the volatiles were removed in 
vacuo. The residue was diluted with CH2Cl2 (~200 mL) and washed with water (40 mL), 
sat. aq. NaHCO3 (40 mL), and water (2 x 40 mL). The organic phase was separated, dried 
with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield the title 
compound as a white amorphous solid in 79% yield (0.70 g, 2.41 mmol). Analytical data 
for 3.8: Rf = 0.46 (ethyl acetate/hexane, 2/3, v/v); []D
27
 +44.2 (c = 1, CHCl3); 
1
H NMR 
(300 MHz, CDCl3): δ, 1.46 (d, 3H, J5,6 = 6.6 Hz, C-6), 3.37 (dd, 1H, J2,3 = 8.2 Hz, H-2), 
3.53 (s, 3H, OCH3), 3.85 (m, 1H, H-5), 3.96 (dd, 1H, J4,5 = 5.7 Hz, H-4), 4.02 (dd, 1H, 
J3,4 = 2.1 Hz, H-3), 4.12 (d, 1H, J1,2 = 8.6 Hz, H-1), 5.91 (s, 1H, >CHPh), 7.25-7.62 (m, 
5H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.5, 56.8, 65.5, 68.8, 76.8, 78.0, 
102.5, 104.5, 126.6 (x 2), 128.5 (x 2), 129.5, 137.2 ppm; HR-FAB MS [M+Na]
+
 calcd for 
C14H17O4NaN3 314.1117, found 314.1123. 
 
Satsawat Visansirikul | UMSL 2018 | Page  75 
 
Methyl 2-azido-4-O-benzyl-2,6-dideoxy-β-D-galactopyranoside (3.9).  A mixture of 
3.8 (0.70 g, 2.41 mmol) and activated molecular sieves (3Å, 800 mg) in THF (20 mL) 
was stirred under argon for 1 h at rt. NaCNBH3 (1.20 g, 19.3 mmol) was added followed 
by a dropwise addition of 2M HCl in diethyl ether (9.6 mL, 19.3 mmol) and the resulting 
mixture was stirred under argon for 1 h at rt. After that, the solids were filtered off and 
rinsed successively with CH2Cl2. The combined filtrate (~100 mL) was washed with 
water (20 mL), sat. aq. NaHCO3 (20 mL), and water (2 x 20 mL). The organic phase was 
separated, dried with MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield the 
title compound as a white amorphous solid in 87% (0.62 g, 2.10 mmol). Analytical data 
for 3.9: Rf = 0.39 (ethyl acetate/hexane, 2/3, v/v); []D
30
 +75.0 (c = 1, CHCl3); 
1
H NMR 
(300 MHz, CDCl3): δ, 1.33 (d, 3H, J5,6 = 6.5 Hz, C-6), 2.17 (m, 1H, OH), 3.40-3.60 (m, 
7H, H-2, 3, 4, 5, OCH3), 4.12 (d, 1H, J1,2 = 7.8 Hz, H-1), 4.77 (dd, 2H, 
2
J = 11.6 Hz, 
CH2Ph), 7.20-7.45 (m, 5H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 17.1, 57.1, 
64.8, 71.0, 73.2, 76.2, 78.7, 103.2, 114.2, 128.3 (x 2), 128.8 (x 2), 138.1 ppm; HR-FAB 
MS [M+Na]
+
 calcd for C14H19O4NaN3 316.1273, found 316.1274. 
 
3.4.3 Assembly of trisaccharide 3.10 from building blocks 3.3, 3.4 and 3.9. 
4-Pentenyl O-(3-O-benzyl-2-O-levulinoyl-4,6-O-p-methoxybenzylidene-β-D-
glucopyranosyl)-(14)-3-O-acetyl-2-azido-2,6-dideoxy-α-L-galactopyranoside (3.5).  
A mixture donor 3.3 (2.0 g, 3.23 mmol), glycosyl acceptor 3.4 (0.74 g, 2.48 mmol), and 
freshly activated molecular sieves (3Å, 2.8 g) in ClCH2CH2Cl (60 mL) was stirred under 
argon for 2 h. Freshly conditioned AgOTf (1.66 g, 6.46 mmol) was added and the 
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resulting mixture was stirred for 1 h at rt. The reaction mixture was then diluted with 
CH2Cl2, the solid was filtered-off, and the residue was rinsed successively with CH2Cl2. 
The combined filtrate (~200 mL) was washed with sat. aq. NaHCO3 (40 mL) and water 
(2 x 40 mL). The organic phase was separated, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate - 
hexane gradient elution) to afford the title compound as a white foam in 78% yield (1.48 
g, 1.93 mmol). Analytical data for 3.5: Rf = 0.47 (ethyl acetate/hexane, 1/1, v/v); []D
24
 -
110.2 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.18 (d, 3H, J5,6 = 6.6 Hz, C-6), 
1.70 (m, 2H, CH2), 1.95- 2.20 (m, 8H, 2 x COCH3, CH2), 2.35-2.90 (m, 4H, 
COCH2CH2CO), 3.25-3.50 (m, 2H, H-5’, OCH2
a
), 3.55-3.80 (m, 5H, H-2, 3’, 4’, 6a’, 
OCH2
b
), 3.82 (s, 3H, OCH3), 3.95 (m, 1H, H-5), 4.06 (d, 1H, J4,5 = 3.0 Hz, H-4), 4.29 
(dd, 1H, J5’,6b’ = 4.9 Hz, J6a’,6b’ = 10.2 Hz, H-6b’), 4.40 (d, 1H, J1’,2’ = 8.0 Hz, H-1’), 4.78 
(dd, 2H, 
2
J = 12.1 Hz, CH2Ph), 4.81 (d, 1H, J1,2 = 3.6 Hz, H-1), 4.90-5.05 (m, 4H, H-2’, 
3, CH=CH2), 5.11 (dd, 1H, J3,4 = 8.6 Hz, H-3), 5.52 (s, 1H, >CHPh), 5.80 (m, 1H, 
CH=CH2), 6.75-7.50 (m, 9H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.2, 21.4, 
28.1, 28.7, 30.0, 30.4, 38.2, 55.5, 57.1, 65.5, 66.5, 67.8, 68.6, 70.6, 73.4, 74.2, 76.1, 78.3, 
81.7, 98.0, 101.5, 102.2, 113.8 (x2), 115.3, 127.5 (x2), 127.8, 128.1 (x 2), 128.4 (x 2), 
129.6, 138.1, 138.4, 160.3, 170.6, 171.5, 206.4 ppm; HR-FAB MS [M+Na]
+
 calcd for 
C39H49NaO13N3 790.3163, found 790.3167. 
 
4-Pentenyl O-(3-O-benzyl-4,6-O-p-methoxybenzylidene-β-D-glucopyranosyl)-(14)-
3-O-acetyl-2-azido-2,6-dideoxy-α-L-galactopyranoside (3.6).  Hydrazine acetate (0.34 
g, 3.78 mmol) was added to a stirred solution of 3.5 (1.45 g, 1.89 mmol) in 
Satsawat Visansirikul | UMSL 2018 | Page  77 
 
CH2Cl2/methanol (20/1, v/v, 21 mL) and the resulting mixture was stirred for 16 h at rt. 
After that, the reaction mixture was diluted with CH2Cl2 (~200 mL) and washed with sat. 
aq. NaHCO3 (40 mL) and water (2 x 40 mL). The organic phase was separated, dried 
over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam in 86% yield (1.09 g, 1.62 mmol). Analytical data for 3.6: Rf 
= 0.54 (ethyl acetate/hexane, 1/1, v/v); []D
25
 -124.4 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.39 (d, 3H, J5,6 = 6.6 Hz, C-6), 1.55-1.85 (m, 2H, CH2), 2.07 (s, 3H, 
COCH3), 2.08-2.20 (m, 2H, CH2), 3.34 (m, 1H, H-5’), 3.44 (m, 2H, OCH2
a
), 3.55-3.75 
(m, 6H, H-2, 2’, 3’, 4’, 6a’, OCH2
b
), 3.78 (s, 3H, OCH3), 4.01 (m, 1H, H-5), 4.10 (d, 1H, 
J4,5 = 2.9 Hz, H-4), 4.25 (dd, 1H, J5’,6b’ = 4.7 Hz, J6a’,6b’ = 9.9 Hz, H-6b’), 4.32 (d, 1H, 
J1’,2’ = 6.9 Hz, H-1’), 4.85 (dd, 2H, 
2
J = 11.6 Hz, CH2Ph), 4.88 (d, 1H, J1,2 = 3.5 Hz, H-
1), 4.93-5.10 (m, 3H, H-3, CH=CH2), 5.49 (s, 1H, >CHPh), 5.78 (m, 1H, CH=CH2), 
6.80-7.50 (m, 9H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.1, 21.4, 28.7, 30.4, 
55.7, 57.3, 65.9, 66.5, 67.9, 68.7, 70.6, 74.6, 74.9, 76.8, 80.7, 81.4, 98.0, 101.4, 104.6, 
113.8 (x 2), 115.3, 127.5 (x 2), 127.9, 128.1 (x 2), 128.5 (x 2), 129.7, 138.0, 138.6, 160.2, 
170.5 ppm; HR-FAB MS [M+Na]
+




(3.7).  A solution of 3.6 (1.07 g, 1.60 mmol) in CH2Cl2 (40 mL) and pyridine (4 mL) was 
cooled to 0 
o
C. Trifluoromethanesulfonic anhydride (0.67 mL, 3.99 mmol) was slowly 
added and the resulting mixture was stirred for 4 h at 0 
o
C.  After that, the reaction was 
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quenched with ice-cold water (~10 mL). The mixture was diluted with CH2Cl2 (~150 
mL) and washed with cold sat. aq. NaHCO3 (20 mL) and cold water (2 x 20 mL), the 
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The crude 
residue was dissolved in DMF (5 mL), NaN3 (0.52 g, 7.99 mmol) was added and the 
resulting suspension was stirred for 3 h at 60 
o
C. After that, ethyl acetate (~100 mL) and 
water (~20 mL) were added. Organic phase was separated and washed with brine (2 x 20 
mL). Combined aqueous phase was extracted with ethyl acetate (3 x 60 mL). The 
combined organic phase was dried over MgSO4 and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (ethyl acetate - hexane gradient 
elution) to afford the title compound as a white foam in 81% (0.91 g, 1.29 mmol). 
Analytical data for 10: Rf = 0.59 (ethyl acetate/hexane, 2/3, v/v); []D
25
 -187.8 (c = 1, 
CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.19 (d, 3H, J5,6 = 6.6 Hz, C-6), 1.70 (m, 2H, 
CH2), 2.01-2.20 (m, 5H, COCH3, CH2), 3.22 (m, 1H, H-5’), 3.45 (m, 1H, CH2
a
), 3.58-
3.68 (m, 2H, H-3’,CH2
b
), 3.70-3.85 (m, 5H, H-2, 6a’, OCH3), 3.95 (dd, 1H, J4’,5’= 9.4 Hz, 
H-4’), 3.99 (m, 1H, H-5), 4.06 (d, 1H, J2’,3’ = 3.5 Hz, H-2’), 4.16 (d, 1H, J4,5 = 3.1 Hz, H-
4), 4.23 (dd, 1H, J5’,6a’ = 4.8 Hz, J6a’,6b’ = 10.2 Hz, H-6b’), 4.50 (s, 1H, H-1’), 4.77 (dd, 
2H, 
2
J = 12.4 Hz, CH2Ph), 4.85 (d, 1H, J1,2 = 3.2 Hz, H-1), 4.92-5.10 (m, 3H, H-3, 
CH=CH2), 5.51 (s, 1H, >CHPh), 5.78 (m, 1H, CH=CH2), 6.80-7.50 (m, 9H, aromatic) 
ppm; 
13
C NMR (75 MHz, CDCl3): δ 16.5, 21.4, 28.6, 30.3, 55.4, 57.0, 62.8, 65.3, 67.6, 
67.9, 68.3, 70.2, 73.0, 76.0, 76.5, 78.4, 98.0, 101.5, 101.7, 113.7 (x 2), 115.2, 127.4 (x 2), 
127.8 (x 2), 128.1, 128.6 (x 2), 129.7, 137.8, 138.0, 160.2, 170.7 ppm; HR-FAB MS 
[M+Na]
+
 calcd for C34H42NaO10N6 717.2860, found 717.2869. 
 




(13)-2-azido-4-O-benzyl-2,6-dideoxy-β-D-galactopyranoside (3.10).  A mixture 
donor 3.7 (0.90 g, 1.30 mmol), acceptor 3.9 (0.35 g, 1.18 mmol), and freshly activated 
molecular sieves (3Å, 800 mg) in ClCH2CH2Cl (30 mL) was stirred under argon for 2 h. 
The reaction mixture was cooled to 0 
o
C, NIS (0.58 g, 2.59 mmol) and TfOH (23 µL, 
0.26 mmol) were added and the resulting mixture was stirred for 1 h at 0 
o
C. After that, 
the solid was filtered-off and rinsed successively with CH2Cl2. The combined filtrate 
(~50 mL) was washed with 10% aq. Na2S2O3 (15 mL) and water (2 x 15 mL). The 
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (acetone - dichloromethane 
gradient elution) to afford the title compound as a white foam in 79% yield (0.85 g, 0.94 
mmol). Analytical data for 3.10: Rf = 0.49 (ethyl acetate/hexane, 1/1, v/v); []D
28
 -130.7 
(c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.13 (d, 3H, J5’,6’ = 6.5 Hz, C-6’), 1.32 
(d, 3H, J5,6 = 6.4 Hz, C-6), 2.14 (s, 3H, COCH3), 3.23 (m, 1H, H-5’’), 3.37-3.58 (m, 6H, 
H-3, 4, 5, OCH3), 3.65 (dd, 1H, J3”,4” = 9.6 Hz, H-3”), 3.74-3.91 (m, 7H, H-1, 2’, 5’, 6a”, 
OCH3), 3.97 (dd, 1H, J4”,5” = 9.2 Hz, H-4”), 4.06 (d, 1H, J2”,3” = 3.7 Hz, H-2”), 4.01-4.18 
(m, 2H, H-1, 4’), 4.25 (dd, 1H, J5’,6b’ = 4.8 Hz, J6a’,6b’ = 10.2 Hz, H-6b’), 4.50 (s, 1H, H-
1”), 4.65-4.78 (m, 2H, CH2Ph), 4.82-4.93 (m, 2H, CH2Ph), 5.03 (dd, 1H, J2’,3’ = 11.3 Hz, 
J3’,4’ = 3.1 Hz, H-3’), 5.31 (d, 1H, J1’,2’ = 3.7 Hz, H-1’), 5.54 (s, 1H, >CHPh), 6.80-7.50 
(m, 14H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ 16.6, 17.2, 21.4, 55.4, 56.8, 57.2, 
62.8, 63.8, 66.1, 67.6, 68.3, 69.8, 70.9, 73.0, 75.1, 75.9, 76.4, 78.1, 78.4, 79.1, 99.4, 
101.5, 101.8, 103.6, 113.7 (x 2), 127.5 (x 2), 127.9 (x 3), 128.0 (x 2), 128.1, 128.5 (x 2), 
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128.7 (x 2), 129.6, 137.8, 138.1, 160.2, 170.6 ppm; HR-FAB MS [M+Na]
+
 calcd for 
C43H51O13N9Na 924.3504, found 924.3512. 
 
3.4.4 Final functionalization of 3.10 into target trisaccharide T2. 
Methyl O-(2-azido-3-O-benzyl-2-deoxy-6-O-p-methoxybenzyl-β-D-
mannopyranosyl)-(14)-O-(3-O-acetyl-2-azido-2,6-dideoxy-α-L-galactopyranosyl)-
(13)-2-azido-4-O-benzyl-2,6-dideoxy-β-D-galactopyranoside (3.11).  A mixture of 
3.10 (0.81 g, 0.90 mmol) and activated molecular sieves (3Å, 1.50 g) in THF (32 mL) 
was stirred under argon for 1 h at rt. NaCNBH3 (0.45 g, 7.19 mmol) was added followed 
by a dropwise addition of 2M HCl in diethyl ether (2.7 mL, 5.4 mmol) and the resulting 
mixture was stirred under argon for 1 h at rt. After that, the solids were filtered off and 
rinsed successively with CH2Cl2. The combined filtrate (~200 mL) was washed with 
water (20 mL), sat. aq. NaHCO3 (20 mL), and water (2 x 20 mL). The organic phase was 
separated, dried with MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield the 
title compound as a white amorphous solid. Analytical data for 3.11: Rf = 0.56 
(acetone/dichloromethane, 1/19, v/v); []D
31
 -149.6 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ 1.04 (d, 3H, J5’,6’ = 6.5 Hz, C-6’), 1.24 (d, 3H, J5,6 = 6.3 Hz, C-6), 2.03 (s, 3H, 
COCH3), 2.68 (d, 1H, J = 2.1 Hz, 4”-OH), 3.19 (m, 1H, H-5’’), 3.28 (dd, 1H, J3”,4” = 9.1 
Hz, H-3”), 3.33-3.49 (m, 6H, H-3, 4, 5, OCH3), 3.58 (m, 2H, H-6a”, 6b”), 3.70 (s, 3H, 
OCH3), 3.71-3.82 (m, 4H, H-2, 2’, 4”, 5’), 3.91 (d, 1H, J2”,3” = 3.5 Hz, H-2”), 4.02-4.10 
(m, 2H, H-1, 4’), 4.34-4.41 (m, 3H, H-1”, CH2Ph), 4.55-4.70 (m, 3H, 1½ CH2Ph), 4.82 
(d, 1H, 
2
J = 11.6 Hz, ½ CH2Ph), 4.99 (dd, 1H, J2’,3’ = 11.3 Hz, J3’,4’ = 3.1 Hz, H-3’), 5.22 
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(d, 1H, J1’,2’ = 3.7 Hz, H-1’), 6.65-7.50 (m, 14H, aromatic) ppm; 
13
C NMR (75 MHz, 
CDCl3): δ 16.6, 17.1, 21.2, 55.4, 56.9, 57.1, 60.7, 63.9, 66.3, 68.2, 69.5, 69.8, 70.9, 72.1, 
73.4, 74.9, 75.1, 75.3, 78.1, 79.1, 79.8, 99.4, 100.8, 103.6, 114.0 (x2), 127.9, 128.0 (x4), 
128.3, 128.5 (x2), 128.8 (x2), 129.6 (x2), 129.7, 137.6, 138.1, 159.5, 170.8 ppm; HR-
FAB MS [M+Na]
+




(13)-2-azido-4-O-benzyl-2,6-dideoxy-β-D-galactopyranoside (3.12).  Silver oxide 
(1.95 g, 8.41 mmol) was added to a stirring solution of 3.11 (0.76 g, 0.84 mmol) and MeI 
(0.79 mL, 12.6 mmol) in DMF (5 mL) and the resulting mixture was stirred for 24 h at rt. 
After that, the solid was filtered-off and rinsed successively with CH2Cl2. The combined 
filtrate (~150 mL) and washed with sat. aq. NaHCO3 (20 mL) and water (2 x 20 mL). The 
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (ethyl acetate - hexane gradient 
elution) to afford the title compound as a white amorphous solid in 79% yield (0.61 g, 
0.66 mmol). Analytical data for 3.12: Rf = 0.62 (acetone/hexane, 1/1, v/v); []D
28
 -79.2 (c 
= 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.11 (d, 3H, J5’,6’ = 6.5 Hz, C-6’), 1.31 (d, 
3H, J5,6 = 6.4 Hz, C-6), 2.13 (s, 3H, COCH3), 3.17 (m, 1H, H-5’’), 3.37-3.58 (m, 16H, H-
3, 3”, 4, 4”, 5, 2 x OCH3), 3.60-3.65 (m, 2H, H-6a”, 6b”), 3.78 (s, 3H, OCH3), 3.80-3.92 
(m, 3H, H-2, 2’, 5’), 3.98 (d, 1H, J2”,3” = 3.5 Hz, H-2”), 4.09-4.18 (m, 2H, H-1, 4’), 4.40 
(s, 1H, H-1”), 4.47 (dd, 2H, 
2
J = 11.5 Hz, CH2Ph), 4.65-4.74 (m, 3H, 1½ CH2Ph), 4.90 
(d, 1H, 
2
J = 11.6 Hz, ½ CH2Ph), 5.07 (dd, 1H, J2’,3’ = 11.3 Hz, J3’,4’ = 3.1 Hz, H-3’), 5.30 
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(d, 1H, J1’,2’ = 3.6 Hz, H-1’), 6.75-7.50 (m, 14H, aromatic) ppm; 
13
C NMR (75 MHz, 
CDCl3): δ, 16.7, 17.2, 21.1, 31.0, 55.4, 56.9, 57.1, 61.1, 61.4, 63.9, 66.3, 68.7, 69.4, 70.9, 
72.1, 73.1, 75.1 (x 2), 75.8, 78.1, 79.1, 80.5, 99.5, 100.8, 103.6, 113.9 (x 2), 127.9 (x 3), 
128.1 (x 3), 128.6 (x 2), 128.7 (x 2), 129.6 (x 2), 130.0, 137.8, 138.1, 159.4, 171.1 ppm; 
HR-FAB MS [M+Na]
+





galactopyranoside (3.13).  Water (5.0 mL), triethylamine (4.0 mL), and 1,3-
propanedithiol (3.95 mL, 39.2 mmol) were added to a solution of trisaccharide 3.12 (0.60 
g, 0.65 mmol) in pyridine (15.0 mL) and the resulting mixture was stirred for 3 h at rt. 
After that, the reaction mixture was concentrated and dried in vacuo. The crude residue 
was dissolved in MeOH (5.0 mL), Ac2O (0.74 mL, 0.78 mmol) was added, and the 
resulting suspension was stirred under argon for 16 h at rt. The reaction mixture was then 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(methanol - dichloromethane gradient elution) to afford the title compound as a white 
foam in 91% (0.57 g, 0.59 mmol). Analytical data for 3.13: Rf = 0.52 
(methanol/dichloromethane, 1/9, v/v); []D
28
 -92.3 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.10 (d, 3H, J5’,6’ = 6.4 Hz, C-6’), 1.31 (d, 3H, J5,6 = 6.3 Hz, C-6), 1.92, 2.00, 
2.04, 2.16 (4s, 12H, 4 x COCH3), 3.17 (m, 1H, H-5’’), 3.30-3.83 (m, 16H, H-3, 3”, 4, 4”, 
5, 6a”, 6b”, 3 x OCH3), 3.85-4.05 (m, 2H, H-4’, 5’), 4.28-4.60 (m, 7H, H-1, 1’, 2, 2’, 1 ½ 
CH2Ph), 4.70-5.00 (m, 6H, H-1”, 2”, 3’, 1 ½ CH2Ph), 6.10 (d, 1H, J2’,NH = 9.3 Hz, 2’-
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NH), 6.84-6.88 (m, 2H, aromatic), 6.92 (d, 1H, J2”,NH = 9.3 Hz, 2”-NH), 7.05 (d, 1H, J2,NH 
= 9.3 Hz, 2-NH), 7.18-7.50 (m, 12H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 
16.5, 17.2, 20.9, 21.1, 23.3, 23.4, 23.6, 46.2, 49.7, 51.5, 55.4 (x2), 56.0, 61.0, 67.0, 67.9, 
70.7, 70.9, 71.2, 73.2, 74.7, 75.1, 75.6, 78.3, 80.9, 99.7, 100.0, 101.7, 113.9 (x 2), 127.4 
(x 2), 127.6, 127.7, 128.2 (x 2), 128.4 (x 2), 128.5 (x 2), 129.4, 129.9 (x 2), 138.3, 138.5, 
159.5, 171.2 (x 2), 172.0, 172.5 ppm; HR-FAB MS [M+Na]
+
 calcd for C50H67O16N3Na 




acetamido-4-O-benzyl-2,6-dideoxy-β-D-galactopyranoside (3.14).  2,3-Dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ, 0.27 g, 1.18 mmol) was added to a mixture of 3.13 
(0.57 g, 0.59 mmol) in CH2Cl2 (10.0 mL) and water (0.5 mL) and the resulting mixture 
was stirred for 6 h at rt. After that, the reaction mixture was diluted with CH2Cl2 (~150 
mL) and washed with water (2 x 20 mL), the organic phase was separated, dried over 
MgSO4, and the reaction mixture was concentrated in vacuo. Then the residue was 
purified by column chromatography on silica gel (methanol - dichloromethane gradient 
elution) to afford the title compound as a white amorphous solid in 84% yield (0.42 g, 
0.50). Analytical data for 3.14: Rf = 0.36 (methanol/dichloromethane, 1/9, v/v); []D
26
 -
90.9 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.10 (d, 3H, J5’,6’ = 6.4 Hz, C-6’), 
1.40 (d, 3H, J5,6 = 6.5 Hz, C-6), 1.94, 2.03, 2.10, 2.11 (4s, 12H, 4 x COCH3), 3.10-3.25 
(m, 2H, H-4”, 5’’), 3.38-3.60 (m, 8H, H-3”, 4, 2 x OCH3), 3.61-4.00 (m, 6H, H-3, 4’, 5, 
5’, 6a”, 6b”), 4.25-4.40 (m, 2H, H-1, 2), 4.43-4.58 (m, 2H, H-1”, ½ CH2Ph), 4.67 (dd, 
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1H, J1’,2’ = 3.5 Hz, J2’,3’ = 11.4 Hz, H-2’), 4.70-5.00 (m, 6H, H-1’, 2”, 3’, 1 ½ CH2Ph), 
5.67 (d, 1H, J2,NH = 9.3 Hz, 2-NH), 6.29 (d, 1H, J2’,NH = 9.3 Hz, 2’-NH), 6.39 (d, 1H, 
J2”,NH = 9.3 Hz, 2”-NH), 7.20-7.50 (m, 10H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): 
δ 16.5, 17.3, 21.2, 23.3, 23.6 (x 2), 46.7, 49.9, 51.6, 55.9 (x 2), 61.1 (x 2), 61.8, 67.4, 
70.8, 71.2, 71.6, 74.6, 75.8, 77.4, 78.2, 80.7, 99.7, 100.1, 101.4, 127.5 (x 2), 127.7, 128.1 
(x 2), 128.5 (x 2), 128.6 (x 4), 138.2, 138.4, 171.4, 171.7, 171.8 ppm; HR-FAB MS 
[M+Na]
+




acetamido-4-O-benzyl-2,6-dideoxy-β-D-galactopyranoside (T2).  Water (4.0 mL), 
2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO, 11 mg, 0.07 mmol) and diacetoxy 
iodobenzene (BAIB, 295 mg, 0.92 mmol) were added to a solution of trisaccharide 3.14 
(310 mg, 0.37 mmol) in CH2Cl2 (4.0 mL) and the resulting mixture was stirred for 16 h at 
rt.  After that, the reaction mixture was passed through a pad of silica gel, concentrated in 
vacuo, and dried. The crude residue was dissolved in 90% aq. ethanol (5.0 mL), 10% Pd 
on activated charcoal (200 mg) was added and the resulting suspension was vigorously 
stirred under H2 atmosphere for 16 h at rt. After that, the solids were filtered off and 
rinsed successively with methanol. The combined filtrate (~35 mL) was concentrated in 
vacuo. The residue was purified by column chromatography on silica gel 
(dichloromethane - methanol gradient elution) to afford the title compound as a white 
amorphous solid in 73% yield (144 mg, 0.21 mmol). Analytical data for T2: Rf = 0.43 
(methanol/dichloromethane, 1/1, v/v); []D
25
 -75.6 (c = 0.6, CH3OH); 
1
H NMR (300 
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MHz, CD3OD): δ, 1.19 (d, 3H, J5’,6’ = 6.5 Hz, C-6’), 1.29 (d, 3H, J5,6 = 6.3 Hz, C-6), 
1.88, 1.93, 2.08, 2.11 (4s, 12H, 4 x COCH3), 3.27 (dd, 1H, J4”,5” = 9.7 Hz, H-4”), 3.42, 
3.48 (2s, 6H, 2 x OCH3), 3.45-3.52 (m, 3H, H-5”, 6a”, 6b”), 3.57-3.68 (m, 4H, H-3, 3’, 4, 
5), 4.00-4.08 (m, 2H, H-2, 4’), 4.12 (m, 1H, H-5’), 4.20 (dd, 1H, J1,2 = 8.4 Hz, H-1), 4.40 
(dd, 1H, J1’,2’ = 8.4 Hz, H-1’), 4.52 (s, 1H, H-1”), 4.56 (d, 1H, J2”,3” = 4.0 Hz, H-2”), 
4.82- 4.90 (m, 1H, H-1’), 4.98 (dd, 1H, J3’,4’ = 2.7 Hz, H-3’) ppm; 
13
C NMR (150 MHz, 
CD3OD):  δ, 16.9 (x 2), 21.5, 23.1, 23.3, 52.6, 54.7, 57.1 (x 2), 60.8 (x 2), 67.6, 71.1, 
71.9, 72.2, 73.8, 78.9, 79.1, 79.6, 81.7, 100.8, 102.2, 103.9, 173.2, 173.4, 173.7, 174.8, 
177.1 ppm; HR-FAB MS [M+Na]
+
 calcd for C28H45O16N3Na 702.2698, found 702.2695. 
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disaccharides between repeating units 
of capsular polysaccharides 
Staphylococcus aureus type 5 and 8 
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4.1 Introduction 
Staphylococcus aureus (S. aureus), a Gram-positive bacterium, is a major 
opportunistic pathogen known to cause infections in newborns and patients with chronic 
conditions such as diabetes and cancer.
1
 The emerging antibiotic resistance of the 
bacteria has seriously affected the global health system. Methicillin-resistant S. aureus 
(MRSA) strain is an example of a “superbug”, which shows resistance to several 
antibiotic drugs.
2
 Due to the continuous occurrences of drug resistance incidents, the 
development of new antibiotics is becoming less effective. Prophylaxis with active and 
passive immunization of patients has been emerging as a promising alternative to control 
and prevent infections caused by MRSAs.
3
 In particular, immunotherapies based on 
capsular polysaccharides of S. aureus have been proposed as promising targets for the 
development of glycoconjugate vaccines.
4
 
Capsular polysaccharides cover the outer part of S. aureus of which 13 serotypes 
have been described so far.
5
 A majority of S. aureus strains express capsular 
polysaccharide serotype 5 (CP5) and serotype 8 (CP8).
6
 Polysaccharides of these two 
serotypes have different sequences composed of the serotype-specific repeating units of 
trisaccharides. The chemical composition of these repeating units has been identified.
7-9
 
The trisaccharide repeating unit of CP5 consists of the terminal 2-N-acetyl-D-
mannosamine uronic acid (D-ManNAcA) residue, which is β-(14)-glycosidically 
linked to 2,3-di-N,O-acetyl-L-fucosamine (3Ac-L-FucNAc). In turn, the latter is 
connected to 2-N-acetyl-D-fucosamine (D-FucNAc) residue by a α-(13)-linkage. In the 
bacterial polysaccharide sequence, the D-FucNAc unit is then connected to another 
repeating unit via a β-(14) linkage to D-ManNAcA (Scheme 4.1). The CP8 
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trisaccharide repeating unit contains 2,4-di-N,O-acetyl-D-mannosamine uronic acid 
(4Ac-D-ManNAcA) residue, which is β-(13)-glycosidically linked to 2-N-acetyl-L-
fucosamine (L-FucNAc). In turn, the latter is connected a D-FucNAc residue by a α-
(13)-linkage. In the bacterial polysaccharide sequence, the D-FucNAc unit is then 
connected to another repeating unit via an α-(13)-linkage to D-ManNAcA (Scheme 
4.1).  




The chemical syntheses of both serotype-specific trisaccharide repeating units 
have been accomplished by several research groups. The CP5 trisaccharide synthesis has 
been achieved by Adamo in 2012,
10
 Boons in 2015,
11
 our group in 2016,
12
 and Codee in 
2017.
13
 All approaches except ours targeted the trisaccharide repeating unit equipped 
with the conjugation-amenable spacer group at the anomeric center of the reducing end 
(Scheme 4.2). The structure accomplished by Adamo included an aminopropyl spacer at 
the anomeric center,
10
 whereas both Boons and Codee installed an aminopentyl 
linker.
11,13
 Our target trisaccharide was designed to study its conjugation to the CRM197 
protein that takes place away from the terminus.
14
 Therefore methyl groups were 
introduced in our trisaccharide target at the points of propagation of the polysaccharide 
sequence (Scheme 4.2).  
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The CP8 trisaccharide synthesis has been achieved by our group in 2015
15
 and a 
partial sequence was reported by Codee in 2017
13
 (Scheme 4.3). Our target also included 
methyl groups at the points of propagation of the polysaccharide sequence.  





To gain a better understanding of the conjugation chemistry taking place at the 
interface of the trisaccharide repeating units we turned our attention to the synthesis of 
disaccharides D1 and D2 representing the connection between the repeating units of CP8 
and CP5, respectively (Scheme 4.4). Based on the structures of the disaccharide subunits, 
the CP8-derived disaccharide D1 consists of a D-FucNAc unit linked to 4-O-Ac-D-
ManNAcA via an α-(13)-glycosidic linkage. The CP5-derived disaccharide D2 
contains the same monosaccharide components, but they are connected via a β-(14)-
glycosidic linkage and lack an O-acetyl group. This Chapter describes the synthesis of 
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two disaccharides corresponding to the connection point of two repeating units of S. 
aureus CP5 and CP8. As in our previous syntheses of trisaccharide repeating units, the 
potential propagation positions will be blocked with methyl groups.  
Scheme 4.4. Structures of disaccharides D1 and D2 derived from the respective CPs. 
 
 
4.2   Results and Discussion 
4.2.1 Retrosynthetic analysis of disaccharides D1 and D2  
Although the disaccharide targets contain the same monosaccharide components, 
the retrosynthetic considerations to access each disaccharide differ. For instance, to 
control the stereoselectivity of α-glycosylation en route to D1, it is necessary to use a 
combination of the azido group at C-2 and a benzoyl group at C-4 of the D-fucosamine 
donor. Conversely, the use of 2-N-phthalimido group protection of the D-fucosamine 
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donor should be sufficient to ensure β-stereoselectivity for the synthesis of D2 due to the 
neighboring group participation. Mannosyl acceptors for the synthesis of D1 and D2 will 
also differ to reflect the differential connection and substitution pattern. For the synthesis 
of D1, we chose a 4,6-O-benzylidene ManNAc derivative and for D2 we decided to 
employ a 6-OBn protecting group that can provide a straightforward access to the 
primary hydroxyl group later in the synthesis (Scheme 4.5). For the synthesis of D1 and 
D2 disaccharides, we decided to synthesize D-fucosyl donor containing p-methoxyphenol 
(PMP) as the protecting group at the anomeric center which can be removed selectively 
by ceric ammonium nitrate (CAN)
16
 to install a suitable anomeric leaving group later in 
the synthesis. For the D-mannosamine acceptor synthesis, we decided to adapt the O-
trichloroacetimidoyl protecting group migration approach developed by van der Marel
17
 
for the one-pot intramolecular epimerization at C-2 to switch from the D-gluco to the D-
manno configuration.  
Scheme 4.5. Retrosynthetic considerations. 
 
 
4.2.2 Synthesis of D-fucosyl donors (4.7 and 4.14) 
The synthesis of D-fucosamine donor required for the assembly of D1 was 
originated from known galactosamine 4.1
18
 obtained from D-galactopyranose in eight 
steps. The methylation of compound 4.1 with methyl iodide in the presence of sodium 
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hydride yielded the methylated compound 4.2 in 89% yield (Scheme 4.6). Then, the 4,6-
O-benzylidene group of 4.2 was oxidatively opened by performing the Hanessian–Hullar 
reaction.
19
 This reaction proceeded smoothly in the presence of N-bromosuccinimide 
(NBS) and benzoyl peroxide in benzene at 85 
o
C to afford the kinetic product
20
 4.3 in 
85% yield.  
Scheme 4.6. Synthesis of fucosyl donor 4.7. 
 
 
After that, compound 4.3 was reduced with tributyl tin(IV) hydride (Bu3SnH) in 
the presence of benzoyl peroxide in benzene at 85 
o
C. Controlling the chemoselectivity of 
debromination versus the reduction of the azide group was proven challenging and as a 
result a mixture of 2-azido (4.4, 53% yield) and 2-amino (4.5, 44% yield) compounds 
was obtained. The compounds could easily be separated by column chromatography and 
the synthesis was continued with compound 4.4 isolated in 53% yield. p-Methoxyphenyl 
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(PMP) at the anomeric center was removed using ceric ammonium nitrate (CAN) to 
afford hemiacetal 4.6 in 63% yield. The latter was treated with trichloroacetonitrile in the 
presence of DBU to afford fucosyl donor 4.7 in 89% yield. 
For the synthesis of D-fucosamine donor required for the assembly of D2, a 
known galactosamine derivative 4.8
21
 was methylated with CH3I in the presence of NaH 
to afford compound 4.9 in 82% yield (Scheme 4.7). The latter was subjected to the 
Hanessian–Hullar reaction
19
 in the presence of NBS and benzoyl peroxide in benzene at 
85 
o
C to yield 6-bromo derivative 4.10 in 81% yield. Subsequent debromination and 
azide reduction were performed concomitantly in the presence of excess Bu3SnH and 
benzoyl peroxide in benzene at 85 
o
C to give mannosamine 4.11 in 87% yield.  
Scheme 4.7. Synthesis of D-fucosyl donor 4.13. 
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The amine group of 4.11 was then protected with phthalic anhydride in the 
presence of TEA. Subsequent acetylation with Ac2O in the presence of pyridine afforded 
compound 4.12 in 74% yield. After that, the PMP group was selectively removed with 
CAN in wet CH3CN to afford hemiacetal 4.13 in 94% yield. The latter was then reacted 
with trichloroacetonitrile in the presence of DBU to afford fucosyl donor 4.14 in 87% 
yield. 
 
4.2.3 Synthesis of D-mannosyl acceptors (4.17 and 4.18) 
The synthesis of D-mannosamine derivatives 4.17 and 4.18 was initiated by the 
selective introduction of the trichloroacetimidoyl group at C-3 of compound 4.15.
22
 As 
depicted in Scheme 4.8, this transformation was accomplished with trichloroacetonitrile 
(CCl3CN) in the presence of DBU in CH2Cl2, followed by the triflylation at 2-OH with 
triflic anhydride in the presence of pyridine at -30 
o
C. After that, N,N-
diisopropylethylamine (DIPEA) was added to enhance the stereocenter inversion at C-2 
to form 2,3-N,O-oxazoline intermediate 4.16 in 55% yield over three steps. The 
oxazoline ring was opened by the treatment with an aqueous sodium hydroxide in 
methanol at 60 
o
C. Subsequent N-acetylation with acetic anhydride (Ac2O) in methanol 
afforded compound 4.17 in 94% yield over two steps. Compound 4.17 will be used as the 
glycosyl acceptor for the synthesis of disaccharide D1.  
In addition, compound 4.17 was subjected to C-3 acetylation in the presence of 
Ac2O in pyridine, followed by selective benzylidene ring opening with sodium 
cyanoborohydride (NaCNBH3) in 2 M hydrogen chloride in diethyl ether in THF to 
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afford compound 4.18 in 97% yield over two steps. The latter compound will be used as 
the glycosyl acceptor for the synthesis of disaccharide D2. 
Scheme 4.8. Synthesis of D-mannosyl acceptors 4.17 and 4.18. 
 
 
4.2.4 The assembly and functionalization of CP8 disaccharide (D1) 
With fucosyl donor 4.7 and mannosyl acceptor 4.17 in hand, we performed the 
glycosylation reaction in the presence of trifluoromethanesulfonic acid (TfOH) as the 
promoter in CH2Cl2 to obtain disaccharide 4.19 in 65% yield with exclusive α-
stereoselectivity (Scheme 4.9). Debenzoylation with sodium methoxide (NaOMe) 
followed by the treatment with levulinic acid (LevOH) in the presence of N,N′-
diisopropylcarbodiimide (DIC) and 4-dimethylaminopyridine (DMAP) afforded 
disaccharide 4.20 in 89% yield over two steps. Then, the azide group in 4.20 was reduced 
with 1,3-propanedithiol in the presence of triethylamine (TEA) in wet pyridine. This was 
followed by acetylation with Ac2O in methanol to give disaccharide 4.21 in 96% yield 
over two steps. The latter was then subjected to the treatment with trifluoroacetic acid 
(TFA) in wet CH2Cl2 to acquire diol 4.22 in 81% yield. After that, the primary hydroxyl 
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was selectively oxidized with 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) and 
(diacetoxyiodo)benzene (BAIB) in wet CH2Cl2.  
Scheme 4.9. Assembly and functionalization of CP8 disaccharide D1. 
 
 
The resulting carboxyl group was protected as a benzyl carboxylate by reaction with 
benzyl bromide (BnBr) in the presence of NaHCO3 in DMF to afford disaccharide 4.23 in 
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76% yield over two steps. Then, the 4-OH group of compound 4.23 was acetylated with 
Ac2O in pyridine to give disaccharide 4.24 in 99% yield. Selective removal of the 
levulinoyl ester in 4.24 was accomplished in the presence of hydrazine acetate in 
methanol-CH2Cl2 in 96% yield. Finally, the benzyl ester was removed by hydrogenation 
with 10% palladium on charcoal in wet ethanol to afford the target disaccharide D1 in 
97% yield. 
 
4.2.5 The assembly and functionalization of CP5 disaccharide (D2) 
The assembly of CP5 disaccharide D2 began with the glycosylation between 
fucosyl donor 4.14 and mannosyl acceptor 4.18. This reaction was performed in the 
presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf) as the promoter in 
CH2Cl2 at 0 
o
C to afford disaccharide 4.26 in 65% yield (Scheme 4.10). Although the 2-
phthalimido group of fucosyl donor 4.14 had been installed to provide high β-
stereoselectivity of the glycosylation via neighboring group participation, a substantial 
amount of the α-anomer of 4.26 was also obtained (α/β = 1/5). This somewhat 
unexpected result could be rationalized by a double stereodifferentiation effect
23
 that 
might be taking place due to the 4-OBz group of fucosyl donor 4.14 and the bulky 
phthalimido group of the glycosyl acceptor. The phthalimide group in α,β-4.26 was 
removed in the presence of hydrazine hydrate in methanol at 80 
o
C. It was observed that 
all other ester groups were also removed. Therefore, the resulting compound was globally 
acetylated to afford disaccharide α,β-4.27 in 81% yield over two steps. Then, the benzyl 
ether at C-6 of compound 4.27 was removed by hydrogenation in the presence of 10% 
palladium on charcoal in wet ethanol. At this stage, the α,β-anomers were separated by 
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column chromatography to afford pure β-linked disaccharide 4.28 in 75% yield. The 
primary hydroxyl group of 4.28 was oxidized with TEMPO and BAIB in wet CH2Cl2 to 
acquire carboxylic acid 4.29 in 70% yield. Finally, O-acetates were removed with NaOH 
in aqueous methanol to afford the target disaccharide D2 in 84% yield (Scheme 4.10). 
Scheme 4.10. Assembly and functionalization of CP5 disaccharide D2. 
 
 
4.3 Conclusions and Outlook 
The synthesis of disaccharide connecting units of S. aureus CP5 and CP8 with 
methyl groups at the point of propagation of the polysaccharide sequence have been 
reported. These compounds will be used to study their conjugation to the carrier protein 
conjugation to understand the sites of activation for conjugation and side reactions that 
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can occur during the conjugation process. With better understanding of the activation and 
conjugation process, it will be possible to improve, control, predict and reliably 
reproduce the outcome of conjugation of large bacterial polysaccharides. In turn, these 




4.4.1 General Methods 
The reactions were performed using commercial reagents (Aldrich or Acros), and 
the ACS grade solvents were purified and dried according to standard procedures.  
Column chromatography was performed on silica gel 60 (EM Science, 70-230 mesh), 
reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). The compounds 
were detected by examination under UV light and by charring with 10% sulfuric acid in 
methanol. Solvents were removed under reduced pressure at <40 
o
C. CH2Cl2 and 
ClCH2CH2Cl were distilled from CaH2 directly prior to application. Molecular sieves (3 
Å or 4 Å), used for reactions, were crushed and activated in vacuo at 390 °C during 8 h in 
the first instance and then for 2-3 h at 390 °C directly prior to application. Optical 
rotations were measured on ‘Jasco P-2000’ polarimeter. 
1
H NMR spectra were recorded 
at 300 MHz (Bruker Avance) or 600 MHz (Agilent), 
13
C NMR spectra were recorded at 
75 MHz (Bruker Avance) or 150 MHz (Agilent). The 
1
H chemical shifts are referenced to 
the signal of the residual CHCl3 (δH = 7.27 ppm) for solutions in CDCl3 or the signal of 
the residual CH3OH (δH = 3.31 ppm) for solutions in CD3OD. The 
13
C chemical shifts are 
referenced to the central signal of CDCl3 (δC = 77.23 ppm) for solutions in CDCl3 or the 
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central signal of CD3OD (δC = 49.24 ppm) for solutions in CD3OD. HRMS 
determinations were made with the use of JEOL MStation (JMS-700) mass spectrometer. 
 
4.4.2 Synthesis of D-fucosyl donors 4.7 and 4.14 
4-Methoxyphenyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-methyl-α-D-
galactopyranoside (4.2).  Methyl iodide (1.75 g, 12.32 mmol) and sodium hydride (739 
mg, 18.48 mmol) were added to a stirring solution of 4-methoxyphenyl-2-azido-4,6-O-
benzylidene-2-deoxy-α-D-galactopyranoside (4.1,
18
 2.46 g, 6.16 mmol) in DMF (20 mL) 
at 0 
o
C. The reaction mixture was allowed to reach rt. After 1 h, the reaction mixture was 
poured into ice-water and the resulting mixture was stirred for 15 min. The aqueous 
phase was extracted with EtOAc/Et2O (1/1, v/v, 3 x 100 mL). The organic extracts were 
combined, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate – hexane gradient elution) to afford 
the title compound as a white amorphous solid (2.26 g, 89%). Analytical data for 4.2: Rf 
= 0.54 (ethyl acetate/hexane, 2/3, v/v); []D
22
 175.3 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 3.60, 3.78 (2 s, 6H, 2 x OCH3), 3.85 (br. s, 1H, H-5) 3.96-4.06 (m, 2H, J2,3 = 
10.7 Hz, , J3,4 = 2.3 Hz, H-2, 3), 4.08 (dd, 1H, J5,6a = 1.6 Hz, J6a,6b = 12.6 Hz, H-6a), 4.28 
(dd, 1H, J5,6b = 1.4 Hz, H-6b), 4.49 (dd, 1H, J4,5 = 2.1 Hz, H-4), 5.59 (d, 1H, J1,2 = 3.0 
Hz, H-1), 5.62 (s, 1H, >CHPh), 6.83 (d, 2H, J = 9.1 Hz, PMP), 7.05 (d, 2H, J = 9.1 Hz, 
PMP), 7.36-7.38 (m, 3H, aromatic), 7.52-7.55 (m, 2H, aromatic) ppm; 
13
C NMR (75 
MHz, CDCl3): δ, 55.8, 56.9, 58.6, 63.6, 69.5, 72.3, 76.0, 98.1, 101.2, 114.8 (x 2), 117.7 
(x 2), 126.4 (x 2), 128.4 (x 2), 129.2, 137.6, 150.7, 155.3 ppm; HR-FAB MS [M+Na]
+
 
calcd for C21H23N3O6 436.1484, found 436.1476. 




galactopyranoside (4.3). N-Bromosuccinimide (419 mg, 2.36 mmol) and benzoyl 
peroxide (29 mg, 0.12 mmol) were added to a solution of 4.2 (974 mg, 2.36 mmmol) in 
benzene (20 mL) and the resulting mixture was heated at reflux for 0.5 h. After that, the 
volatiles were removed in vacuo. The residue was diluted with CH2Cl2 (~150 mL) and 
washed with water (20 mL), 10% aq. Na2S2O3 (20 mL), and water (20 mL). The organic 
phase was separated, dried with MgSO4, and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) 
to yield the title compound as a white foam (990 mg, 85%). Analytical data for 4.3: Rf = 
0.64 (ethyl acetate/hexane, 2/3, v/v); []D
23
 174.8 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 3.39-3.42 (m, 2H, H-6a, 6b), 3.57 (s, 3H, OCH3), 3.78 (dd, 1H, J2,3 = 10.7 Hz, 
H-2), 3.80 (s, 3H, OCH3), 4.06 (dd, 1H, J3,4 = 2.2 Hz, H-3), 4.39-4.44 (m, 1H, H-5), 5.51 
(d, 1H, J1,2 = 3.5 Hz, H-1), 5.98 (dd, 1H, J4,5 = 2.1 Hz, H-4), 6.86 (d, 2H, J = 9.1 Hz, 
PMP), 7.11 (d, 2H, J = 9.1 Hz, PMP), 7.47-7.52 (m, 2H, aromatic), 7.59-7.65 (m, 1H, 
aromatic), 8.07-8.10 (m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 29.2, 55.8, 
57.8, 59.3, 67.1, 70.6, 76.5, 98.6, 114.9 (x 2), 118.6 (x 2), 128.8 (x 2), 129.3, 130.1 (x 2), 
133.8, 150.8, 155.8, 165.6 ppm; HR-FAB MS [M+Na]
+
 calcd for C21H22BrN3O6Na 
514.0590, found 514.0571. 
 
4-Methoxyphenyl 2-azido-4-O-benzoyl-2,6-dideoxy-3-O-methyl-α-D-
galactopyranoside (4.4) and 4-methoxyphenyl 2-amino-4-O-benzoyl-2,6-dideoxy-3-
O-methyl-α-D-galactopyranoside (4.5).  Tributyl tin hydride (2.46 mL, 9.14 mmol) and 
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benzoyl peroxide (123 mg, 0.38 mmol) were added to a solution of 4.3 (3.75 g, 7.62 
mmol) in benzene (50 mL) and the resulting mixture was heated at reflux for 3 h. After 
that, the volatiles were removed in vacuo. The residue was diluted with CH2Cl2 (~300 
mL) and washed with water (60 mL). The organic phase was separated, dried with 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - toluene gradient elution) to yield individual compounds 4.4 
(1.66 g, 53%) as a syrup and 4.5 (1.31 g, 44%) as a clear syrup. Analytical data for 4.4: 
Rf = 0.62 (ethyl acetate/hexane, 2/3, v/v); []D
22
 151.9 (c = 1, CHCl3); 
1
H NMR (300 
MHz, CDCl3): δ, 1.21 (d, 3H, H-6), 3.55 (s, 3H, OCH3), 3.79-3.85 (m, 4H, J2,3 = 10.7 Hz, 
OCH3, H-2), 4.06 (dd, 1H, J3,4 = 2.5 Hz, H-3), 4.32 (m, 1H, J5,6 = 6.5 Hz, H-5), 5.50 (d, 
1H, J1,2 = 3.5 Hz, H-1), 5.71 (dd, 1H, J4,5 = 2.5 Hz, H-4), 6.85 (d, 2H, J = 9.0 Hz, PMP), 
7.05 (d, 2H, J = 9.1 Hz, PMP), 7.46-7.51 (m, 2H, aromatic), 7.58-7.64 (m ,1H, aromatic), 
8.08-8.10 (m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.6, 55.8, 57.5, 59.3, 
66.3, 69.5, 76.6, 98.3, 114.9 (x 2), 118.2 (x 2), 128.7 (x 2), 129.7, 130.1 (x 2), 133.6, 
150.9, 155.5, 166.2 ppm; HR-FAB MS [M+Na]
+
 calcd for C21H23O6N3 436.1485, found 
436.1480. Analytical data for 4.5: Rf = 0.57 (methanol/dichloromethane, 1/9, v/v); []D
23
 
133.0 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.18 (d, 3H, H-6), 3.28 (dd, 1H, 
J2,3 = 10.3Hz, H-2), 3.47 (s, 3H, OCH3), 3.56 (dd, 1H, J3,4 = 2.2 Hz, H-3), 3.75 (s, 3H, 
OCH3), 4.26 (m, 1H, J5,6 = 6.5 Hz, H-5), 5.52 (d, 1H, J1,2 = 3.2 Hz, H-1), 5.61 (dd, 1H, 
J4,5 = 2.1 Hz, H-4), 6.82 (d, 2H, J = 9.1 Hz, PMP), 7.04 (d, 2H, J = 9.1 Hz, PMP), 7.41-
7.47 (m, 2H, aromatic), 7.53-7.58 (m ,1H, aromatic), 8.09-8.12 (m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.7, 51.3, 55.6, 57.4, 66.3, 69.0, 80.3, 99.8, 114.6 (x 2), 
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118.1 (x 2), 128.5 (x 2), 129.8, 129.9 (x 2), 133.3, 151.1 (x 2), 166.2 ppm; HR-FAB MS 
[M+Na]
+
 calcd for C21H25O6N3Na 410.1580, found 410.1578. 
 
2-Azido-4-O-benzoyl-2,6-dideoxy-3-O-methyl-D-galctopyranose (4.6). A solution of 
CAN (3.80 g, 6.89 mmol) in water (40 mL) was added dropwise to a stirring solution of 
4.4 (1.14 g, 2.76 mmol) in CH3CN (20 mL) at 0 
o
C. The reaction mixture was then 
allowed to reach rt. After 4 h, the volatiles were removed in vacuo. The residue was 
diluted with CH2Cl2 (~150 mL) and washed with water (2 x 30 mL). The organic phase 
was separated, dried with MgSO4, and concentrated in vacuo. The residue was purified 
by column chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield 
the title compound as a white amorphous solid (532 mg, 63%). Analytical data for 4.6: Rf 
= 0.50 (α-4.6), Rf = 0.38 (β-4.6, ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.19 (d, 3H, H-6α), 1.26 (d, 3H, H-6β), 3.30 (dd, 1H, J3β,4β = 3.33 Hz, H-3β), 
3.47 (m, 4H, OCH3, OHα), 3.49 (s, 3H, OCH3), 3.62 (dd, 1H, J2β,3β = 10.29 Hz, H-2β), 
3.74-3.84 (m ,2H, J2α,3α = 10.56 Hz, J5β,6β = 6.57 Hz, H-2α, 5β), 3.87 (dd, 1H, J3α,4α = 
3.15 Hz, H-3α) , 4.09 (d, 1H, OHβ), 4.37 (m, 1H, J5α,6α = 6.57 Hz, H-5α), 4.62 (dd, 1H, 
J1β,2β = 13.08 Hz, H-1β), 5.37 (dd, 1H, J1α,2α = 2.73 Hz, H-1α), 5.53 (dd, 1H, J4β,5β = 2.79 
Hz, H-4β), 5.62 (dd, 1H, J4α,5α = 2.19 Hz, H-4α), 7.44-7.57 (m, 4H, aromatic), 7.57-7.62 
(m, 2H, aromatic), 8.08-8.09 (m, 4H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3) α-4.6: 
δ, 16.6, 57.5, 60.0, 65.5, 69.6, 77.1, 92.5, 128.7 (x 2), 129.7, 130.1 (x 2), 133.6, 166.3 
ppm; β-4.6: δ, 16.7, 58.0, 64.0, 68.5, 70.0, 80.9, 96.3, 128.7 (x 2), 129.5, 130.2 (x 2), 
133.7, 166.3 ppm; HR-FAB MS [M+H]
+
 calcd for C14H18O5N3 308.1246, found 
308.1268. 




trichloroacetimidate (4.7) To the solution of 4.6 (339 mg, 1.10 mmol) in dry CH2Cl2 (10 
mL), trichloroacetonitrile (1.59 g, 11.03 mmol) and DBU (84 mg, 0.55 mmol) were 
added at rt and the resulting mixture was stirred for 30 min under argon. After that, the 
reaction was concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - hexane gradient elution) to yield the title compound as a 
white foam (440 mg, 89%). Analytical data for 4.7: Rf = 0.71 (ethyl acetate/hexane, 2/3, 
v/v); []D
22
 126.2 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.24 (d, 3H, H-6), 3.53 
(s, 3H, OCH3), 3.91-4.01 (m, 2H, J3,4 = 2.8 Hz, H-2, 3), 4.32 (m, 1H, J5,6 = 6.5 Hz, H-5), 
5.71 (dd, 1H, J4,5 = 1.2 Hz, H-4), 6.44 (d, 1H, J1,2 = 3.1 Hz, H-1), 7.47-7.57 (m, 2H, 
aromatic), 7.59-7.65 (m ,1H, aromatic), 8.08-8.12 (m, 2H, aromatic) ppm; 
13
C NMR (75 
MHz, CDCl3): δ, 16.6, 57.5, 58.8, 68.3, 70.0, 76.9, 91.2, 95.4, 128.8 (x 2), 129.5, 130.1 
(x 2), 133.7, 161.0. 166.1 ppm; HR-FAB MS [M+Na]
+
 calcd for C16H17O5 N4Cl3Na 
473.0162, found 473.0126. 
 
4-Methoxyphenyl 2-azido-4,6-O-benzylidene-2-deoxy-3-O-methyl-β-D-
galactopyranoside (4.9).  Methyl iodide (1.41 g, 9.91 mmol) and sodium hydride (595 
mg, 14.88 mmol) were added to a stirring solution of 4-methoxyphenyl-2-azido-4,6-O-
benzylidene-2-deoxy-β-D-galactopyranoside
21
 (4.8, 1.98 g, 4.96 mmol) in DMF (20 mL) 
at 0 
o
C. The reaction was allowed to reach rt. After 1 h, the reaction was poured into ice 
water and was stirred for 15 min. Then, the aqueous phase was extracted with 
EtOAc/Et2O (1/1, v/v, 3 x 150 mL). The organic phase was collected, dried over MgSO4, 
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and concentrated in vacuo. The residue was purified by column chromatography on silica 
gel (ethyl acetate – hexane gradient elution) to afford the title compound as a white 
amorphous solid (1.69 g, 82%). Analytical data for 4.9: Rf = 0.48 (ethyl acetate/ hexane, 
7/3, v/v); []D
23
 18.7 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 3.20-3.24 (dd, 1H, 
J3,4 = 3.48 Hz, H-3), 3.46 (br. s, 1H, H-5), 3.48, 3.74 (2 s, 6H, 2 x OCH3), 3.98-4.06 (m, 
2H, J2,3 = 10.4 Hz, J5,6a = 1.6 Hz, J6a,6b = 12. 5 Hz, H-2, H-6a), 4.30 (dd, 1H, H-4), 4.32-
4.36 (dd, 1H, J5,6b = 1.6  Hz, H-6b), 4.71 (d, 1H, J1,2 = 8.13 Hz, H-1), 5.56 (s, 1H, CHPh), 
6.78 (d, 2H, J = 9.09 Hz, PMP), 7.04 (d, 2H, J = 9.09 Hz, PMP), 7.31-7.34 (m, 3H, 
aromatic), 7.49-7.52 (m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 55.8, 57.5, 
61.8, 66.8, 69.3, 71.6, 80.0, 101.4, 102.1, 114.6 (x 2), 119.2 (x 2), 126.6 (x 2), 128.4 (x 
2), 129.3, 137.6, 151.2, 155.8 ppm; HR-FAB MS [M+Na]
+
 calcd for C21H23N3O6 
436.1484, found 436.1510. 
 
4-methoxyphenyl 2-azido-4-O-benzoyl-6-bromo-2,6-dideoxy-3-O-methyl-β-D-
galactopyranoside (4.10) N-bromosuccinimide (1.24 g, 6.97 mmol) and benzoyl 
peroxide (113 mg, 0.35 mmol) were added to a solution of 4.9 (2.88 g, 6.97 mmol) in 
benzene (70 mL) and the resulting mixture was refluxed for 2 h. After that, solvent was 
removed in vacuo. The residue was diluted with CH2Cl2 (~300 mL) and washed with 
water (50 mL), 10% aq. Na2S2O3 (50 mL), and water (50 mL). The organic phase was 
separated, dried with MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield the 
title compound as a clear syrup (2.78 g, 81%). Analytical data for 4.10: Rf = 0.62 (ethyl 
acetate/hexane, 2/3, v/v); []D
23
 76.0 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 
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3.32 (dd, 1H, J3,4 = 2.6 Hz, H-3), 3.47-3.51 (m, 5H, OCH3, H-6a, 6-b), 3.88-3.98 (m, 2H, 
J2,3 = 10.3 Hz, H-2, 5), 4.79 (d, 1H, J1,2 = 8.19 Hz, H-1), 5.84 (dd, 1H, J4,5 = 2.6 Hz, H-
4), 6.86 (d, 2H, J = 9.1 Hz, PMP), 7.13 (d, 2H, J = 9.1 Hz, PMP), 7.47-7.52 (m, 2H, 
aromatic), 7.60-7.66 (m, 1H, aromatic), 8.10-8.14 (m, 2H, aromatic) ppm; 
13
C NMR (75 
MHz, CDCl3): δ, 29.2, 55.8, 58.4, 62.4, 66.1, 74.5, 80.5, 102.0, 114.8 (x 2), 118.8 (x 2), 
128.8 (x 2), 129.1, 130.3 (x 2), 133.9, 151.2, 156.0, 165.7 ppm; HR-FAB MS [M+Na]
+
 
calcd for C21H22BrN3O6Na 514.0590, found 514.0572. 
 
4-Methoxyphenyl 2-amino-4-O-benzoyl-2,6-dideoxy-3-O-methyl-β-D-
galactopyranoside (4.11).  Tributyl tin hydride (2.5 g, 8.59 mmol) and benzoyl peroxide 
(46 mg, 0.14 mmol) were added to a solution of 4.10 (1.41 g, 2.86 mmol) in benzene (20 
mL) and the resulting mixture was heated at reflux for 16 h. After that, the volatiles were 
removed in vacuo. The residue was diluted with CH2Cl2 (~ 200 mL) and washed with 
water (40 mL). The organic phase was separated, dried with MgSO4, and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate - 
hexane gradient elution) to yield the title compound as a clear syrup (965 mg, 87%). 
Analytical data for 4.11: Rf = 0.5 (methanol/dichloromethane, 1/9, v/v); []D
23
 -12.6 (c = 
1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.31 (d, 3H, C-6), 3.30 (dd, 1H, J3,4 = 3.1 Hz, 
H-3), 3.39-3.50 (m, 4H, J2,3 = 10.2 Hz, OCH3, H-2), 3.78 (s, 3H, OCH3), 3.88 (m, 1H, J5,6 
= 6.5 Hz, H-5), 4.75 (d, 1H, J1,2 = 7.7 Hz, H-1), 5.56 (dd, 1H, J4,5 = 0.9 Hz, H-4), 6.82 (d, 
2H, J = 9.1 Hz, PMP), 7.04 (d, 2H, J = 9.1 Hz, PMP), 7.43-7.48 (m, 2H, aromatic), 7.55-
7.58 (m, 1H, aromatic), 8.12-8.15 (m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 
17.0, 52.8, 55.8, 57.8, 67.9, 70.0, 82.5, 103.9, 114.6 (x 2), 118.8 (x 2), 128.6 (x 2), 129.7, 
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130.2 (x 2), 133.4, 151.6, 155.5, 166.3 ppm; HR-FAB MS [M+Na]
+
 calcd for 
C21H25O6NNa 410.1580, found 410.1578. 
 
4-Methoxyphenyl 4-O-benzoyl-2,6-dideoxy-3-O-methyl-2-phthalimido-β-D-
galactopyranoside (4.12). To a solution of 4.11 (545 mg, 1.41 mmol) in pyridine (10 
mL), phthalic anhydride (217 mg, 1.46 mmol) and triethylamine (0.20 mL, 1.41 mmol) 
were added at rt. The reaction was stirred under argon for 3h. After that, acetic anhydride 
was added (0.50 mL, 5.30 mmol). The resulting solution was stirred under argon 
overnight. Then, the solvent was removed in vacuo. The residue was diluted with CH2Cl2 
(~120 mL) and washed with water (20 mL), sat. aq. NaHCO3 (20 mL), and water (20 
mL). The organic phase was separated, dried with MgSO4, and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to yield the title compound as a white amorphous solid (538 mg, 74%). 
Analytical data for 4.12: Rf = 0.70 (ethyl acetate/hexane, 7/3, v/v); []D
23
 135.0 (c = 1, 
CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.35 (d, 3H, C-6), 3.32 (s, 3H, OCH3), 3.72 (s, 
3H, OCH3), 4.08 (m, 1H, J5,6 = 6.4 Hz,  H-5), 4.41 (dd, 1H, J3,4 = 3.2 Hz, H-3), 4.74 (dd, 
1H, J3,4 = 11.3 Hz, H-2), 5.70-5.73 (m, 2H, J1,2 = 8.5 Hz,  H-1, 4), 6.73 (d, 2H, J = 9.1 
Hz, PMP), 6.88 (d, 2H, J = 9.1 Hz, PMP), 7.48-7.53 (m, 2H, aromatic), 7.57-7.58 (m, 1H, 
aromatic), 7.60-7.62 (m, 2H, aromatic), 7.81-7.92 (m, 2H, aromatic), 8.13-8.26 (m, 2H, 
aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.8, 52.8, 55.5, 57.5, 68.6, 69.9, 76.1, 
98.0, 114.4 (x 2), 118.5 (x 2), 123.2, 123.7, 128.6 (x 2), 129.5, 130.1 (x 2), 131.5, 131.7, 
133.4, 134.2, 134.3, 151.0, 155.4, 166.3, 167.8, 168.9 ppm; HR-FAB MS [M+Na]
+
 calcd 
for C29H27O8Na N 540.1634, found 540.1629. 
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4-O-Benzoyl-2,6-dideoxy-3-O-methyl-2-phthalimido-D-galactopyranose (4.13). A 
solution of CAN (1.43 g, 2.60 mmol) in water (10 mL) was added dropwise to a stirring 
solution of 4.12 (538 mg, 1.04 mmol) in CH3CN (5 mL) at 0
o
C. The reaction was allowed 
to reach rt. After 4 h, the solvent was removed in vacuo. The residue was diluted with 
CH2Cl2 (~80 mL) and washed with water (2 x 20 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield the title 
compound as a white amorphous solid (403 mg, 94%). Analytical data for 4.23: Rf = 0.55 
(ethyl acetate/hexane, 3/7, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.24 (d, 3H, H-6α), 1.30 
(d, 3H, H-6β), 3.29 (s, 3H, OCH3), 3.33 (s, 3H, OCH3), 3.99 (m, 1H, J5β,6β = 6.4 Hz, H-
5β), 4.14 (d, 1H, J1β,2β = 8.6 Hz, H-1β), 4.36 (d, 1H, J1α,2α = 3.7 Hz, H-1α), 4.41 (m, 3H, 
OHα, OHβ, H-3 β), 4.52 (m, 1H, J5α,6α = 6.9 Hz, H-5α), 4.75 (dd, 1H, J3α,4α = 3.2 Hz, H-
3α), 5.37 (dd, 1H, J2β,3β = 8.4 Hz, H-2β), 5.46 (dd, 1H, J2α,3α = 11.8 Hz, H-2α), 5.65 (dd, 
1H, J4β,5β = 1.4 Hz, H-4β), 5.73 (dd, 1H, J4α,5α = 2.3 Hz, H-4α), 7.41-7.49 (m, 4H, 
aromatic), 7.53-7.57 (m, 2H, aromatic), 7.67-7.71 (m, 4H, aromatic), 7.84-7.87 (m, 4H, 
aromatic), 8.12-8.16 (m, 4H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3) α-4.13: 16.8, 
52.6, 56.8, 65.5, 69.5, 71.7, 93.0, 123.4, 123.8, 128.6 (x 2), 129.7, 130.1, 130.2 (x 2), 
131.8, 133.4 (x 2), 134.4, 166.5, 168.7, 169.0  δ, ppm; β-4.13: δ, 16.9, 54.9, 57.5, 68.7, 
70.1, 75.9, 93.5, 123.6, 128.6 (x 2), 129.6, 130.1, 130.2 (x 2), 131.8 (x 2), 133.5, 134.3 (x 
2), 166.5 (x 3) ppm; HR-FAB MS [M+Na]
+
 calcd for C22H21O7NaN 434.1216, found 
434.1222. 
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4-O-Benzoyl-2,6-dideoxy-3-O-methyl-2-phthalimido-D-galactopyranosyl 
trichloroacetimidate (4.14). To the solution of 4.13 (812 mg, 1.97 mmol) in dry CH2Cl2 
(20 mL), trichloroacetonitrile (1.98 mL, 19.74 mmol) and DBU (0.15 mL, 0.50 mmol) 
were added at rt. The reaction was stirred for 30 min under argon. After that, it was 
concentrated in vacuo and the residue was purified by column chromatography on silica 
gel (ethyl acetate - hexane gradient elution) to yield the title compound as a white 
amorphous solid (958 mg, 87%). Analytical data for 4.14: Rf  α-4,14 = 0.64, β-4.14 = 
0.52 (ethyl acetate/hexane, 1/1, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.29 (d, 3H, H-6α), 
1.36 (d, 3H, H-6β), 3.23, 3.41 (2s, 6H, 2 x OCH3), 4.18 (m, 1H, J5β,6β = 6.4 Hz, H-5β), 
4.46-4.53 (m, 2H, J5α,6α = 6.5 Hz, H-3β, 5α), 4.75 (dd, 1H, J2β,3β = 11.2 Hz, H-2β), 4.84 
(dd ,1H, J2α,3α = 11.7 Hz, H-2α), 5.26 (dd, 1H, J3α,4α = 3.1 Hz, H-3α), 5.73 (dd, 1H, J4β,5β 
= 3.1 Hz, H-4β), 5.83 (dd, 1H, J4α,5α = 2.8 Hz, H-4α), 6.47 (m, 2H, J1α,2α = 3.1 Hz, J1β,2β = 
8.9 Hz, H-1α, 1β), 7.47-7.53 (m, 4H, aromatic), 7.57-7.63 (m, 2H, aromatic), 7.68-7.73 
(m, 4H, aromatic), 7.80-7.84 (m, 4H, aromatic), 8.13-8.19 (m, 4H, aromatic), 8.58 (s, 1H, 
NH), 8.62 (s, 1H, NH) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.7, 16.8, 51.5, 52, 56.6, 
57.8, 68.5, 68.6, 68.8, 71.2, 71.6, 76.0, 90.6, 91.0, 94.7, 95.8, 123.4, 123.5, 123.7, 128.8, 
129.5, 130.1, 130.2, 133.6, 134.5, 161.3, 161.5, 163.9, 166.3, 166.5, 168.1, 175.0 ppm; 
HR-FAB MS [M+Na]
+
 calcd for C24H21O7Na N2Cl3 577.0312, found 577.0313. 
 
4.4.3 Synthesis of D-mannosyl acceptors 4.17 and 4.18 
Methyl 2-amino-4,6-O-benzylidene-2-deoxy-2,3-N,O-(2,2,2-trichloroethylylidene)-β-
D-mannopyranoside (4.16). DBU (0.15 mL, 0.98 mmol) and trichloroacetonitrile (1.17 
mL, 11.7 mmol) were added to a solution of methyl 4,6-O-benzylidene-β-D-




 (4.15, 2.76 g, 9.78 mmol) in dry CH2Cl2 (120 mL) and the resulting 
mixture was stirred under argon for 5 h at rt. After that, the reaction mixture was cooled 
to -30 
o
C, pyridine (3.94 mL, 48.9 mmol) and Tf2O (1.96 mL, 11.7 mmol) were added, 
and the resulting mixture was stirred under argon for 2 h at -30 
o
C. The reaction mixture 
was then allowed to warm to rt, DIPEA (17.0 mL, 97.8 mmol) was added, and the 
resulting mixture was stirred under argon for 16 h at rt. After that, the volatiles were 
removed in vacuo, the residue was diluted with CH2Cl2 (~300 mL) and washed with 
water (2 x 40 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) to yield the title compound as a white amorphous 
solid (2.20 g, 55%). Analytical data for 4.16: Rf = 0.50 (ethyl acetate/hexane, 2/3, v/v); 
[]D
22
 -76.5 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ 3.46 (s, 3H, OCH3), 3.64 (m, 
1 H, J5,6a = 10.1 Hz, J5,6b = 4.4 Hz, H-5), 3.72 (dd, 1H, J6a,6b = 10.0 Hz, H-6a), 4.38 (dd, 
1H, H-6b), 4.56-5.65 (m, 2H, H-2, 4), 4.92 (d, 1H, J1,2 = 3.5 Hz, H-1), 5.02 (dd, 1H, J2,3 = 
7.4 Hz, J3,4 = 9.8 Hz, H-3), 5.61 (s, 1H, CHPh), 7.34-7.42 (m, 3H, aromatic), 7.46-7.55 
(m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ 56.1, 64.5, 67.4, 70.3, 76.9, 82.6, 
86.5, 97.5, 101.8, 126.4 (x 2), 128.5 (x 2), 129.5, 136.9, 164.7 ppm; HR-FAB MS: 
[M+Na]
+
 calcd for C16H16Cl3NO5Na, 429.9992; found, 430.0003. 
 
Methyl 2-acetamido-4,6-O-benzylidene-2-deoxy-β-D-mannopyranoside (4.17).   
A 1 M aq. soln. of NaOH (10 mL) was added dropwise to a solution of 4.16 (63 mg, 0.16 
mmol) in MeOH (10 mL) and the resulting mixture was refluxed for 12 h. The reaction 
mixture was then allowed to cool to rt, Amberlite IR120 resin was added until pH = 7. 
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The resin was filtered off, rinsed successively with MeOH (7 x 5 mL), and the combined 
filtrate was concentrated in vacuo. The residue was dissolved in MeOH (10 mL), Ac2O 
(0.5 mL, 5.30 mmol) was added, and the mixture was stirred for 2 h at rt. After that, the 
volatiles were removed in vacuo and the residue was purified by column chromatography 
on silica gel (methanol - dichloromethane gradient elution) to yield the title compound as 
a white amorphous solid (50 mg, 94%). Analytical data for 4.17: Rf = 0.50 
(methanol/dichloromethane, 1/9, v/v); []D
22
 -42.0 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ 2.11 (s, 3H, COCH3), 3.46 (m, 1H, J5,6a = 10.2 Hz, J5,6b = 4.9 Hz, H-5), 3.52 (s, 
3H, OCH3), 3.70 (dd, 1H, J4,5 = 9.4 Hz, H-4), 3.80 (dd, 1H, J6a, 6b = 10.2 Hz, H-6a), 4.00 
(dd, 1H, J3,4 = 9.5 Hz, H-3), 4.34 (dd, 1 H, H-6b), 4.52 (br dd, 1H, J2,3 = 4.0 Hz, H-2), 
4.64 (d, 1H, J1,2 = 1.7 Hz, H-1), 5.57 (s, 1H, CHPh), 5.98 (br. d, 1H, J2,NH = 6.0 Hz, NH), 
7.30-7.40 (m, 3H, aromatic), 7.44-7.53 (m, 2H, aromatic); 
13
C NMR (75 MHz, CDCl3): 
δ, 23.3, 54.9, 57.3, 67.4, 68.6, 71.6, 79.7, 100.6, 102.3, 126.4 (x 2), 128.4 (x 2), 129.3, 
137.1, 173.8 ppm; HR-FAB MS: [M+Na]
+
 calcd for C16H21NO6Na, 346.1267; found, 
346.1254. 
 
Methyl 2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy-β-D-mannopyranoside (4.18). 
Ac2O (4.0 mL, 42.40 mmol) was added to a solution of 4.17 (1.00 g, 3.09 mmol) in 
pyridine (20 mL) and the resulting mixture was stirred under argon for 3 h at rt. After 
that, methanol (20 mL) was added and the resulting mixture was concentrated in vacuo. 
The residue was dissolved in THF (40.0 mL), activated molecular sieves (3 Å, 1.50 g) 
were added and the resulting mixture was stirred under argon for 1 h at rt. NaCNBH3 
(2.68 g, 42.6 mmol) was added followed by a dropwise addition of a 2M solution of HCl 
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in diethyl ether (21.3 mL, 42.6 mmol). The resulting mixture was stirred under argon for 
1 h at rt. After that, the solids were filtered off and rinsed successively with CH2Cl2. The 
combined filtrate (~150 mL) was washed with water (30 mL), sat. aq. NaHCO3 (30mL), 
and water (30 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(methanol - dichloromethane gradient elution) to yield the title compound as a white 
foam (1.10 g, 97%). Analytical data for 4.18: Rf = 0.39 (methanol/dichloromethane, 1/9, 
v/v); []D
22
 -55.3 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ 1.98 (s, 3 H, COCH3), 
2.04 (s, 3 H, COCH3), 3.24 (d, 1H, J6,OH = 3.72 Hz, OH), 3.45-3.50 (m, 4 H, OCH3, H-5), 
3.75-3.83 (m, 6H, OCH3, H-4, 6a, 6b), 4.52 (d, 1H, J1,2 = 1.3 Hz, H-1), 4.56-4.65 (m, 3H, 
J2,3 = 3.9 Hz, CH2Ph, H-2), 4.75 (dd, 1H, J3,4 = 9.8 Hz, H-3), 5.80 (br. d, 1 H, J2,NH = 8.6 
Hz, NH), 7.28-7.36 (m, 5H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 21.2, 23.4, 
50.5, 57.1, 66.5, 69.7, 73.8, 74.9, 75.3, 100.2, 127.8 (x 2), 128.1, 128.7 (x 2), 137.9, 
171.0, 171.2 ppm; HR-FAB MS: [M+Na]
+
 calcd for C18H25NO7Na, 390.1529; found, 
390.1550. 
 
4.4.4 Assembly and functionalization of CP8 disaccharide D1 
Methyl O-(2-azido-4-O-benzoyl-2,6-dideoxy-3-O-methyl-α-D-galactopyranosyl)-
(13)-2-acetamido-2-deoxy-4,6-O-benzylidene-β-D-mannopyranoside (4.19). A 
mixture of donor 4.7 (596 mg, 1.32 mmol), acceptor 4.17 (470 mg, 1.45 mmol), and 
freshly activated molecular sieves (4 Å, 800 mg) in CH2Cl2 (20 mL) was stirred under 
argon for 2 h at rt. The resulting mixture was cooled to 0 
o
C, triflic acid (40 mg, 0.26 
mmol) was added and the resulting mixture was allowed to warm to rt and stirred for 2 h. 
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After that, the solids were filtered-off and rinsed successively with CH2Cl2. The 
combined filtrate (~150 mL) was washed with water (30 mL), sat. aq. NaHCO3 (30 mL) 
and water (30 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(methanol - dichloromethane gradient elution) to afford the title compound as a white 
amorphous solid (528 mg, 65%). Analytical data for 4.19: Rf = 0.66 
(methanol/dichloromethane, 1/9, v/v); []D
23
 103.7 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.21 (d, 3H, H-6’), 2.11 (s, 3H, COCH3), 3.47-3.50 (m, 5H, J5,6b = 4.8 Hz, H-
2’, 5, OCH3), 3.54 (s, 3H, OCH3), 3.81-3.90 (m, J3’,4’ = 2.4 Hz, H-3’, 4, 6a), 4.08 (dd, 1H, 
J3,4 = 10.4 Hz, H-3), 4.38 (dd, 1H, J6a,6b = 10.4 Hz, H-6b), 4.2-4.69 (m, 2H, J1,2 = 1.71 
Hz,  J5’,6’ = 6.5 Hz, H-1, 5’), 4.70 (dd, 1H, J2,3 = 4.4 Hz, H-2), 5.40 (d, 1H, J1’,2’ = 3.4 Hz, 
H-1’), 5.65 (s, 1H, CHPh), 5.69 (dd, 1H, J4’,5’ = 2.3 Hz, H-4’), 5.74 (d, 1H, J2,NH = 9.3 
Hz, NH), 7.37-7.57 (m, 8H, aromatic), 8.06-8.11 (m, 2H, aromatic) ppm; 
13
C NMR (75 
MHz, CDCl3): δ, 16.5, 23.7, 52.6, 57.4 (x 2), 59.0, 66.1, 67.1, 68.6, 70.0, 73.3, 75.2, 80.0, 
99.3, 101.4, 101.8, 126.1 (x 2), 128.5 (x 2), 128.5 (x 2), 129.2, 129.8, 130.0 (x 2), 133.3, 
137.1, 166.1, 171.1 ppm; HR-FAB MS [M+Na]
+




(13)-2-acetamido-2-deoxy-4,6-O-benzylidene-β-D-mannopyranoside (4.20). A 1 M 
solution of sodium methoxide in methanol (2.0 mL) was added to a solution of 
disaccharide 4.19 (321 mg, 0.52 mmol) in methanol (10.0 mL) and the resulting mixture 
was stirred under argon at rt for 16 h. After that, Amberlite IR120 resin was added until 
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pH = 7. Then, the resin was filtered-off, rinsed successively with methanol (7 x 5 mL), 
and the combined filtrate was concentrated in vacuo and dried. The crude residue was 
dissolved in dry CH2Cl2 (20 mL), levulinic acid (80 mg, 0.69 mmol), DIC (0.16 mL, 1.05 
mmol) and DMAP (14 mg, 0.11 mmol) were added, and the resulting mixture was stirred 
under argon for 24 h at rt. After that, the reaction mixture was diluted with CH2Cl2 (~100 
mL) and washed with water (20 mL) sat. aq. NaHCO3 (20 mL) and water (20 mL). The 
organic phase was separated, dried over MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (methanol - dichloromethane 
gradient elution) to afford the title compound as a white amorphous solid (281 mg, 89%). 
Analytical data for 4.20: Rf = 0.63 (methanol/dichloromethane, 1/9, v/v); []D
22
 71.8 (c = 
1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.15 (d, 3H, H-6’), 2.05, 2.16 (2 s, 6H, 2 x 
COCH3), 2.58-2.77 (m, 4H, 2 x CH2), 3.27 (dd, 1H, J2’,3’ = 10.9 Hz, H-2’), 3.38 (s, 3H, 
OCH3), 3.41 (dd, 1H, J5,6a = 4.7 Hz, J5,6b = 5.1 HzH-5), 3.51 (s, 3H, OCH3), 3.70 (dd, 1H, 
J2’,3’ = 10.9 Hz, J3’,4’ = 3.1 Hz, H-3’), 3.76 (m, 2H, J4,5 = 9.5 Hz, J6a,6b = 10.41 Hz, H-4, 
6a), 4.02 (dd, 1H, J3,4 = 9.9 Hz, H-3), 4.34 (dd, 1H, H-6b), 4.48 (m, 1H, J5’,6’ = 6.5 Hz, 
H-5’), 4.57 (d, 1H, J1,2 = 1.7 Hz, H-1), 6.64 (dd, J2,3 = 4.5 Hz, 1H, H-2), 5.31 (d, 1H, J1’,2’ 
= 3.5 Hz, H-1’), 5.40 (dd, 1H, J4’,5’ = 2.3 Hz, H-4’), 5.61 (s, 1H, CHPh), 5.74 (d, 1H, 
J2,NH = 9.3 Hz, NH), 7.34-7.37 (m, 3H, aromatic), 7.45-7.48 (m, 2H, aromatic) ppm; 
13
C 
NMR (75 MHz, CDCl3): δ, 16.4, 23.7, 28.0, 30.0, 38.1, 52.5, 57.3, 57.4, 58.8, 65.9, 67.1, 
68.5, 69.7, 73.2, 74.9, 80.0, 99.2, 101.4, 101.7, 126.0 (x 2), 128.4 (x 2), 129.2, 137.1, 
171.0, 172.4, 206.5  ppm; HR-FAB MS [M+Na]
+
 calcd for C28H38NaO11N4 629.2435, 
found 629.2445. 
 




mannopyranoside (4.21). Water (1.5 mL), triethylamine (1.0 mL, 7.1 mmol) and 1.3-
propanedithiol (0.71 mL, 7.0 mmol) were added to a solution of disaccharide 4.20 (212 
mg, 0.35 mmol) in pyridine (35.0 mL) and the resulting mixture was stirred for 24 h at rt. 
After that, the reaction mixture was concentrated in vacuo and dried. The crude residue 
was dissolved in MeOH (5.0 mL), Ac2O (0.4 mL, 4.20 mmol) was added, and the 
resulting suspension was stirred under argon for 16 h at rt. Upon completion, the reaction 
mixture was concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (methanol - dichloromethane gradient elution) to afford the title compound 
as a white amorphous solid (210 mg, 96%). Analytical data for 4.21: Rf = 0.54 
(methanol/dichloromethane, 1/9, v/v); []D
22
 11.4 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.09 (d, 3H, H-6’), 1.43, 2.03, 2.11 (3s, 9H, 3 x COCH3), 2.57 (m, 2H, CH2), 
2.67 (m, 2H, CH2), 3.19 (s, 3H, OCH3), 3.31-3.39 (m, 2H, H-3’, 5), 3.43 (s, 3H, OCH3), 
3.75-3.88 (m ,3H, 3, 4, 6a), 4.23-4.39 (m, 3H, J5’,6’ = 6.5 Hz, H-2’, 5’, 6b), 4.50 (d, 1H, , 
J1,2 = 1.4 Hz, H-1), 4.62 (dd, 1H, , J2,3 = 6.7 Hz, H-2), 4.95 (dd, 1H, J1’,2’ = 3.4 Hz, H-1’), 
5.29 (dd, 1H, J4’,5’ = 2.0 Hz, H-4’), 5.56 (s, 1H, CHPh), 6.10 (d, J2’,NH = 9.7 Hz, 2’-NH), 
6.28 (d, J2,NH = 9.7 Hz, 2-NH), 7.23-7.36 (m, 5H, aromatic) ppm; 
13
C NMR (75 MHz, 
CDCl3): δ, 16.4, 22.7, 23.5, 28.1, 29.9, 38.1, 48.6, 52.9, 57.1, 57.3, 66.2, 67.2, 68.5, 69.0, 
76.2, 76.6, 78.7, 100.8, 101.5, 102.3, 126.1 (x 2), 128.6 (x 2), 129.6, 136.8, 170.3, 171.2, 
172.4, 206.8 ppm; HR-FAB MS [M+Na]
+
 calcd for C30H42NaO12N2 645.2636, found 
645.2618. 
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Methyl O-(2-acetamido-2,6-dideoxy-4-O-levulinoyl-3-O-methyl-α-D-
galactopyranosyl)-(13)-2-acetamido-2-deoxy-β-D-mannopyranoside (4.22).  
Trifluoroacetic acid (20 mL) was added to a mixture of disaccharide 4.21 (1.15 g, 1.85 
mmol) in CH2Cl2 (80.0 mL) and water (5 mL), and the resulting mixture was stirred for 2 
h at rt. After that, the reaction mixture was concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (methanol - dichloromethane gradient 
elution) to afford the title compound as a white amorphous solid (798 mg, 81%). 
Analytical data for 4.22: Rf = 0.74 (methanol/CH2Cl2, 3/7, v/v); []D
22
 42.6 (c = 1, 
CH3OH);  
1
H NMR (300 MHz, CD3OD): δ, 1.11 (d, 3H, H-6’), 1.97, 2.01, 2.18 (3s, 9H, 3 
x COCH3), 2.63 (m, 2H, CH2), 2.80 (m, 2H, CH2), 3.23 (dd, 1H, H-5), 3.29, 3.47 (2s, 6H, 
2 x OCH3), 3.50 (dd, 1H, J3’,4’ = 3.1 Hz, H-3’), 3.66-3.69 (m, 2H, H-3, 4), 3.86 (m, 2H, 
H-6a, 6b), 4.16 (dd, 1H, J2’,3’ = 11.3 Hz, H-2’), 4.47-4.52 (m, 2H, J5’,6’ = 6.5 Hz, H-2, 5’), 
4.55 (d, 1H, J1,2 = 1.4 Hz, H-1), 5.09 (d, 1H, J1’,2’ = 3.6 Hz, H-1), 5.35 (dd, 1H, J4’,5’ = 2.3 
Hz, H-4’) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.9, 22.9, 29.1, 29.9, 38.9, 50.9, 54.4, 
57.1, 57.4, 61.7, 66.9, 68.1, 70.7, 77.0, 78.4, 80.7, 101.4, 102.0, 173.9, 174.2, 209.6 ppm; 
HR-FAB MS [M+Na]
+




mannopyranosid)uronate (4.23). Water (25 mL), 2,2,6,6-tetramethylpiperidine 1-oxyl 
(TEMPO, 226 mg, 1.44 mmol) and diacetoxy iodobenzene (BAIB, 4.64 mg, 14.4 mmol) 
were added to a solution of disaccharide 4.22 (771 mg, 1.44 mmol) in CH2Cl2 (50.0 mL) 
and the resulting mixture was stirred for 16 h at rt.  After that, the reaction mixture was 
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concentrated in vacuo, passed through a pad of silica gel. The eluate was concentrated in 
vacuo and dried. The crude residue was dissolved in DMF (20 mL), benzyl bromide (1.03 
mL, 8.64 mmol) and NaHCO3 (1.21 g, 14.4 mmol) were added, and the resulting mixture 
was stirred under argon for 16 h at rt. After that, the reaction mixture was mixed with ice-
cold water (~30 mL) and the resulting mixture was extracted with ethyl acetate (3 x 100 
mL). The combined organic extract was washed with brine (2 x 30 mL). The organic 
phase was separated, dried with MgSO4, and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (methanol - dichloromethane gradient 
elution) to afford the title compound as a white amorphous solid (700 mg, 76%). 
Analytical data for 4.23: Rf = 0.38 (methanol/dichloromethane, 1/9, v/v); []D
22
 45.3 (c = 
1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.17 (d, 3H, H-6’), 1.97, 2.04, 2.19 (3s, 9H, 3 
x COCH3), 2.65 (m, 2H, CH2), 2.75 (m, 2H, CH2), 3.33 (s, 3H, OCH3), 3.37 (d, 1H, J3’,4’ 
= 2.5 Hz, H-3’), 3.47 (s, 3H, OCH3), 3.75 (dd, 1H, J3,4 = 7.8 Hz, H-3), 3.85-3.96 (m, 2H, 
H-4, 5), 4.08 (dd, 1H, J2’,3’ = 10.8 Hz,  H-2’), 4.44 (m, 1H, J5’,6’ = 6.5 Hz, H-5’), 4.52-
4.58 (m, 2H, J2,3 = 3.7 Hz, H-1, 2), 5.27 (s, 2H, CH2Ph), 5.37 (dd, 1H, J4’,5’ = 1.9 Hz, H-
4’), 5.42 (d, 1H, J1’,2’ = 3.6 Hz, H-1’), 5.87 (d, J2’,NH = 9.6 Hz, 2’-NH), 6.02 (d, J2,NH = 6.8 
Hz, 2-NH), 7.38-7.43 (m, 5H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.6, 23.6, 
23.7, 28.1, 30.0, 38.2, 50.0, 51.4, 57.1, 57.5, 65.9, 67.7, 68.6, 69.1, 75.0, 76.2, 77.4, 78.7, 
99.9, 101.0, 128.5 (x 2), 128.8 (x 2), 135.0, 169.7, 171.0, 171.5, 172.6, 206.7 ppm; HR-
FAB MS [M+Na]
+
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mannopyranosid)uronate (4.24). Ac2O (3.0 mL) was added to a solution of 
disaccharide 4.23 (498 mg, 0.72 mmol) in pyridine (10.0 mL) and the resulting mixture 
was stirred under argon for 16 h. After that, the reaction was quenched with MeOH 
(~10.0 mL), the volatiles were removed in vacuo, and the residue was co-evaporated with 
toluene (3 x 5 mL). The residue was purified by column chromatography on silica gel 
(methanol - dichloromethane gradient elution) to afford the title compound as a white 
amorphous solid (490 mg, 99%). Analytical data for 4.24: Rf = 0.40 
(methanol/dichloromethane, 1/9, v/v); []D
23
 44.0 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.15 (d, 3H, H-6’), 1.83, 1.97, 2.04, 2.16 (4s, 12H, 4 x COCH3), 2.58-2.82 (m, 
4H, 2 x CH2), 3.23-3.27 (m, 4H, J3’,4’ = 2.9 Hz, OCH3, H-3’), 3.43 (s, 3H, OCH3), 3.83 
(dd, 1H, J3,4 = 8.0 Hz, H-3), 4.03 (d, 1H, J4,5 = 7.6 Hz, H-5), 4.28 (ddd, 1H, J2’,3’ = 9.2 
Hz, H-2’), 4.46-4.98 (m, 2H, J2,3 = 3.8 Hz, J5’,6’ = 6.5 Hz, H-2, 5’), 4.59 (d, 1H, J1,2 = 2.0 
Hz, H-1), 4.90 (d, 1H J1’,2’ = 3.7 Hz, H-1’), 5.10 (dd, 2H, 
2
J = 14.0 Hz,  CH2Ph), 5.27-
5.35 (m, 2H, H-4, 4’), 5.69 (d, J2’,NH = 9.0 Hz, 2’-NH), 6.21 (d, J2,NH = 9.2 Hz, 2-NH), 
7.35-7.42 (m, 5H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.6, 20.7, 23.3, 23.6, 
28.1, 29.9, 38.2, 48.6, 50.5, 57.3, 57.8, 66.3, 68.0, 68.8, 69.0, 72.3, 75.6, 76.1, 77.2, 
100.4, 128.9 (x4), 129.1 134.6, 168.2, 170.4, 170.7, 171.1, 172.5, 206.7 ppm; HR-FAB 
MS [M+Na]
+
 calcd for C32H44NaO14N2 703.2690, found 703.2701. 
 
Methyl O-(2-acetamido-2,6-dideoxy-3-O-methyl-α-D-galactopyranosyl)-(13)-
(benzyl 2-acetamido-4-O-acetyl-2-deoxy-β-D-mannopyranosid)uronate (4.25). 
Hydrazine acetate (15 mg, 0.17 mmol) was added to a solution of disaccharide 4.24 (56 
mg, 0.09 mmol) in CH2Cl2/methanol (10.5 mL, 20/1, v/v) and the resulting mixture was 
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stirred for 4 h at rt. After that, the reaction mixture was diluted with CH2Cl2 (~50 mL) 
and washed with sat. aq. NaHCO3 (10 mL) and water (10 mL). The organic phase was 
separated, dried with MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford 
the title compound as a white foam (48 mg, 96%). Analytical data for 4.25: Rf = 0.33 
(methanol/dichloromathane, 1/9, v/v); []D
22
 32.5 (c = 1, CHCl3); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.29 (d, 3H, H-6’), 1.80, 1.95, 2.02 (3s, 9H, 3 x COCH3), 3.13 (dd, 1H, J3’,4’ = 
2.9 Hz, H-3’), 3.33, 3.41 (2s, 6H, 2 x OCH3), 3.82 (dd, 1H, J3,4 = 8.3 Hz, H-3), 3.91 (dd, 
J4’,5’ = 1.8 Hz, 1H, H-4’), 4.02 (d, 1H, H-5), 4.31-4.41 (m, 2H, J2’,3’ = 10.9 Hz, J5’,6’ = 6.5 
Hz, H-2’, 5’), 4.47 (ddd, 1H, J2,3 = 3.9 Hz, H-2), 4.57 (d, 1H, J1,2 = 2.1 Hz, H-1), 4.80 (d, 
1H, J1’,2’ = 3.8 Hz, H-1’), 5.13 (br. s, 2H, CH2Ph), 5.26 (dd, 1H, J4,5 = 7.8 Hz, H-4), 5.78 
(d, J2’,NH = 9.0 Hz, 2’-NH), 6.29 (d, J2,NH = 8.7 Hz, 2-NH), 7.29-7.41 (m, 5H, aromatic) 
ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.6, 20.7, 23.3, 23.5, 47.6, 50.6, 56.9, 57.7, 66.9, 
67.5, 67.9, 68.9, 72.2, 75.3, 77.2, 78.3, 100.5, 128.8 (x 4), 129.0, 134.6, 168.1, 170.4, 
170.5, 171.0 ppm; HR-FAB MS [M+Na]
+




acetamido-4-O-acetyl-2-deoxy-β-D-mannopyranosid)uronic acid (D1). 10% Pd on 
activated charcoal (100 mg) was added to a solution of disaccharide 4.25 (48 mg, 0.082 
mmol) in 90% aq. ethanol (10 mL) and the resulting suspension was stirred vigorously 
under H2 atmosphere for 24 h at rt. After that, the solids were filtered off and rinsed 
successively with methanol. The combined filtrate (~50 mL) was concentrated in vacuo. 
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The residue was purified by column chromatography on silica gel (dichloromethane - 
methanol gradient elution) to afford the title compound as a white amorphous solid (39 
mg, 97% yield). Analytical data for D1: Rf = 0.21 (methanol/dichloromethane, 3/7, v/v); 
[]D
23
 64.0 (c = 1, CH3OH); 
1
H NMR (300 MHz, CD3OD): δ, 1.24 (d, 3H, H-6’), 1.92, 
2.00, 2.05 (3s, 9H, 3 x COCH3), 3.33-3.37 (m, 4H, J3’,4’ = 2.9 Hz, OCH3, H-3’), 3.47 (1s, 
3H, OCH3), 3.70 (d, 1H, H-5), 3.89 (dd, 1H, J4’,5’ = 2.3 Hz, H-4’), 3.96 (dd, 1H, J2,3 = 4.1 
Hz, J3,4 = 10.0 Hz, H-3), 4.14 (ddd, 1H, J2’,3’ = 11.7 Hz, H-2’), 4.44-4.50 (m ,2H, J5’,6’ = 
6.6 Hz, H-2, 5’), 4.64 (d, 1H, J1,2 = 1.1 Hz, H-1), 4.91 (d, 1H, J1,2 = 3.8 Hz,  H-1), 5.14 
(dd, 1H, J4,5 = 10.1 Hz, H-4), 7.86 (d, J2’,NH = 8.4 Hz, 2’-NH), 6.29 (d, J2,NH = 9.7 Hz, 2-
NH) ppm; 
13
C NMR (75 MHz, CD3OD): δ, 16.9, 21.2, 22.9, 23.0, 49.9, 54.3, 56.5, 57.3, 
67.9, 68.4, 71.8, 75.9, 76.9, 78.2, 100.2, 101.3, 171.6, 173.8, 173.9, 174.1 ppm; HR-FAB 
MS [M+2Na]
+
 calcd for C20H32O12N2Na2 537.1672, found 537.1668. 
 
4.4.5 Assembly and functionalization of CP5 disaccharide D2 
Methyl O-(4-O-benzoyl-2,6-dideoxy-3-O-methyl-2-phthalimido-β-D-
galactopyranosyl)-(14)-2-acetamido-3-O-acetyl-6-O-benzyl-2-deoxy-β-D-
mannopyranoside (4.26). A mixture of donor 4.14 (163 mg, 0.29 mmol), acceptor 4.18 
(140 mg, 0.38 mmol), and freshly activated molecular sieves (4Å, 400 mg) in CH2Cl2 (10 
mL) was stirred under argon for 2 h at rt. TMSOTf (11 µL, 0.06 mmol) was added at 0 
o
C 
and the resulting mixture was allowed to reach rt and stirred under argon for 4 h. After 
that, the solids were filtered-off and rinsed successively with CH2Cl2. The combined 
filtrate (~100 mL) was washed with water (20 mL), sat. aq. NaHCO3 (20 mL) and water 
(20 mL). The organic phase was separated, dried with MgSO4, and concentrated in 
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vacuo. The residue was purified by column chromatography on silica gel (methanol - 
dichloromethane gradient elution) to afford the title compound as a white amorphous 
solid (121 mg, 63%, α/β = 1/5). The yield calculation is based on acceptor 4.18 recovered 
(61 mg, 0.17 mmol). Analytical data for 4.26: Rf = 0.58 (methanol/dichloromethane, 1/9, 
v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.26 (d, 3H, H-6’), 1.96, 2.05 (2s, 6H, 2 x COCH3), 
3.25, 3.40 (2s ,6H, 2 x OCH3), 3.45-3.50 (m, 2H, H-5, 6a), 3.70-3.81 (m, 1H, H-6b), 3.84 
(m, 1H, J5’,6’ = 6.4 Hz, H-5’), 3.95 (m, 2H, 
2
J = 12.1 Hz, ½ CH2Ph, H-4), 4.12 (d, 1H, 
2
J 
= 12.1 Hz, ½ CH2Ph), 4.26 (dd, 1H, J3’,4’ = 3.2 Hz, H-3’), 4.39 (d, 1H, J1,2 = 2.4 Hz, H-
1), 4.48 (d, 1H, J2’,3’ = 9.5 Hz, H-2’), 4.60 (dd, 1H, J2,3 = 4.1 Hz, H-2), 5.04 (dd, 1H, J3,4 
= 9.5 Hz, H-3), 5.32 (d, 1H, J1’,2’ = 8.5 Hz, H-1’), 5.59-5.63 (m, 2H, NH, H-4’), 7.07-
8.16 (m, 14H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.8, 21.2, 23.6, 50.6, 53.4, 
57.0, 57.6, 68.4, 68.5, 69.9, 72.6, 73.1, 73.2, 74.9, 76.1, 98.3, 100.1, 127.1 (x 4), 127.6 (x 
2), 128.4 (x 4), 128.7 (x 2), 129.6, 130.2 (x 2), 133.5, 134.3, 138.4, 166.4, 168.0, 169.2, 
170.0, 170.8 ppm; HR-FAB MS [M+Na]
+





Hydrazine hydrate (0.19 mL, 3.96 mmol) was added to a stirring solution of disaccharide 
4.26 (118 mg, 0.13 mmol) in MeOH (10 mL). The reaction was stirred at 80 
o
C for 24 h. 
After that, the solution was concentrated in vacuo, and dried. Then, the crude residue was 
dissolved in pyridine (5.0 mL), Ac2O (0.5 mL, 5.30 mmol) was added, and the resulting 
mixture was stirred under argon for 16 h at rt. After that, MeOH (5 mL) was added and 
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the volatiles were removed in vacuo. The residue was diluted with CH2Cl2 (~100 mL), 
washed with water (20 mL), sat. aq. NaHCO3 (20 mL) and water (20 mL). The organic 
phase was separated, dried with MgSO4, and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (methanol - dichloromethane gradient 
elution) to afford the title compound as a white amorphous solid (65 mg, 81%). 
Analytical data for 4.27: Rf = 0.51 (methanol/dichloromethane, 1/9, v/v); 
1
H NMR (300 
MHz, CD3OD): δ, 1.11 (d, 3H, H-6’), 1.94, 1.95, 1.99, 2.01 (4 s, 12H, 4 x COCH3), 3.33, 
3.46 (2 s, 6H, 2 x OCH3), 3.53-3.63 (2H, H-3’, 5), 3.65 (m, 1H, J5’,6’ = 6.4 Hz, H-5’), 
3.78-3.92 (m, 3H, H-4, 6a, 6b), 4.53-4.65 (m, 6H, J2,3 = 4.4 Hz, CH2Ph, H-1, 1’, 2, 2’), 
4.98 (dd, 1H, J3,4 = 9.4 Hz, H-3), 5.30 (dd, 1H, J4’,5’ = 1.6 Hz, H-4’), 7.30-7.46 (m, 14H, 
aromatic) ppm; 
13
C NMR (75 MHz, CD3OD): δ, 17.0, 20.8, 21.4, 22.6, 23.4, 51.9, 54.1, 
57.3, 58.1, 69.6, 70.1, 70.3, 73.8, 74.4, 74.8, 76.0, 79.8, 101.3, 102.0, 129.3, 129.5 (x 2), 
129.8 (x 2), 139.3, 171.8, 172.4, 173.8, 174.1 ppm; HR-FAB MS [M+Na]
+
 calcd for 
C29H42O12N2Na 633.2636, found 633.2622. 
 
Methyl O-(2-acetamido-4-O-acetyl-2,6-dideoxy-3-O-methyl-β-D-galactopyranosyl)-
(14)-2-acetamido-3-O-acetyl-2-deoxy-β-D-mannopyranoside (4.28). 10% Pd on 
activated charcoal (100 mg) was added to a solution of disaccharide 4.27 (64 mg, 0.10) 
mmol) in 90% aq. ethanol (10 mL) and the resulting mixture was stirred vigorously under 
H2 atmosphere for 24 h at rt. After that, the solids were filtered-off, rinsed successively 
with methanol (7 x 5), and the combined filtrate (~50 mL) was concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (dichloromethane - 
methanol gradient elution) to afford the title compound as a white amorphous solid (41 
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mg, 75% yield). Analytical data for 4.28: Rf = 0.24 (methanol/dichloromethane, 1/9, v/v); 
[]D
22
 14.4 (c = 1, CHCl3); 
1
H NMR (300 MHz, CD3OD): δ, 1.11 (d, 3H, H-6’), 1.98, 
1.99, 2.00, 2.11 (4s, 12H, 4 x COCH3), 3.32 (s ,3H, OCH3), 3.40-3.49 (m, 5H, OCH3, H-
3’, 5), 3.68-3.78 (m, 2H, J2’,3’ = 9.5 Hz,  J5’,6’ = 6.4 Hz, H-2’, 5’), 3.81-3.92 (m, 3H, H-4, 
6a, 6b), 4.52-4.55 (m, 2H, J1’,2’ = 8.3 Hz, H-1’, 2), 4.64 (d, 1H, J1,2 = 1.4 Hz, H-1), 4.97 
(dd, 1H, J3’,4’ = 4.3 Hz, H-3’), 5.28 (dd, 1H, J4’,5’ = 2.8 Hz, H-4’) ppm; 
13
C NMR (75 
MHz, CD3OD): δ, 17.0, 20.8, 21.4, 22.5, 23.2, 52.1, 53.7, 57.2, 58.1, 61.4, 69.6, 70.3, 
73.8, 75.1, 76.7, 80.3, 101.1, 102.8, 171.8, 172.5, 174.0 (x 2) ppm; HR-FAB MS 
[M+Na]
+
 calcd for C22H36O12N2Na 543.2166, found 543.2180.  
 
Methyl O-(2-acetamido-4-O-acetyl-2,6-dideoxy-3-O-methyl-β-D-fucopyranosyl)-
(14)-(2-acetamido-3-O-acetyl-2-deoxy-β-D-mannopyranosid)uronic acid (4.29).  
Water (5.0 mL), TEMPO (21 mg, 0.14 mmol), and BAIB (271 mg, 0.84 mmol) were 
added to a solution of disaccharide 4.28 (175 mg, 0.34 mmol) in CH2Cl2 (10.0 mL) and 
the resulting mixture was stirred for 16 h at rt. After that, the reaction mixture was 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(dichloromethane - methanol gradient elution) to afford the title compound as a white 
amorphous solid in (125 mg, 70%). Analytical data for 4.29: Rf = 0.44 
(methanol/dichloromethane, 3/7, v/v); []D
22
 -12.9 (c = 1, CH3OH); 
1
H NMR (300 MHz, 
CD3OD): δ, 1.08 (d, 3H, H-6’), 1.95, 1.97, 2.01, 2.07 (4s, 12H, 4 x COCH3), 3.23-3.41 
(m, 7H, J3’,4’ = 3.2 Hz, 2 x OCH3, H-3’), 3.63-3.76 (m ,3H, J2’,3’ = 7.8 Hz, J5’,6’ = 6.4 Hz, 
H-2’, 5, 5’), 3.81 (dd, 1H, J4,5 = 9.6 Hz, H-4), 4.43-4.51 (m, 2H, J1’,2’ = 8.6 Hz, J2,3 = 4.2 
Hz, H-1’, 2), 4.91 (d, 1H, J1,2 = 1.2 Hz, H-1), 4.86 (dd, 1H J3,4 = 9.6 Hz, H-3), 5.22 (dd, 
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1H, J4’,5’ = 2.9 Hz, H-4’) ppm; 
13
C NMR (75 MHz, CD3OD): δ, 17.0, 20.8, 21.3, 22.6, 
23.5, 52.1, 53.1, 57.3, 58.2, 69.8, 70.6, 74.0, 76.6, 79.3, 81.2, 101.1, 102.5, 172.2, 172.5, 
174.1 (x 2), 174.5 ppm; HR-FAB MS: [M+Na]
+




acetamido-2-deoxy-β-D-mannopyranosid)uronic acid (D2).  NaOH (4.0 mL, 1M aq.) 
was added dropwise to the solution of 4.29 (125 mg, 0.23 mmol) in MeOH (4 mL) and 
the mixture was stirred overnight at rt. After that, Amberlite IR120 resin was added to the 
solution until pH was 7. Then, the solid was filtered-off and the solution was 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(methanol - dichloromethane gradient elution) to yield the title compound as white 
amorphous solid (89 mg, 84%). Analytical data for D2: Rf = 0.15 
(methanol/dichloromethane, 3/7, v/v); []D
22
 -36.1 (c = 1, CH3OH); 
1
H NMR (300 MHz, 
CD3OD): δ, 1.28 (d, 3H, H-6’), 2.02 (br. s, 6H, 2 x COCH3), 3.21 (dd, 1H, J3’,4’ = 3.0 Hz, 
H-3’), 3.38, 3.43 (2s, 6H, 2 x OCH3), 3.59-3.72 (m, 4H, J5’,6’ = 6.4 Hz,  H-1, 2, 4, 5’), 
3.85 (dd, 1H, J4’,5’ = 2.7 Hz, H-4’), 3.91 (dd, 1H, J2’,3’ = 10.8 Hz, H-2’), 4.41 (d, 1H, J1’,2’ 
= 8.5 Hz, H-1’), 4.49-4.52 (m, 2H, H-3, 5) ppm; 
13
C NMR (75 MHz, CD3OD):  δ, 16.9, 
22.9, 23.5, 52.2, 53.4, 57.2, 57.6, 68.0, 72.3, 72.4, 79.0, 80.3, 82.8, 101.9, 102.7, 174.4 (x 
2), 176.6 ppm; HR-FAB MS: [M+Na]
+
 calcd for C18H30N2O11Na, 473.1747; found, 
473.1744. 
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The synthesis of the hexasaccharide 
subunit of the capsular polysaccharide 
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5.1 Introduction 
Staphylococcus aureus (S. aureus), Gram positive normal flora bacteria, is one of 
the most common opportunistic pathogens. It is usually found in human mucous 
membrane and skin.
1
 When the integrity of skin is broken and the immune system is 
weakened, it may cause bloodstream infection which leads to a variety of potentially 
serious infections. Recently, one of the greatest concerns, methicillin-resistant S. aureus 
(MRSA), a drug-resistant strain, has emerged. The treatment options for the MRSA 
infections have been restricted due to the increasing drug resistance rates.
2
 The 
alternative treatments such as immunotherapies or prophylactic vaccines might be the 
solutions of these issues. Since the outer part of the S aureus is surrounded by capsular 
polysaccharides, the preventive vaccination based on the capsular polysaccharide 
conjugates may become a promising approach to protect against S. aureus infections.
3
 
A majority of S. aureus strains express either capsular polysaccharide type 5 
(CP5) or type 8 (CP8).
4
 The chemical structures of both types have been established
5
 and 
the chemical syntheses of oligosaccharide derivatives of each serotype have been 
reported.
6-10
 The structure of the CP8 capsular polysaccharide consists of a trisaccharide 
repeating unit composed of rather unique building blocks. The terminal 2,4-di-N,O-
acetyl-D-mannosamine uronic acid (4-Ac-D-ManNAcA) residue is β-(13)-
glycosidically linked to 2-N-acetyl-L-fucosamine (L-FucNAc). In turn, the L-FucNAc is 
connected a D-FucNAc residue via a α-(13)-linkage. In the bacterial polysaccharide 
capsule sequence, the D-FucNAc unit is then connected to another repeating unit via an 
α-(13)-linkage to D-ManNAcA (Scheme 5.1).  
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The chemical synthesis of CP8 repeating unit has been achieved by our group in 
2015
8
 and a partial sequence has been reported by Codee in 2017
10
 (Scheme 5.1). Our 
synthetic CP8 trisaccharide was equipped with methyl groups at the propagation termini. 
This model was designed as a tool to study the activation and conjugation of the full 
length CP8 polysaccharide obtained by fermentation of S. aureus. To enhance our 
understanding of the conjugation process, we decided to synthesize a hexasaccharide 
comprising two sequential repeating units of CP8 (H1, Scheme 5.2). It is expected that 
the study of this larger polysaccharide and its conjugates will be beneficial for eliciting 
serotype-specific antibodies offering a window of opportunity for developing novel 
synthetic vaccines. To preserve the structural features and restrict the number of possible 
conjugation sites, the hexasaccharide will be capped with the terminal methyl groups.  
The synthesis of the CP8 hexasaccharide represents several synthetic challenges. 
For instance, the introduction of 1,2-cis glycosidic linkages
11
 often proceeds with low 
selectivity, and our synthetic target H1 contains six such linkages. Moreover, multiple 
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azido groups are present in the molecule, which may require the development of suitable 
reaction conditions for their concomitant reduction.
12
 In addition, access to multiple 
ManNAcA residues via the oxidation of the respective multiple sites may require 
different reaction conditions than the previously used, mild secondary oxidant 




Scheme 5.2. Structure of hexasaccharide H1 derived from the two consecutive 
repeating units of CP8. 
 
  
5.2   Results and Discussion 
5.2.1 Retrosynthetic analysis of hexasaccharide H1  
In order to assemble the CP8 hexasaccharide subunit, we decided to utilize a [3 + 
3] glycosylation strategy using a trisaccharide donor and a trisaccharide acceptor as 
depicted in Scheme 5.3. We anticipated that this approach would allow us to apply 
similar synthetic considerations to those used in our previous syntheses of staphylococcal 
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trisaccharides. First, to obtain β-mannosidic linkages we chose to proceed via 
glucosylation using neighboring group participation to ensure the β-linkage, followed by 
epimerization of the stereocenter at C-2 to obtain the mannosamine residue. Second, the 
S-benzoxazolyl (SBox) leaving group of the glucosyl donor should allowed us to 
selectively activate the SBox leaving group in the presence of ethylthio glycoside by 
using silver(I) trifluoromethanesulfonate (AgOTf) as the promoter. Third, we chose to 
employ p-methoxyphenyl (PMP) as a temporary anomeric protecting group
14
 that can be 
converted to the trichloroacetimidoyl leaving group for subsequent glycosylation.  
Scheme 5.3. Structure and retrosynthesis of CP8 hexasaccharide H1. 
 
 
5.2.2 Synthesis of L-fucosyl acceptor 5.4 
The synthesis of L-fucosyl acceptor for the introduction at the middle part of each 
trisaccharide was prepared from a known thioglycoside 5.1
15
 as depicted in Scheme 5.4. 
Satsawat Visansirikul | UMSL 2018 | Page  137 
 
Deacetylation of compound 5.1 was affected with sodium methoxide (NaOMe) in 
methanol (MeOH) to obtain compounds 5.2a and 5.2b in 83% yield. The β-anomer 5.2b 
was subjected to the benzylidene introduction with dimethoxytoluene (DMT) and 
camphorsulfonic acid (CSA) in acetonitrile (CH3CN) to yield compound 5.3 in 78% 
yield. The latter was then reacted with sodium cyanoborohydride (NaCNBH3) in 2 M 
hydrogen chloride solution in diethyl ether (2M HCl/Et2O) in THF to afford the fucosyl 
acceptor 5.4 in 78% yield.  
Scheme 5.4. Synthesis of L-fucosyl acceptor 5.4. 
 
 
5.2.3 Synthesis of D-fucosyl acceptor 5.9 
The synthesis of the D-fucosyl acceptor for the introduction of the reducing end 
unit in the trisaccharide donor was initiated from D-galactose derivative 5.5
16
 as depicted 
in Scheme 5.5. The introduction of  the tert-Butyldiphenylsilyl (TBDPS) group was 
performed with TBDPSCl in the presence of imidazole in CH2Cl2 to acquire compound 
5.6 in 93% yield. The latter was reacted with copper(II) trifluoromethansulfonate 
(Cu(OTf)2) and a borane-tetrahydrofuran complex solution in THF to regioselectively 
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open benzylidene ring to obtain 5.7 in 95% yield. The primary hydroxyl group of 5.7 was 
reacted with trifluoromethanesulfonic anhydride (Tf2O) in the presence of pyridine in 
CH2Cl2 at -30 
o
C, followed by the substitution of triflate by a hydride with sodium 
borohydride to give D-fucosamine 5.8 in 47% yield. After that, the silyl ether was 
removed with tetrabutylammonium fluoride (TBAF) in THF to afford D-fucosyl acceptor 
5.9 in 91% yield.  
Scheme 5.5. Synthesis of D-fucosyl acceptor 5.9. 
 
 
5.2.4 Synthesis of D-glucosyl donor 5.12 
The synthesis of glycosyl donor started from the known glucosyl derivative 5.10
17
 
as depicted in Scheme 5.6. Compound 5.10 was subjected to the introduction of the 
levulinoyl group with levulinic acid (LevOH) in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and 4-dimethylaminopyridine (DMAP) to 
yield compound 5.11 in 92% yield.  The latter thioglycoside was converted to glucosyl 
bromide with bromine in dichloromethane at 0 
o
C, followed by the introduction of the S-
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benzoxazolyl (SBox) leaving group with KSBox
18
 in the presence of 18-crown-6 (18-c-6) 
in acetone to give thioimidate donor 5.12 in 67% yield over two steps.  
Scheme 5.6. Synthesis of D-glucosyl donor 5.12. 
 
 
5.2.5 Synthesis of trisacchride donor 5.19 
With all building blocks in hand, we conducted the selective activation of the 
SBox leaving group in the presence of the anomeric SEt group in the acceptor. Thus, 
glucosyl donor 5.13
8
 was glycosylated with fucosyl acceptor 5.4 in the presence of 
AgOTf in CH2Cl2 to acquire disaccharide 5.14 in 85% yield (Scheme 5.7). The latter was 
reacted with hydrazine acetate in CH2Cl2 and MeOH to affect the selective removal of the 
levulinoyl ester to give disaccharide 5.15 in 85% yield. After that, disaccharide 5.15 was 
epimerized into the manno-configuration by a two-step procedure involving sulfonation 
at C-2’ with Tf2O in the presence of pyridine in CH2Cl2 at 0 
o
C, followed by 
epimerization by sodium azide (NaN3) in DMF at 70 
o
C to yield D-mannosyl 
disaccharide 5.16 in 59% yield over two steps. After that, glycosylation between 
disaccharide donor 5.16 and D-fucosyl acceptor 5.9 was performed in the presence of N-
iodosuccinimide (NIS) and trifluoromethanesulfonic acid (TfOH) in CH2Cl2 at 0 
o
C to 
afford trisaccharide 5.17 in 75% yield. Selective removal of the anomeric PMP group 
with cerium ammonium nitrate (CAN) in wet CH3CN gave hemiacetal 5.18 in 29% yield. 
The reaction yield of PMP removal was low due to the low reactivity of the PMP group 
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at the reducing end of trisaccharide 5.17. Then, the 1-OH group of trisaccharide 5.18 was 
reacted with trichloroacetonitrile (CCl3CN) in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in CH2Cl2 to obtain trisaccharide donor 5.19 in 
41% yield. 
Scheme 5.7. Synthesis of trisaccharide donor 5.19. 
 
 
5.2.6 Synthesis of trisaccharide acceptor 5.25 
The assembly of the trisaccharide acceptor was initiated by the glycosylation of 
the D-glucosyl donor 5.12 and the L-fucosyl acceptor 5.4 by selective activation of SBox 
in the presence of SEt with AgOTf to obtain disaccharide 5.20 in 74% yield (Scheme 
5.8). Then, the C-2’ of disaccharide 5.20 was converted into the D-manno isomer via 
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sequential selective removal of the levulinoyl group with hydrazine acetate in CH2Cl2 to 
yield 2’-OH disaccharide 5.21 in 69% yield, sulfonation with Tf2O, and epimerization 
with NaN3
19
 to give disaccharide 5.22 in 67% yield over two steps. The latter was 
subjected to glycosylation with the D-fucosyl acceptor 5.23 in the presence of NIS and 
TfOH in CH2Cl2 at 0 
o
C to afford trisaccharide 5.24 in 62% yield with exclusive α-
selectivity. Debenzoylation at C-3” of trisaccharide 5.24 with NaOMe in MeOH provided 
the trisaccharide acceptor 5.25 in 88% yield.  
Scheme 5.8. Synthesis of trisaccharide acceptor 5.25 and the [3 + 3] glycosylation. 
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5.2.7 The [3 + 3] glycosylation 
With the trisaccharide donor 5.19 and trisaccharide acceptor 5.25 in hand, we 
attempted to perform glycosylation in the presence of TMSOTf as a promoter in CH2Cl2 
at 0 
o
C (Scheme 5.8). However, the desired hexasaccharide was not observed, and only 
the trisaccharide acceptor 5.25 was recovered from the reaction. We hypothesized that 
this failure could have been due to the substantial steric bulk of the trisaccharide donor. 
To test the viability of this hypothesis, we decided to synthesize D-fucosyl donor 5.31, 
which could be used for a model glycosylation. 
 
5.2.8 Model glycosylation of D-fucosyl donor 5.31 and trisaccharide acceptor 5.25 
The synthesis of the D-fucosyl donors 5.31 started from the known fucosyl 
compound 5.26
7
 as depicted in Scheme 5.9. First, the thioethyl leaving group was 
introduced using EtSH in the presence of BF3-Et2O in CH2Cl2 to afford thioglycoside 
5.27 in 83% yield.  Deacetylation of compound 5.27 was performed in the presence of 
NaOMe in MeOH to yield diols 5.28a and 5.28b (5.28a/5.28b = 1.4/1) in 88% yield. The 
isolated α-isomer 5.28a was subjected to benzylidene acetal introduction at C-3,4 with 
DMT in the presence of CSA in CH3CN to give compound 5.29 in 81% yield. 
Regioselective benzylidene ring opening was achieved by the treatment with NaCNBH3 
in a HCl (2M in Et2O) in THF to acquire 3-OH intermediate 5.30 in 81% yield. The latter 
was methylated with CH3I in the presence of NaH in DMF to afford D-fucosyl donor 
5.31 in 91% yield. 
With D-fucosyl donor 5.31 in hand, we conducted the glycosylation between the 
D-fucosyl donor 5.31 and the trisaccharide acceptor 5.25 in the presence of NIS and 
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TfOH as the promoter system. As the result, tetrasaccharide 5.32 was smoothly produced 
in 89% yield with exclusive α-selectivity (Scheme 5.9).  
Scheme 5.9. Synthesis of D-fucosyl donor 5.31 and model glycosylation of D-fucosyl 
donor 5.31 and trisaccharide acceptor 5.25. 
 
 
5.2.9 The revised retrosynthetic analysis of a key hexasaccharide intermediate 5.36 
Based on the success in preparing tetrasaccharide 5.32, we decided to revise our 
synthetic approach by utilizing the [2 + 1 + 3] strategy to obtain hexasaccharide 5.36 as 
depicted in Scheme 5.10. This strategy should allow us to use disaccharide 5.14 and 
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trisaccharide acceptor 5.25 that have been synthesized previously. However, D-fucosyl 
donor 5.33, which connects these two subunits, will have to be prepared.  
Scheme 5.10. The revised retrosynthesis of a key hexasaccharide intermediate 5.36. 
 
 
5.2.10 Synthesis of D-fucosyl donors 5.33 and tetrasaccharide acceptor 5.35 
The D-fucosyl donor 5.33 used in the synthesis of tetrasaccharide acceptor 5.35 
was obtained by benzoylation of compound 5.30 with BzCl in the presence of DMAP in 
pyridine to afford D-fucosyl donor 5.33 in 96% yield (Scheme 5.11). To obtain 
tetrasaccharide acceptor 5.34, the glycosylation of D-fucosyl donor 5.29 and trisaccharide 
acceptor 5.22 was conducted in the presence of NIS and TfOH as the promoter system in 
CH2Cl2 at 0 
o
C (Scheme 5.11). As a result, tetrasacharide 5.34 was isolated in 81% yield 
exclusively as the α-linked anomer. After that, the 3”’-OBz group was removed in the 
presence of NaOMe in MeOH to give the tetrasaccharide acceptor 5.35 in 76% yield.  
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Scheme 5.11. Synthesis of D-fucosyl donor 5.33 and tetrasaccharide acceptor 5.35. 
 
 
5.2.11 Assembly and functionalization to hexasaccharide H1 
The [2 + 4] glycosylation of disaccharide donor 5.14 and tetrasacchride acceptor 
5.35 was affected by NIS and TfOH in CH2Cl2 at 0 
o
C to afford the desired 
hexasaccharide 5.36 in 85% yield (Scheme 5.12). After that, the azido groups of 
hexasaccharide 5.36 were reduced by 1,3-propanedithiol and triethylamine (TEA) in wet 
pyridine at 70 
o
C, followed by N-acetylation in the presence of acetic anhydride (Ac2O) 
in pyridine. After that, an additional one pot reduction-N-acetylation with zinc dust in 
acetic acid and acetic anhydride was performed to ensure the complete reduction of all 
azide groups. As a result, hexasaccharide 5.37 was obtained in 64% yield.  
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Scheme 5.12. Assembly and functionalization to CP8 hexasaccharide H1. 
 
 
Then, benzylidine removal was affected by acetic acid in water at 90 
o
C to acquire 
tetraol 5.38 in 76% yield. To obtain the fully protected hexasaccharide 5.39, the primary 
hydroxyl groups of compound 5.38 were selectively oxidized by TEMPO and BAIB in 
wet CH2Cl2.
20
 However, the reaction processed slowly, and no dicarboxylic acid 
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derivative was observed due to the low reactivity of the secondary oxidizing reagent. To 
overcome this issue, we decided to perform the oxidation with a modified method
21
 
involving the reaction with TEMPO in the presence of sodium chlorite (NaClO2), sodium 
hypochlorite (NaClO), brine solution (NaCl), saturated sodium bicarbonate solution 
(NaHCO3) and a borax buffer pH 9 in CH3CN to obtain the dicarboxylic acid derivative. 
The latter was then converted into the benzyl dicarboxylate with benzyl bromide (BnBr) 
in the presence of NaH in DMF and the secondary hydroxyl groups were acetylated with 
Ac2O in pyridine. Unexpectedly, the mass spectrometry and NMR experiments indicated 
that methyl ester derivative 5.40 was formed instead of benzyl ester hexasaccharide 5.39 
in 31% yield over three steps. The transesterification might have occurred during the 
methanol quenching after the acetylation step.  However, the hexasaccharide 5.40 should 
be useful for chemical activation study of CP8 and the structure-activity relationship 
study to determine the required minimal epitope for immune response. 
 
5.3 Conclusions and Outlook 
We successfully assembled in the assembly of the CP8 hexasaccharide bearing 
methyl groups as the capping groups. The original [3 + 3] glycosylation strategy was 
unsucceessful due to the repulsive  interactions between the reaction counterparts. 
However, we modified the synthethic plan as a [1 + 2 + 3] glycosylation strategy that has 
been utilized. We succeeded in synthesizing the key intermediate hexasaccharide 
sequence 5.36 which was subjected to structure modification to obtain CP8 
hexasaccharide H1. However, during the functionalization we unexpectedly obtained the 
methyl ester hexasaccharide 5.40, probably due to the transesterification that have 
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ocurred during the methanol quench step. Nevertheless, we believe that methyl ester  CP8 
hexasaccharide 5.40 as well as the tetrasaccharide derivative 5.32 will be useful 
compounds to study protein conjugation. In turn, this will lead to a better understanding 
of the activation process of native polysaccarides and will ultimately allow us to control, 
predict and reliably reproduce polysaccharide conjugations. 
 
5.4 Experimental 
5.4.1 General Methods 
The reactions were performed using commercial reagents (Aldrich or Acros) and 
ACS grade solvents were purified and dried according to standard procedures.  Column 
chromatography was performed on silica gel 60 (EM Science, 70-230 mesh), reactions 
were monitored by TLC on Kieselgel 60 F254 (EM Science). The compounds were 
detected by examination under UV light and by charring with 10% sulfuric acid in 
methanol. Solvents were removed under reduced pressure at <40 
o
C. CH2Cl2 and 
ClCH2CH2Cl were distilled from CaH2 directly prior to application. Molecular sieves (3 
Å or 4 Å), used for reactions, were crushed and activated in vacuo at 390 °C during 8 h in 
the first instance and then for 2-3 h at 390 °C directly prior to application. The borax 
buffer solution (pH 9) was prepared with 0.05 M sodium tetraborate (Na2B4O7) solution 
(85.6 mL) and 0.1 M hydrochloric acid (HCl) solution (14.4 mL). Optical rotations were 
measured at ‘Jasco P-2000’ polarimeter. 
1
H NMR spectra were recorded at 300 MHz 
(Bruker Avance) or 600 MHz (Agilent), 
13
C-NMR spectra were recorded at 75 MHz 
(Bruker Avance) or 150 MHz (Agilent). The 
1
H chemical shifts are referenced to the 
signal of the residual CHCl3 (δH = 7.27 ppm) for solutions in CDCl3 or the signal of the 
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residual CH3OH (δH = 3.31 ppm) for solutions in CD3OD. The 
13
C chemical shifts are 
referenced to the central signal of CDCl3 (δC = 77.23 ppm) for solutions in CDCl3 or the 
central signal of CD3OD (δC = 49.15 ppm) for solutions in CD3OD. HRMS 
determinations were made with the use of JEOL MStation (JMS-700) mass spectrometer. 
 
5.4.2 Synthesis of L-fucosyl acceptor 5.4 
Ethyl 2-azido-2,6-dideoxy-1-thio-α-L-galactopyranoside (5.2a) and ethyl 2-azido-2,6-
deoxy-1-thio-β-L-galactopyranoside (5.2b). A 1M solution of NaOMe in MeOH (4.0 
mL) was added to a stirring solution of ethyl 3,4-di-O-acetyl-2-azido-2,6-dideoxy-1-thio-
L-galactopyranoside
15
 (5.1, 4.98 g, 15.7 mmol) in methanol (50 mL) and the resulting 
mixture was stirred under argon for 2 h at rt. After that, Amberlite IR120 H+ resin was 
added to the solution until pH = 7. Then, the resin was filtered-off, rinsed successively 
with MeOH (7 x 5 mL), and the combined filtrate was concentrated in vacuo. The residue 
was separated by column chromatography on silica gel (ethyl acetate - hexane gradient 
elution) to yield 5.2a (1.61 g, 40%) and 5.2b (1.73 g, 43%) as a white amorphous solid. 
Analytical data for 5.2a: Rf = 0.31 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.28-1.33 (m, 6H, CH2CH3, H-6), 2.54 (q, 2H, CH2CH3), 3.80-3.84 (m, 2H, 
H-3, 4), 4.00 (dd, 1H, J2,3 = 9.8 Hz, H-2), 4.32 (m, 1H, H-5), 5.41 (d, 1H, J1,2 = 5.6 Hz, 
H-1) ppm; 5.2b: Rf = 0.26 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): 
δ, 1.30-1.36 (m, 6H, CH2CH3, H-6), 2.71 (q, 2H, CH2CH3), 3.42-3.56 (m, 2H, J2,3 = 9.5 
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Ethyl 2-azido-3,4-O-benzylidene-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.3). 
Dimethoxytoluene (2.4 mL, 15.78 mmol) and camphorsulfonic acid (92 mg, 0.39 mmol) 
we added to a solution of 5.2b (1.73 g, 7.89 mmol) in acetonitrile (30 mL) and the 
resulting mixture was stirred under argon for 1 h at rt. After that, triethylamine (~0.3 mL) 
was added and the volatiles were removed in vacuo. The residue was diluted with CH2Cl2 
(~200 mL) and washed with water (30 mL), sat. aq. NaHCO3 (30 mL), and water (30 
mL). The organic phase was separated, dried with MgSO4, and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to yield the title compound as a white amorphous solid (1.90 g, 78%). 
Analytical data for 5.3: Rf = 0.64 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.28 (t, 3H, CH2CH3), 1.49 (d, 3H, H-6), 2.66 (q, 2H, CH2CH3), 3.39 (dd, 1H, 
J2,3 = 7.4 Hz, H-2), 3.88 (m, 1H, J5,6 = 6.6 Hz, H-5), 4.09 (dd, 1H, J4,5 = 2.3 Hz, H-4), 
4.17 (dd, 1H, J3,4 = 5.6 Hz, H-3), 4.25 (d, 1H, J1,2 = 10.6 Hz, H-1), 6.00 (s, 1H, CHPh), 
7.39-7.42 (m, 3H, aromatic), 7.50-7.54 (m, 2H, aromatic) ppm. 
 
Ethyl 2-azido-4-O-benzyl-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.4). A solution 
of compound 5.3 (1.21 g, 3.78 mmol) and activated molecular sieves (3 Å, 1.50 g) in 
THF (30 mL) was stirred under argon for 1 h at rt. NaCNBH3 (3.17 g, 50.27 mmol) was 
added in one portion, 2M HCl in diethyl ether (25.1 mL, 50.27 mmol) was added 
dropwise, and the resulting mixture was kept for 1 h at rt. After that, the solids were 
filtered off and rinsed successively with CH2Cl2. The combined filtrate (~150 mL) was 
washed with water (30 mL), sat. aq. NaHCO3 (30 mL), and water (30 mL). The organic 
phase was separated, dried with MgSO4, and concentrated in vacuo. The residue was 
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purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) 
to yield the title compound as a clear syrup (957 mg, 78%). Analytical data for 5.4: Rf = 
0.59 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.28-1.36 (CH2CH3, 
H-6), 2.29 (d, 1H, J3,OH = 8.1 Hz, OH), 2.70 (q, 2H, CH2CH3), 3.46-3.62 (m, 4H, H-2, 3, 
4, 5), 4.22 (d, 1H, J1,2 = 9.6 Hz, H-1), 4.66 (dd, 1H, 
2
J = 11.6 Hz, ½ CH2Ph), 4.83 (dd, 
1H, 
2
J = 11.6 Hz, ½ CH2Ph), 7.32-7.39 (m, 5H, aromatic) ppm. 
 
5.4.3 Synthesis of D-fucosyl acceptor 5.9 
4-Methoxyphenyl 2-azido-4,6-O-benzylidene-3-O-tert-butyldiphenylsilyl-2-deoxy-β-
D-galactopyranoside (5.6). tert-Butyldiphenylchlorosilane (1.56 mL, 6.01 mmol) and 
imidazole (819 mg, 12.03 mmol) were added to a stirring solution of 4-methoxyphenyl-2-
azido-4,6-O-benzylidene-2-deoxy-β-D-galactopyranoside
16
 (5.5, 1.60 g, 4.01 mmol) in 
CH2Cl2 (50 mL). The resulting mixture was stirred under argon for 1 h at rt. After that, 
the volatiles were removed in vacuo. The residue was diluted with CH2Cl2 (~200 mL) 
and washed with water (30 mL), sat. aq. NaHCO3 (30 mL), and water (30 mL). The 
organic phase was separated, dried with MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography on silica gel (ethyl acetate - hexane gradient 
elution) to yield the title compound as a white amorphous solid (2.37 g, 93%). Analytical 
data for 5.6: Rf = 0.67 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 
1.10 (s, 9H, C(CH3)3), 3.16 (m, 1H, H-5), 3.53 (dd, 1H, J4,5 = 3.2 Hz, H-4), 3.61 (dd, 1H, 
J3.4 = 3.5 Hz, H-3), 3.77-3.82 (m, 4H, OCH3, H-6a), 4.09 (dd, 1H, J2,3 = 10.1 Hz, H-2), 
4.20 (m, 1H, H-6b), 4.63 (d, 1H, J1,2 = 8.2 Hz, H-1), 5.22 (s, 1H, CHPh), 6.79 (d, 2H, J = 
Satsawat Visansirikul | UMSL 2018 | Page  152 
 
9.1 Hz, PMP), 7.04 (d, 2H, J = 9.0 Hz, PMP), 7.29-7.34 (m, 2H, aromatic), 7.40-7.46 (m, 
7H, aromatic), 7.53-7.65 (m, 2H, aromatic), 7.74-7.86 (m, 4H, aromatic) ppm. 
 
4-Methoxyphenyl 2-azido-4-O-benzyl-3-O-tert-butyldiphenylsilyl-2-deoxy-β-D-
galactopyranoside (5.7). Copper(II) trifluoromethanesulfonate (145 mg, 0.40 mmol) was 
added to a stirring solution of compound 5.6 (2.37 g, 3.72 mmol) in a 1.0 M borane-
tetrahydrofuran complex solution in THF (18.6 mL, 18.60 mmol) and the resulting 
mixture was stirred under argon for 4 h at rt. After that, triethylamine (~3.0 mL) and 
MeOH were added at 0 
o
C. Then, the volatiles were removed in vacuo. The residue was 
purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) 
to yield the title compound as a white amorphous solid (2.26 g, 95%). Analytical data for 
5.7: Rf = 0.51 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.11 (s, 
9H, C(CH3)3), 3.30-3.38 (m, 3H, H-5, 6a), 3.44 (dd, 1H, J4,5 = 2.7 Hz, H-4), 3.63-3.71 
(m, 5H, OCH3, H-3, 6a), 4.02 (dd, 1H, J2,3 = 10.2 Hz, H-2), 4.35 (d, 1H, 
2
J = 11.5 Hz, ½ 
CH2Ph), 4.55 (d, 1H, J1,2 = 8.0 Hz, H-1), 4.88 (d, 1H, 
2
J = 11.5 Hz, ½ CH2Ph), 6.72 (d, 
2H, J = 9.1 Hz, PMP), 6.88 (d, 2H, J = 9.09 Hz, PMP), 7.17-7.21 (m, 2H, aromatic), 
7.34-7.43 (m, 9H, aromatic), 7.72-7.76 (m, 4H, aromatic) ppm. 
 
4-Methoxyphenyl 2-azido-4-O-benzyl-3-O-tert-butyldiphenylsilyl-2,6-dideoxy-β-D-
galactopyranoside (5.8). Pyridine (5.0 mL) was added to a solution of compound 5.7 
(2.26 g, 3.53 mmol) in CH2Cl2 (20.0 mL) and the resulting mixture was cooled to -78 
o
C. 
Trifluoromethanesulfonic anhydride (0.71 mL, 4.24 mmol) was added dropwise and the 
reaction mixture was allowed to reach 0 
o
C in 30 mins. After that, the reaction was 
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quenched with ice-cold water (~5 mL), diluted with CH2Cl2 (~200 mL), and washed with 
1 N HCl solution (50 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The crude residue was dissolved in CH3CN (20.0 mL), NaBH4 
(401 mg, 10.59 mmol) was added, and the resulting suspension was stirred for 48 h at rt. 
Upon completion, CH2Cl2 (~200 mL) was added. Organic layer was washed with water 
(50 mL), 1 N aq. HCl solution (50 mL) and water (50 mL). The organic extract was dried 
with MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate-hexane gradient elution) to afford the title 
compound as a white foam (1.03 g, 47%). Analytical data for 5.8: Rf = 0.75 (ethyl 
acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.11 (s, 9H, C(CH3)3), 3.30-
3.38 (m, 3H, H-5, 6a), 3.44 (dd, 1H, J4,5 = 2.7 Hz, H-4), 3.63-3.71 (m, 5H, OCH3, H-3, 
6a), 4.02 (dd, 1H, J2,3 = 10.2 Hz, H-2), 4.35 (d, 1H, 
2
J = 11.5 Hz, ½ CH2Ph), 4.55 (d, 1H, 
J1,2 = 8.0 Hz, H-1), 4.88 (d, 1H, 
2
J = 11.5 Hz, ½ CH2Ph), 6.72 (d, 2H, J = 9.1 Hz, PMP), 
6.88 (d, 2H, J = 9.1 Hz, PMP), 7.17-7.21 (m, 2H, aromatic), 7.34-7.43 (m, 9H, aromatic), 
7.72-7.76 (m, 4H, aromatic) ppm. 
 
4-Methoxyphenyl 2-azido-4-O-benzyl-2,6-dideoxy-β-D-galactopyranoside (5.9). 1 M 
tetrabutylammonium fluoride solution in THF (2.0 mL, 1.99 mmol) was added to a 
solution of compound 5.8 (1.03 g, 1.66 mmol) in THF (20.0 mL) and the resulting 
mixture was stirred under argon for 3 h at rt. After that, the organic phase was removed in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate-
hexane gradient elution) to afford the title compound as a white foam (581 mg, 91%). 
Analytical data for 5.9: Rf = 0.47 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, 
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CDCl3): δ, 1.15-1.17 (m, 12H, C(CH3)3, H-6), 3.25 (dd, 1H, J4,5 = 2.6 Hz, H-4), 3.39 (m, 
1H, H-5), 3.70 (dd, 1H, J3,4 = 2.7 Hz, H-3), 3.78 (s, 3H, OCH3), 4.03 (dd, 1H, J2,3 = 10.3 
Hz, H-2), 4.43 (d, 1H, 
2
J = 11.4 Hz, ½ CH2Ph), 4.55 (d, 1H, J1,2 = 8.0 Hz, H-1), 4.94 (d, 
1H, 
2
J = 11.4 Hz, ½ CH2Ph), 6.76 (d, 2H, J = 9.0 Hz, PMP), 6.96 (d, 2H, J = 9.0 Hz, 
PMP), 7.29-7.34 (m, 3H, aromatic), 7.36-7.49 (m, 8H, aromatic), 7.72-7.77 (m, 4H, 
aromatic) ppm. 
 
5.4.4 Synthesis of D-fucosyl donors 5.31 and 5.33 
Ethyl 3,4-di-O-acetyl-2-azido-2,6-dideoxy-1-thio-D-galactopyranoside (5.27). Ethane 
thiol (1.1 mL, 8.70 mmol) and BF3-Et2O (4.2 mL, 33.45 mmol) were added to a stirring 
solution of 1,3,4-tri-O-acetyl-2-azido-2,6-dideoxy-D-galactopyranose
7
 (5.26, 2.11 g, 6.69 
mmol) in CH2Cl2 (40 mL) at 0 
o
C. The reaction was stirred under argon and allowed to 
reach rt. After 3 h, the reaction was diluted with CH2Cl2 (~200 mL) and washed with 
water (30 mL), sat. aq. NaHCO3 (30 mL) and water (30 mL). The organic phase was 
separated, dried over MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford 
the title compound as a white amorphous solid (1.76 g, 83%). Analytical data for 5.27: Rf 
= 0.72 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.14 (d, 3H, H-
6α), 1.20 (d, 3H, H-6β), 1.28-1.36 (2t, 6H, 2 x CH2CH3), 2.04, 2.05, 2.17, 2.18 (4s, 12H, 
4 x COCH3), 2.58 (q, 2H, CH2CH3), 2.77 (q, 2H, CH2CH3), 3.60 (dd, 1H, J2β,3β = 10.3 
Hz, H-2β), 3.72 (m ,1H, J5β,6β = 6.5 Hz, H-5β), 4.19 (dd, 1H, J2α,3α = 11.0 Hz, H-2α), 4.34 
(d, 1H, , J1β,2β = 10.1 Hz, H-1β), 4.47 (m, 1H, J5α,6α = 6.5 Hz, H-5α), 4.85 (dd, 1H, J3β,4β = 
3.3 Hz, H-3β), 5.10 (dd, J3α,4α = 3.3 Hz, 1H, H-3α), 5.22 (dd, 1H, J4β,5β = 0.8 Hz, H-4β), 
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5.27 (dd, 1H, J4α,5α = 1.1 Hz, H-4α), 5.44 (d, 1H, J1α,2α = 5.6 Hz, H-1α) ppm; HR-FAB 
MS [M+Na]
+
 calcd for C12H19NaN3O5S 340.0943, found 340.0934. 
 
Ethyl 2-azido-2,6-dideoxy-1-thio-α-D-galactopyranoside (5.28a) and ethyl 2-azido-
2,6-dideoxy-1-thio-β-D-galactopyranoside (5.28b). A 1M solution of NaOMe in MeOH 
(3.0 mL) was added to a stirring solution of thiol compound 5.27 (6.38 g, 20.10 mmol) in 
methanol (60 mL) and the resulting mixture was stirred under argon for 4 h at rt. After 
that, Amberlite IR120 resin was added to the solution until pH was 7. Then, the solid was 
filtered-off and the solution was concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield 
5.28a (2.45 g, 52%) and 5.28b (1.70 g, 36%) as a white amorphous solid. 5.28a: Rf = 
0.52 (ethyl acetate/hexane, 7/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.28-1.33 (m, 6H, 
CH2CH3, H-6), 2.27 (d, 1H, JOH,4 = 3.7 Hz, 4-OH), 2.51-2.70 (m, 3H, CH2CH3, 3-OH), 
3.79-3.85 (m, 2H, H-3, 4), 4.00 (m, 1H, J2,3 = 9.9 Hz, H-2), 4.32 (m, 1H, H-5), 5.41 (d, 
1H, J1,2 = 5.6 Hz, H-1) ppm; 5.28b: Rf = 0.39 (ethyl acetate/hexane, 7/3, v/v);  
1
H NMR 
(300 MHz, CDCl3): δ, 1.30-1.35 (m, 6H, CH2CH3, H-6), 2.68-2.83 (m, 3H, CH2CH3, 4-
OH), 3.21 (d, 1H, JOH,3 = 7.0 Hz, 3-OH), 3.46-3.56 (m, 2H, J2,3 = 9.3 Hz, J3,4 = 2.3 Hz, 
H-2, 3), 3.61 (m, 1H, H-5), 3.76 (dd, 1H, H-4), 4.26 (d, 1H, J1,2 = 9.6 Hz, H-1) ppm;  
 
Ethyl 2-azido-3,4-O-benzylidene-2,6-dideoxy-1-thio-α-D-galactopyranoside (5.29). 
Dimethoxytolulene (0.76 mL, 5.04 mmol) and camphorsulfonic acid (29 mg, 0.13 mmol) 
we added to a solution of 5.28a (552 mg, 2.52 mmol) in acetonitrile (15 mL) and the 
resulting mixture was stirred under argon for 2 h at rt. After that, triethylamine (~0.3 mL) 
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was added and the volatiles were removed in vacuo. The residue was diluted with CH2Cl2 
(~120 mL) and washed with water (10 mL), sat. aq. NaHCO3 (10 mL), and water (20 
mL). The organic phase was separated, dried with MgSO4, and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
gradient elution) to yield the title compound as a colorless syrup (657 mg, 81%). 
Analytical data for 5.29: Rf = 0.69 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.29 (t, 3H, CH2CH3), 1.44 (d, 3H, H-6), 2.56 (m, 2H, CH2CH3), 3.87 (dd ,1H, 
J2,3 = 8.3 Hz, H-2), 4.13 (dd, 1H, J4,5 = 2.6 Hz, H-4), 4.34 (dd, 1H, J3,4 = 5.7 Hz, H-3), 
4.53 (m, 1H, J5,6 = 6.7 Hz, H-5), 5.27 (d, 1H, J1,2 = 5.3 Hz, H-1), 5.97 (s, 1H, CHPh), 
7.40-7.44 (m, 3H, aromatic), 7.52 (m, 2H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 
15.0, 16.4, 25.0, 62.4, 64.2, 74.7, 78.1, 82.3, 104.1, 126.6 (x 2), 128.7 (x 2), 129.6, 137.6 
ppm; HR-FAB MS [M+Na]
+
 calcd for C15H19O3NaSN3 344.1045, found 344.1053. 
 
Ethyl 2-azido-4-O-benzyl-2,6-deoxy-1-thio-α-D-galactopyranoside (5.30). A solution 
of compound 5.29 (657 mg, 2.04 mmol) and activated molecular sieves (3Å, 800 mg) in 
THF (10 mL) was stirred under argon for 1 h at rt. NaCNBH3 (1.71 g, 27.19 mmol) was 
added in one portion, 2M HCl in diethyl ether (13.3 mL, 27.19 mmol) was added 
dropwise, and the resulting mixture was kept for 1 h at rt. After that, the solids were 
filtered off and rinsed successively with CH2Cl2. The combined filtrate (~120 mL) was 
washed with water (20 mL), sat. aq. NaHCO3 (20 mL), and water (20 mL). The organic 
phase was separated, dried with MgSO4, and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) 
to yield the title compound as a clear syrup (536 mg, 81%). Analytical data for 5.30: Rf = 
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0.69 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.29-1.32 (m, 6H, 
CH2CH3, H-6), 2.15 (d, 1H, JOH,3 = 8.6 Hz, 4-OH), 2.52 (m, 2H, CH2CH3), 3.65 (dd, 1H, 
J4,5 = 1.0 Hz, H-4), 3.82 (m, 1H, J3,4 = 3.3 Hz, H-3), 3.98 (dd, 1H, J2,3 = 10.4 Hz, H-2), 
4.28 (m, 1H, H-5), 4.68 (d, 1H, 
2
J = 11.5 Hz, ½ CH2Ph), 4.81 (d, 1H, 
2
J = 11.4 Hz, ½ 
CH2Ph), 5.39 (d, 1H, J1,2 = 5.5 Hz, H-1), 7.33-7.38 (m, 5H, aromatic) ppm. 
 
Ethyl 2-azido-4-O-benzyl-2,6-dideoxy-3-O-methyl-1-thio-α-D-galactopyranoside 
(5.31). Methyl iodide (246 mg, 1.73 mmol) and sodium hydride (104 mg, 2.61 mmol) 
were added to a stirring solution of compound 5.30 (280 mg, 0.87 mmol) in DMF (5.0 
ml) at 0
o
C. The reaction was allowed to reach at rt. After 2 h, the reaction was poured 
into iced water and was stirred for 15 mins. Then, the aqueous phase was extracted with 
EtOAc/Et2O (1:1) (3 x 50 mL). The organic phase was collected, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate – hexane gradient elution) to afford the title compound as a white 
amorphous solid (226 mg, 91%). Analytical data for 5.30: Rf = 0.70 (ethyl acetate/ 
hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.19 (d, 3H, H-6), 1.26 (t, 3H, 
CH2CH3), 2.51 (m, 2H, CH2CH3), 3.47-3.52 (m, 4H, J3,4 = 2.8 Hz, OCH3, H-3), 3.71 (dd, 
1H, J4,5 = 1.7 Hz, H-4), 4.16-4.29 (m, 2H, J2,3 = 10.6 Hz, J5,6 = 6.5 Hz, H-2, 5), 4.62 (d, 
1H, 
2
J = 11.5 Hz, ½ CH2Ph), 4.93 (d, 1H, 
2
J = 11.5 Hz, ½ CH2Ph), 5.37 (d, 1H, J1,2 = 5.6 
Hz, H-1), 7.28-7.40 (m, 5H, aromatic) ppm. 
 
Ethyl 2-azido-3-O-benzoyl-4-O-benzyl-2,6-dideoxy-1-thio-α-D-galactopyranoside 
(5.33). Benzoyl chloride (0.29 mL, 2.49 mmol) and DMAP (41 mg, 0.33 mmol) we 
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added to a solution of compound 5.30 (536 mg, 1.66 mmol) in acetonitrile (10 mL) and 
the resulting mixture was stirred under argon for 4 h at rt. After that, the volatiles were 
removed in vacuo. The residue was diluted with CH2Cl2 (~120 mL) and washed with 
water (20 mL), sat. aq. NaHCO3 (20 mL), and water (20 mL). The organic phase was 
separated, dried with MgSO4, and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (ethyl acetate - hexane gradient elution) to yield the 
title compound as a colorless syrup (682 mg, 96%). Analytical data for 5.30: Rf = 0.73 
(ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.22 (d, 3H, H-6), 1.29 
(t, 3H, CH2CH3), 2.53 (m, 2H, CH2CH3), 3.97 (dd, 1H, J4,5 = 2.3 Hz, H-4), 4.39 (m, 1H, 
J5,6 = 6.5 Hz, H-5), 4.51-4.60 (m, 2H, J2,3 = 11.0 Hz,  ½ CH2Ph, H-2), 4.65 (d, 1H, 
2
J = 
11.3 Hz, ½ CH2Ph), 5.28 (dd, 1H, J3,4 = 2.9 Hz, H-3), 5.50 (d, 1H, J1,2 = 5.6 Hz, H-1), 
7.25-7.26 (m, 5H, aromatic), 7.46-7.51 (m, 2H, aromatic), 7.59-7.64 (m, 1H, aromatic), 
8.07-8.10 (m, 2H, aromatic) ppm. 
 
5.4.5 Synthesis of D-glucosyl donor 5.12 
Ethyl 3-O-benzoyl-4,6-O-benzylidene-2-O-levulinyl-1-thio-β-D-glucopyranoside 
(5.11). Levulinic acid (972 mg, 8.37 mmol), EDC (2.47 g, 12.86 mmol) and DMAP (159 
mg, 1.29 mmol) were added to a stirring solution of ethyl 4,6-O-benzylidene-3-O-
benzoyl-1-thio-β-D-glucopyranoside
17
 (5.10, 2.68 g, 6.43 mmol) in CH2Cl2 (80 mL) and 
the resulting mixture was stirred for 1 h at rt. After that, the reaction mixture was diluted 
with CH2Cl2 (~300 mL) and washed with water (50 mL) sat. aq. NaHCO3 (50 mL) and 
water (50 mL). The organic phase was separated, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate - 
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hexane gradient elution) to afford the title compound as a white amorphous solid (3.05 g, 
92%). Analytical data for 5.11: Rf = 0.47 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 
MHz, CDCl3): δ, 1.26 (t, 3H, CH2CH3), 2.02 (s, 3H, COCH3), 2.46-2.54 (m, 4H, 
COCH2CH2CO), 2.72 (q, 2H, CH2CH3), 3.65 (m, 1H, J5,6b = 4.8 Hz, H-5), 3.78-3.87 (m, 
2H, H-4, 6a), 4.38 (m, 1H, J6a,6b = 10.41 Hz, H-6b), 4.65 (d, 1H, J1,2 = 10.1 Hz, H-1), 
5.20 (dd, 1H, J2,3 = 9.5 Hz, H-2), 5.51 (s, 1H, CHPh), 5.58 (dd, 1H, J3,4 = 9.4 Hz, H-3), 
7.28-7.31 (m, 3H, aromatic), 7.37-7.45 (m, 4H, aromatic), 7.52-7.58 (m, 1H, aromatic) 
7.99-8.02 (m, 2H, aromatic) ppm. 
 
Benzoxazolyl 3-O-benzoyl-4,6-O-benzylidene-2-O-levulinoyl-1-thio-β-D-
glucopyranoside (5.12). A solution of 5.11 (5.70 g, 11.08 mmol) and activated molecular 
sieves (3Å, 5.54 g) in CH2Cl2 (166 mL) was stirred under argon for 1 h at rt. The mixture 
was cooled to 0 
o
C, freshly prepared solution of Br2 in CH2Cl2 (106.4 mL, 1/165, v/v) 
was added, and the resulting mixture was stirred for 30 min at 0 
o
C. After that, the solid 
was filtered off, rinsed successively with CH2Cl2 and the combined filtrate (~300 mL) 
was concentrated under reduced pressure at rt and dried in vacuo for 2 h. The crude 
residue was dissolved in dry acetone (100 mL), KSBox
18
 (6.29 g, 33.23 mmol) and 18-
crown-6 (878 mg, 3.32 mmol) were added and the reaction mixture was stirred under 
argon for 3 h at rt. After that, the reaction mixture was concentrated in vacuo. The residue 
was dissolved in CH2Cl2 (~400 mL), washed with 1% aq. NaOH (60 mL) and water (3x 
60 mL). The organic phase was separated, over MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate - hexane 
graduate elution) to afford the title compound as a white amorphous solid (4.47 g, 67 %). 
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Analytical data for 5.12: Rf = 0.41 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.97 (s, 3H, COCH3), 2.43-2.50 (m, 2H, COCH2), 2.55-2.63 (m, 2H, COCH2), 
3.79-3.97 (m, 3H, 4, 5, 6a), 4.42 (m, 1H, J5,6a = 3.1 Hz, J6a,6b = 8.3 Hz, H-6b), 5.42 (dd, 
1H, J2,3 = 9.2 Hz, H-2), 5.54 (s, 1H, CHPh), 5.72 (dd, 1H, J3,4 = 9.0 Hz, H-3), 5.85 (d, 
1H, J1,2 = 10.4 Hz, H-1), 7.29-7.41 (m, 10H, aromatic), 7.44 (m, 1H, aromatic), 7.47-7.50 
(m, 1H, aromatic), 7.98-8.06 (m, 2H, aromatic) ppm. 
 
5.4.6 Synthesis of trisaccharide donor 5.19 
Ethyl O-(4,6-O-benzylidene-2-O-levulinoyl-3-O-methyl-β-D-glucopyranosyl)-(13)-
2-azido-4-O-benzyl-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.14).  A mixture of 
donor 5.13 (1.44 g, 2.81 mmol), acceptor 5.4 (700 mg, 2.16 mmol), and freshly activated 
molecular sieves (3Å, 3.0 g) in CH2Cl2 (50 mL) was stirred under argon for 2 h at rt. 
Freshly conditioned AgOTf (1.11 g, 4.32 mmol) was added and the resulting mixture was 
stirred under argon for 2 h at rt. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~200 mL) was washed with water (40 
mL), sat. aq. NaHCO3 (40 mL) and water (40 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam (831 mg, 85%). The yield calculation is based on acceptor 5.4 
recovered (254 mg, 0.73 mmol). Analytical data for 5.14: Rf = 0.32 (ethyl acetate/hexane, 
2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.19 (d, 3H, H-6), 1.24 (t, 3H, CH2CH3), 2.09 
(s, 3H, COCH3), 2.61-2.77 (m, 4H, COCH2CH2CO, CH2CH3), 3.51-3.56 (m, 3H, J5,6 = 
6.3 Hz, H-3’, 5, 5’), 3.58 (s, 3H, OCH3), 3.61-3.65 (m, 2H, H-3, 4), 3.74-3.89 (m, 3H, H-
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2, 4’, 6a’), 4.20 (d, 1H, J1,2 = 9.4 Hz, H-1), 4.40 (m, 1H, H-6b’), 4.50 (dd, 1H, 
2
J = 11.6 
Hz, ½ CH2Ph), 4.84 (d, 1H, J1’,2’ = 7.5 Hz, H-1’), 4.88 (dd, 1H, 
2
J = 11.6 Hz, ½ CH2Ph), 




benzyl-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.15). Hydrazine acetate (185 mg, 
2.06 mmol) was added to a solution of disaccharide 5.14 (940 mg, 1.37 mmol) in 
CH2Cl2/MeOH (32 mL, 20/1, v/v) and the resulting mixture was stirred for 1 h at rt. After 
that, the reaction mixture was diluted with CH2Cl2 (~200 mL) and washed with water (40 
mL), sat. aq. NaHCO3 (40 mL) and water (40 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam (681 mg, 85%). Analytical data for 5.15: Rf = 0.51 (ethyl 
acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.18 (d, 3H, H-6), 1.25 (t, 3H, 
CH2CH3), 2.70 (m, 2H, CH2CH3), 3.38-3.48 (m, 3H, J5,6 = 6.4 Hz, J5’,6b’ = 4.9 Hz, H-3’, 
5, 5’), 3.53 (dd, 1H, J2’,3’ = 8.7 Hz, H-2’), 3.60-3.70 (m, 3H, OCH3, H-4, 4’), 3.77-3.85 
(m, 3H, J6a’,6b’ = 10.4 Hz, H-2, 3, 6a’), 4.18 (d, 1H, J1,2 = 9.8 Hz, H-1), 4.33 (d, 1H, H-
6b’), 4.62 (d, 1H, J1’,2’ = 7.6 Hz, H-1’), 4.72 (dd, 1H, 
2
J = 11.7 Hz, ½ CH2Ph), 4.94 (dd, 
1H, 
2
J = 11.8 Hz, ½ CH2Ph), 5.55 (s, 1H, CHPh), 7.25-7.48 (m, 10H, aromatic) ppm. 
 
Ethyl O-(2-azido-4,6-O-benzylidene-2-deoxy-3-O-methyl-β-D-mannopyranosyl)-
(13)-2-azido-4-O-benzyl-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.16). Pyridine 
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(3.0 mL) was added to a solution of disaccharide 5.15 (590 mg, 1.00 mmol) in CH2Cl2 
(25.0 mL) and the resulting mixture was cooled to 0 
o
C. Trifluoromethanesulfonic 
anhydride (0.42 mL, 2.50 mmol) was added dropwise and the reaction mixture was kept 
for 4 h at 0 
o
C. After that, the reaction was quenched with ice-cold water (~30 mL), 
diluted with CH2Cl2 (~150 mL), and washed with cold sat. aq. NaHCO3 (30 mL) and cold 
water (30 mL). The organic phase was separated, dried over MgSO4, and concentrated in 
vacuo. The crude residue was dissolved in DMF (5.0 mL), NaN3 (390 mg, 6.00 mmol) 
was added, and the resulting suspension was stirred for 16 h at 60 
o
C. Upon completion, 
ethyl acetate (~150 mL) and water (~150 mL) were added. Organic layer was separated 
and washed with sat. aq. NaCl (2 x 30 mL). The combined aqueous phase was extracted 
with ethyl acetate (3 x 50 mL). The combined organic extract was dried with MgSO4 and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate-hexane gradient elution) to afford the title compound as a white foam (363 
mg, 59%). Analytical data for 5.16: Rf = 0.49 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR 
(300 MHz, CDCl3): δ, 1.28 (t, 3H, CH2CH3), 1.35 (d, 3H, H-6), 2.72 (m, 2H, CH2CH3), 
3.20 (m, 1H, J5’,6a’ = 4.7 Hz, J5’,6b’ = 4.9 Hz, H-5’), 3.30 (dd, 1H, J3’,4’ = 9.6 Hz, H-3’), 
3.51-3.62 (m, 5H, J2’,3’ = 3.7 Hz, J5,6 = 6.4 Hz, OCH3, H-2’, 5), 3.65 (dd, 1H, J4,5 = 1.9 
Hz, H-4), 3.73-3.96 (m, 4H, J6a’,6b’ = 10.5 Hz, H-2, 3, 4’, 6a’), 4.22 (d, 1H, J1,2 = 9.4 Hz, 
H-1), 4.28 (d, 1H, H-6b’), 4.50 (d, 1H, J1’,2’ = 1.0 Hz, H-1’), 4.65 (dd, 1H, 
2
J = 12.1 Hz, 
½ CH2Ph), 4.84 (dd, 1H, 
2
J = 12.1 Hz, ½ CH2Ph), 5.55 (s, 1H, CHPh), 7.35-7.48 (m, 
10H, aromatic) ppm. 
 




(13)-2-azido-4-O-benzyl-2,6-dideoxy-α-D-galactopyranoside (5.17).  A mixture of 
disaccharide donor 5.16 (280 mg, 0.46 mmol), acceptor 5.9 (229 mg, 0.59 mmol), and 
freshly activated molecular sieves (4Å, 500 mg) in CH2Cl2 (20 mL) was stirred under 
argon for 2 h at rt. The resulting mixture was cooled to 0 
o
C, N-iodosuccinimide (206 mg, 
0.914 mmol) and trifluoromethanesulfonic acid (14 mg, 0.09 mmol) were added, and the 
resulting mixture was stirred under argon for 2 h at 0 
o
C. After that, the solids were 
filtered-off and rinsed successively with CH2Cl2. The combined filtrate (~120 mL) was 
washed with water (30 mL), 10% aq. Na2S2O3 (30 mL) and water (30 mL). The organic 
phase was separated, dried with MgSO4, and concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (ethyl acetate - hexane gradient elution) 
to afford the title compound as a white foam (230 mg, 75%). The yield calculation is 
based on acceptor 5.9 recovered (103 mg, 0.27 mmol). Analytical data for 5.17: Rf = 0.27 
(ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.24 (d, 3H, H-6), 1.36 
(d, 3H, H-6’), 3.26 (m, 1H, J5”,6a” = 4.8 Hz, J5”,6b” = 4.9 Hz, H-5”), 3.40 (dd, 1H, J3”,4” = 
9.6 Hz, H-3”), 3.50 (dd, 1H, J4’,5’ = 3.2 Hz, H-4’), 3.58 (m, 4H, OCH3, H-4), 3.60-3.68 
(m, 3H, J5’,6’ = 6.3 Hz,  H-2’, 3, 5’), 3.75-3.78 (m, 5H, J2”,3” = 3.6 Hz, OCH3, H-2”), 3.81-
3.89 (m, 2H, J5,6 = 6.5 Hz, H-5, 6a”), 3.95 (dd, 1H, J4”,5” = 9.5 Hz, H-4”), 4.14-4.21 (m, 
3H, H-2, 3’, 6b”), 6.62 (d, 1H, H-1”), 4.70-4.79 (m, 4H, 3 x ½ CH2Ph, H-1), 4.84 (d, 1H,
 
2
J = 11.5 Hz, ½ CH2Ph), 5.35 (d, 1H, J1’,2’ = 3.66 Hz, H-1’), 5.58 (s, 1H, CHPh), 6.81 (d, 
2H, J = 9.1 Hz, PMP), 7.04 (d, 2H, J = 9.1 Hz, PMP), 7.35-7.51 (m, 15H, aromatic) ppm. 
 




2,6-dideoxy-D-galactopyranose (5.18).  A solution of CAN (337 mg, 0.62 mmol) in 
water (10 mL) was added dropwise to a stirring solution of trisaccharide 5.17 (230 mg, 
0.25 mmol) in CH3CN (5 mL) at 0
o
C. The reaction was allowed to reach rt. After 2 h, the 
solvent was removed in vacuo. The residue was diluted with CH2Cl2 (~100 mL) and 
washed with water (20 mL). The organic phase was separated, dried with MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate - hexane gradient elution) to yield the title compound as a white amorphous 
solid (59 mg, 29%). Analytical data for 5.18: Rf = 0.29 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.22-1.29 (m, 12H, H-6α, 6β, 6’α, 6’β), 3.24-3.31 (m, 
2H, H-5”α, 5”β), 3.37-3.68 (m, 14H, 2 x OCH3, H-2α, 3”α, 3”β, 4α, 4β, 4’α, 4’β, 5’β), 
3.72-3.75 (m, 2H, H-2”α, 2”β), 3.78-3.86 (m, 4H, H-2β, 5’α, 6a”α, 6a”β), 3.91-3.98 (m, 
4H, H-2’β, 4”α, 4”β, 5α), 4.07-4.25 (m, 6H, H-3α, 3β, 3’α, 3’β, 5β, 6b”α, 6b”β), 4.48 (d, 
1H, J1β,2β = 7.8 Hz, H-1β), 4.60-4.61 (m, 2H, H-1”α, 1”β), 4.65-4.86 (m, 8H, 4 x CH2Ph), 
5.25 (d, 1H, J1’α,2’α = 3.6 Hz, H-1’α), 5.29 (d, 1H, J1α,2α = 3.7 Hz, H-1α), 5.34 (d, 1H, 




2,6-dideoxy-α-D-galactopyranosyl trichloroacetimidate (5.19).  To the solution of 5.16 
(39 mg, 0.05 mmol) in dry CH2Cl2 (5 mL), trichloroacetonitrile (0.05 mL, 0.47 mmol) 
and DBU (5.0 µL, 0.03 mmol) were added at rt. The reaction was stirred for 2 h under 
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argon. After that, the reaction mixture was concentrated in vacuo, passed through a pad 
of silica gel, concentrated in vacuo, and dried. The crude residue (19 mg, 41%) was used 
for the next step.  
 
5.4.7 Synthesis of trisaccharide acceptor 5.25 
Ethyl O-(3-O-benzoyl-4,6-O-benzylidene-2-O-levulinoyl-β-D-glucopyranosyl)-(13)-
2-azido-4-O-benzyl-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.20).  A mixture of 
donor 5.12 (1.51 g, 2.50 mmol), acceptor 5.4 (622 mg, 1.92 mmol), and freshly activated 
molecular sieves (3Å, 3.0 g) in CH2Cl2 (70 mL) was stirred under argon for 2 h at rt. 
Freshly conditioned AgOTf (1.28 g, 5.00 mmol) was added and the resulting mixture was 
stirred under argon for 5 h at rt. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~200 mL) was washed with water (40 
mL), sat. aq. NaHCO3 (40 mL) and water (40 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam (647 g, 74%). The yield calculation is based on acceptor 5.4 
recovered (254 mg, 0.79 mmol). Analytical data for 5.20: Rf = 0.49 (ethyl acetate/hexane, 
2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.20 (d, 3H, H-6), 1.29 (t, 3H, CH2CH3), 1.95 
(s, 3H, COCH3), 2.33 (m, 2H, COCH2), 2.42 (m, 2H, COCH2), 2.73 (m, 2H, CH2CH3), 
3.51 (m, 1H, J5,6 = 6.4 Hz, H-5), 3.68-3.76 (m, 2H, H-4, 6a’), 3.79-3.87 (m, 2H, H-2, 3), 
3.90-4.00 (m, 2H, H-4, 6b’), 4.21 (d, 1H, J1,2 = 9.7 Hz, H-1), 4.46 (dd, 1H, J5’,6a’ = 5.0 
Hz,  H-5’), 4.51 (dd, 1H, 
2
J = 11.4 Hz, ½ CH2Ph), 4.87 (dd, 1H, 
2
J = 11.6 Hz, ½ CH2Ph), 
5.00 (d, 1H, J1’,2’ = 7.5 Hz, H-1’), 5.24 (dd, 1H, J2’,3’ = 9.0 Hz, H-2’), 5.54 (s, 1H, ½ 
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CH2Ph), 5.60 (dd, 1H, J3’,4’ = 9.3 Hz, H-3’), 7.28-7.43 (m, 12H, aromatic), 7.52-7.56 (m, 
1H, aromatic), 8.00-8.03 (m, 2H, aromatic) ppm. 
 
Ethyl O-(3-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl)-(13)-2-azido-4-O-
benzyl-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.21). Hydrazine acetate (150 mg, 
1.67 mmol) was added to a solution of disaccharide 5.20 (647 mg, 0.83 mmol) in 
CH2Cl2/MeOH (21 mL, 20/1, v/v) and the resulting mixture was stirred for 3 h at rt. After 
that, the reaction mixture was diluted with CH2Cl2 (~200 mL) and washed with water (40 
mL), sat. aq. NaHCO3 (40 mL) and water (40 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam (390 mg, 69%). Analytical data for 5.21: Rf = 0.60 (ethyl 
acetate/toluene, 1/4, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.21 (d, 3H, H-6), 1.28 (t, 3H, 
CH2CH3), 2.72 (m, 2H, CH2CH3), 2.96 (d, 1H, JOH,2’ = 3.6 Hz, 2’-OH), 3.49 (m, 1H, J5,6 
= 6.4 Hz, H-5), 3.57 (m, 1H, J5’,6a’ = 5.0 Hz, J5’,6b’ = 5.0 Hz, H-5’), 3.69 (dd, 1H, J4,5 = 
2.3 Hz, H-4), 3.76-3.92 (m, 4H, J2’,3’ = 9.4 Hz, J6a’,6b’ = 10.6 Hz, H-2’, 3, 4’, 6a’), 4.21 (d, 
1H, J1,2 = 9.7 Hz, H-1), 4.40 (dd, 1H, H-6b’), 4.71 (dd, 1H, 
2
J = 11.7 Hz, CHHPh), 4.76 
(d, 1H, J1’,2’ = 7.7 Hz, H-1’), 4.93 (dd, 1H, 
2
J = 11.7 Hz, CHHPh), 5.42 (dd, 1H, J3’,4’ = 
9.3 Hz, H-3’), 5.56 (s, 1H, CHPh), 7.26-7.47 (m, 12H, aromatic), 7.55-7.58 (m, 1H, 
aromatic), 8.06-8.08 (m, 2H, aromatic) ppm. 
 
Ethyl O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-β-D-mannopyranosyl)-
(13)-2-azido-4-O-benzyl-2,6-dideoxy-1-thio-β-L-galactopyranoside (5.22). Pyridine 
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(2.0 mL) was added to a solution of disaccharide 5.20 (390 mg, 0.58 mmol) in CH2Cl2 
(15.0 mL) and the resulting mixture was cooled to 0 
o
C. Trifluoromethanesulfonic 
anhydride (0.24 mL, 1.44 mmol) was added dropwise and the reaction mixture was kept 
for 4 h at 0 
o
C. After that, the reaction was quenched with ice-cold water (~20 mL), 
diluted with CH2Cl2 (~150 mL), and washed with cold sat. aq. NaHCO3 (30 mL) and cold 
water (30 mL). The organic phase was separated, dried over MgSO4, and concentrated in 
vacuo. The crude residue was dissolved in DMF (5.0 mL), NaN3 (224 mg, 3.45 mmol) 
was added, and the resulting suspension was stirred for 16 h at 60 
o
C. Upon completion, 
ethyl acetate (~150 mL) and water (~150 mL) were added. Organic layer was separated 
and washed with sat. aq. NaCl (2 x 30 mL). The combined aqueous phase was extracted 
with ethyl acetate (3 x 50 mL). The combined organic extract was dried with MgSO4 and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate-hexane gradient elution) to afford the title compound as a white foam (270 
mg, 67%). Analytical data for 5.22: Rf = 0.55 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR 
(300 MHz, CDCl3): δ, 1.29 (m, 6H, CH2CH3, H-6), 2.74 (m, 2H, CH2CH3), 3.38 (m, 1H, 
J5’,6a’ = 4.9 Hz, J5’,6b’ = 4.89 Hz, H-5’), 3.61 (m, 1H, H-5), 3.67 (dd, 1H, J4,5 = 2.1 Hz, H-
4), 3.75-3.86 (m, 3H, J2’,3’ = 3.8 Hz, H-2, 2’, 3), 3.90 (dd, 1H, J6a’,6b’ = 10.4 Hz, H-6a’), 
4.11 (dd, 1H, J4’,5’ = 9.7 Hz, H-4’), 4.23 (d, 1H, J1,2 = 9.2 Hz, H-1), 4.34 (dd, 1H, H-6b’), 
4.70-4.81 (m, 3H, J1’,2’ = 1.1 Hz, CH2Ph, H-1’), 5.21 (dd, 1H, J3’,4’ = 10.1 Hz, H-3’), 5.57 
(s, 1H, CHPh), 7.28-7.50 (m, 12H, aromatic), 7.58-7.61 (m, 1H, aromatic), 8.09-8.12 (m, 
2H, aromatic) ppm. 
 




O-benzyl-2,6-dideoxy-α-D-galactopyranoside (5.24).  A mixture of donor 5.22 (183 
mg, 0.26 mmol), acceptor 5.23 (100 mg, 0.34 mmol), and freshly activated molecular 
sieves (4Å, 400 mg) in CH2Cl2 (20 mL) was stirred under argon for 2 h at rt. The 
resulting mixture was cooled to 0 
o
C, N-iodosuccinimide (117 mg, 0.52 mmol) and 
trifluoromethanesulfonic acid (8 mg, 0.05 mmol) were added, and the resulting mixture 
was stirred under argon for 2 h at 0 
o
C. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~120 mL) was washed with water (30 
mL), 10% aq. Na2S2O3 (30 mL) and water (30 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam (150 mg, 62%). The yield calculation is based on acceptor 
5.23 recovered (103 mg, 0.27 mmol). Analytical data for 5.24: Rf = 0.65 (ethyl 
acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.23 (2d, 6H, H-6, 6’), 3.42-
3.51 (m, 5H, OCH3, H-5’, 5”), 3.60 (dd, 1H, J4,5 = 1.7 Hz, H-4), 3.67 (dd, 1H, J4’,5’ = 1.9 
Hz, H-4’), 3.76 (dd, 1H, J2’,3’ = 10.7 Hz, H-2’), 3.86-4.02 (m, 4H, H-2, 2”, 5, 6a”), 4.07-
4.27 (m, 4H, H-3, 3’, 4”, 6b”), 4.67-4.89 (m, 6H, 2 x CH2Ph, H-1, 1”), 5.26-5.31 (m, 2H, 
J1’,2’ = 3.6 Hz, H-1’, 3”), 5.59 (s, 1H, CHPh), 7.30-7.41 (m, 17H, aromatic), 7.59-7.61 (m, 
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dideoxy-α-D-galactopyranoside (5.25).  1M NaOMe in MeOH (1.0 mL) was added to a 
stirring solution of thiol compound 5.24 (214 mg, 0.23 mmol) in methanol (10.0 mL) and 
the resulting mixture was stirred under argon for 1 h at rt. After that, Amberlite IR120 
resin was added to the solution until pH = 7. The resin was filtered-off, rinsed 
successively with MeOH (7 x 5 mL), and the combined filtrate was concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate - 
hexane gradient elution) to yield the title compound as a white foam (167 mg, 88%). 
Analytical data for 5.25: Rf = 0.47 (ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, 
CDCl3): δ, 1.23 (2d, 6H, H-6, 6’), 3.22 (m, 1H, J5”,6b” = 4.9 Hz,H-5”), 3.41 (s, 3H, 
OCH3), 3.58 (dd, 1H, J4,5 = 1.9 Hz, H-4), 3.65 (dd, 1H, J4’,5’ = 2.0 Hz, H-4’), 3.75-3.83 
(m, 5H, J2’,3’ = 10.7 Hz, H-2’, 2”, 3”, 4”, 6a”), 3.91-4.00 (m, 3H, H-2, 5, 5’), 4.06 (dd, 
1H, J3,4 = 2.7 Hz, H-3), 4.12 (dd, 1H, J6a”,6b” = 10.7 Hz, H-6b”), 4.22 (dd, 1H, J3’,4’ = 2.8 
Hz, H-3’), 4.66-4.88 (m, 6H, J1,2 = 3.5 Hz,  2 x CH2Ph, H-1, 1”), 5.26 (d, 1H, J1’,2’ = 3.7 
Hz, H-1’), 5.53 (s, 1H, CHPh), 7.30-7.50 (m, 15H, aromatic) ppm.  
 




O-benzyl-2,6-dideoxy-α-D-galactopyranoside (5.32).  A mixture of donor 5.31 (35 mg, 
0.10 mmol), trisaccharide acceptor 5.25 (66 mg, 0.08 mmol), and freshly activated 
molecular sieves (4Å, 100 mg) in CH2Cl2 (10 mL) was stirred under argon for 2 h at rt. 
The resulting mixture was cooled to 0 
o
C, N-iodosuccinimide (47 mg, 0.21 mmol) and 
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trifluoromethanesulfonic acid (3 mg, 0.02 mmol) were added, and the resulting mixture 
was stirred under argon for 3 h at 0 
o
C. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~100 mL) was washed with water (20 
mL), 10% aq. Na2S2O3 (20 mL) and water (20 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white amorphous solid (79 mg, 89%). Analytical data for 5.32: Rf = 0.51 
(ethyl acetate/hexane, 2/3, v/v); 
1
H NMR (300 MHz, CDCl3): δ, 1.18 (d, 3H, H-6”’), 1.24 
(2d, 6H, H-6, 6’), 3.16 (m, 1H, J5”,6a” = 4.9 Hz, J5”,6b” = 4.83 Hz, H-5”), 3.42 (s, 3H, 
OCH3), 3.58 (s, 3H, OCH3), 3.58 (dd, 1H, J4,5 = 2.13 Hz, H-4), 3.64-3.70 (m, 2H, H-2”’, 
4’), 3.74-3.94 (m, 8H, J2’,3’ = 10.7 Hz, J6a”,6b” = 10.6 Hz, H-2, 2”, 3”, 3”’, 4”’, 5, 5’, 6a”), 
3.96-4.10 (m, 3H, J5’”,6’”= 6.5 Hz, H-3, 4’, 5’”), 4.13 (dd, 1H, H-6b”), 4.23 (dd, 1H, J3’,4’ 
= 2.8 Hz, H-3’), 4.58 (dd, 1H, H-1”), 4.63-4.79 (m, 4H, 4 x ½ CH2Ph), 4.83-4.87 (m, 2H, 
½ CH2Ph, H-1), 4.92 (d, 1H, 
2
J = 11.5 Hz, ½ CH2Ph), 5.26 (2d, 2H, J1”’,2”’ = 3.4 Hz, H-1’, 
1”’) 5.60 (s, 1H, CHPh), 7.30-7.53 (m, 20H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): 
δ, 16.9, 17.0, 17.1, 55.5, 57.7, 58.4, 59.0, 60.8, 64.8, 66.8, 67.5, 67.7, 67.8, 68.3, 74.9, 
75.0, 75.1, 75.5, 75.7, 76.5, 76.7, 77.0, 77.4, 78.4, 79.8, 97.5, 99.1, 100.0, 100.9, 101.5, 
126.0 (x 2), 127.9 (x 2), 128.1 (x 2), 128.4 (x 4), 128.5 (x 2), 128.6 (x 5), 128.7 (x 2), 
129.1, 137.1, 137.8, 138.1, 138.3  ppm. 
 
5.4.9 Synthesis of hexasaccharide 5.40  
Methyl O-(2-azido-3-O-benzoyl-4-O-benzyl-2,6-dideoxy-α-D-galactopyranosyl)-
(13)-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-β-D-mannopyranosyl)-
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(13)-O-(2-azido-4-O-benzyl-2,6-dideoxy-α-L-galactopyranosyl)-(13)-2-azido-4-
O-benzyl-2,6-dideoxy-α-D-galactopyranoside (5.31).  A mixture of donor 5.33 (59 mg, 
0.14 mmol), trisaccharide acceptor 5.25 (76 mg, 0.09 mmol), and freshly activated 
molecular sieves (4Å, 200 mg) in CH2Cl2 (5 mL) was stirred under argon for 1 h at rt. 
The resulting mixture was cooled to 0 
o
C, N-iodosuccinimide (62 mg, 0.27 mmol) and 
trifluoromethanesulfonic acid (4.0 µL, 0.04 mmol) were added, and the resulting mixture 
was stirred under argon for 2 h at 0 
o
C. After that, the solids were filtered-off and rinsed 
successively with CH2Cl2. The combined filtrate (~100 mL) was washed with water (20 
mL), 10% aq. Na2S2O3 (20 mL) and water (20 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate - hexane gradient elution) to afford the title 
compound as a white foam (89 mg, 81%). Analytical data for 5.34: Rf = 0.44 (ethyl 
acetate/hexane, 2/3, v/v); []D
23
 -4.4 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.17 
(d, 3H, H-6”’), 1.23 (2d, 6H, H-6, 6’), 3.25 (m, 1H, J5”,6a” = 5.2 Hz, J5”,6b” = 4.7 Hz, H-
5”), 3.41 (s, 3H, OCH3), 3.58 (dd, 1H, H-4), 3.65 (dd, 1H, H-4’), 3.74-3.99 (m, 8H, J2’”,3”’ 
= 11.3 Hz, H-2, 2’, 2”, 2’”, 4”’, 5, 5’, 6a”), 4.05-4.08 (m, 2H, H-3, 4”), 4.11 (dd, 1H, 
J6a”,6b” = 10.7 Hz,  H-6b”), 4.21-4.25 (m, 2H, H-3’, 5”’), 4.51 (d, 1H, 
2
J = 11.3 Hz, ½ 
CH2Ph), 4.57-4.62 (m, 2H, ½ CH2Ph, H-1”), 4.65-4.86 (m, 5H, 4 x CHHPh, H-1), 5.25 
(d, 1H, J1’,2’ = 3.6 Hz, H-1’), 5.37 (d, 1H, J1’”,2’” = 3.7 Hz,  H-1”’), 5.60 (s, 1H, CHPh), 
5.61 (dd, 1H, J3”’,4”’ = 2.8 Hz, H-3”’), 7.32-7.39 (m, 20H, aromatic), 7.43-7.48 (m, 2H, 
aromatic), 7.57-7.60 (m, 1H, aromatic), 8.08 -8.10 (m, 2H, aromatic)  ppm; 
13
C NMR: δ, 
16.9 (x 2), 17.0, 29.9, 55.6, 57.7, 58.5, 60.9, 64.7, 66.8, 67.4, 67.6, 67.9, 68.4, 71.4, 75.2, 
75.5, 75.8 (x 2), 75.9, 76.7, 77.0, 77.4, 79.8, 98.0, 99.1, 100.0, 100.8, 101.6, 126.1 (x 2), 
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127.9 (x 2), 128.1, 128.2, 128.4 (x 6), 128.5 (x 3), 128.6 (x 6), 128.8 (x 4), 130.1, 137.2, 
137.6, 137.9, 138.4, 165.9 ppm; HR-ESI MS [M+K]
+
 calcd for C60H66N12O15K 





dideoxy-α-D-galactopyranoside (5.35).  A 1M solution of NaOMe in MeOH (0.5 mL) 
was added to a stirring solution of thiol compound 5.34 (104 mg, 0.09 mmol) in methanol 
(5.0 mL) and the resulting mixture was stirred under argon for 2 h at rt. After that, 
Amberlite IR120 resin was added to the solution until pH = 7. The resin was filtered-off, 
rinsed successively with MeOH (7 x 5 mL), and the combined filtrate was concentrated 
in vacuo. The residue was purified by column chromatography on silica gel (ethyl acetate 
- hexane gradient elution) to yield the title compound as a white foam (72 mg, 76%). 
Analytical data for 5.35: Rf = 0.39 (ethyl acetate/hexane, 2/3, v/v); []D
22
 -4.4 (c = 1, 
CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 1.19-1.27 (3d, 9H, H-6, 6’, 6”’), 2.12 (d, JOH,3’” 
= 8.2 Hz,  1H, 3”’-OH), 3.22 (m, 1H, J5”,6a” = 4.7 Hz, J5”,6b” = 4.8 Hz, H-5”), 3.38 (dd, 1H, 
H-2”’), 3.41 (s, 3H, OCH3), 3.59 (dd, 1H, H-4), 3.65 (dd, 1H, H-4’), 3.71 (dd, 1H, H-
4”’), 3.76-3.84 (m, 3H, J2”,3” = 9.6 Hz, H-2’, 2”, 6a”), 3.85 (dd, 1H, J3”,4” = 3.8 Hz, H-3”), 
3.91-4.11 (m, 5H, H-2, 3, 4”, 5, 5’), 4.12 (m, 2H, H-3”’, 6b”), 4.23 (m, 2H, H-3’, 5’”), 
4.61-4.77 (m, 6H, 5 x ½ CH2Ph, H-1”), 4.84-4.87 (m, 2H, ½ CH2Ph, H-1), 5.26-5.30 (2d, 
2H, H-1’, 1’”), 5.58 (s, 1H, CHPh), 7.26-7.50 (m, 20H, aromatic) ppm; 
13
C NMR (75 
MHz, CDCl3): δ, 16.9, 17.0, 17.1, 29.9, 55.6, 58.5, 60.6, 60.9, 64.8, 66.8, 67.6 (x 2), 67.9, 
Satsawat Visansirikul | UMSL 2018 | Page  173 
 
68.3, 68.4, 75.0, 75.5, 75.8, 76.4, 76.6, 77.0, 77.4, 79.8, 79.9, 97.7, 99.1, 100.0, 100.7, 
101.6, 126.1 (x 2), 127.9 (x 2), 128.1, 128.4 (x 2), 128.5 (x 6), 128.6 (x 2), 128.8 (x 2), 
128.9 (x 2), 129.2, 137.2, 137.9 (x 2), 138.4 ppm; HR-FAB MS [M+Na]+ calcd for 







galactopyranoside (5.36).  A mixture of disaccharide donor 5.14 (180 mg, 0.29 mmol), 
acceptor 5.35 (72 mg, 0.07 mmol), and freshly activated molecular sieves (4Å, 200 mg) 
in ClCH2CH2Cl (10 mL) was stirred under argon for 2 h at rt. The resulting mixture was 
cooled to 0 
o
C, N-iodosuccinimide (132 mg, 0.59 mmol) and trifluoromethanesulfonic 
acid (5.0 µL, 0.06 mmol) were added, and the resulting mixture was stirred under argon 
for 4 h at 0 
o
C. After that, the solids were filtered-off and rinsed successively with 
CH2Cl2. The combined filtrate (~150 mL) was washed with water (20 mL), 10% aq. 
Na2S2O3 (20 mL) and water (20 mL). The organic phase was separated, dried with 
MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate - hexane gradient elution) to afford the title compound as a 
white amorphous solid (92 mg, 85%). Analytical data for 5.36: Rf = 0.29 (ethyl 
acetate/hexane, 2/3, v/v); []D
23
 -65.9 (c = 1, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ, 
1.22-1.29 (m, 12H, H-6, 6’, 6’”, 6””), 3.23-3.30 (m, 2H, H-5”, 5’””), 3.37 (dd, 1H, H-
3’””), 3.42 (s, 3H, OCH3), 3.55-3.60 (m, 5H, H-4, 4’”), 3.62-3.67 (m, 2H, H-4’, 4’”), 
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3.70-4.01 (m, 11H, J2””’,3”’” = 3.69 Hz, H-2, 2’, 2”, 2’”, 2””, 2’””, 3”, 4’””, 5’, 5””, 6a’””, 
6b’””), 4.07-4.29 (m, 10H, H-3, 3’, 3’”, 3””, 4”, 4””, 5, 5’”, 6a”, 6b”), 4.61-4.88 (m, 11H, 
4 x CH2Ph, H-1, 1”, 1’””), 5.27 (d, 1H, J1’,2’ = 3.5 Hz, H-1’), 5.31 (d, 1H, J1’”,2’” = 3.6 Hz, 
H-1’”), 5.34 (d, 1H, J1””,2”” = 3.5 Hz, H-1””), 5.55 (s, 1H, CHPh), 5.60 (s, 1H, CHPh), 
7.34-7.51 (m, 30H, aromatic) ppm; 
13
C NMR (75 MHz, CDCl3): δ, 16.9, 17.0 (x 2), 17.1, 
55.5, 58.4 (x 2), 59.3, 59.8, 60.8, 62.5, 64.7, 66.8, 67.5, 67.6, 67.7 (x 2), 67.8, 68.3, 68.4, 
74.8, 75.0, 75.5, 75.6, 75.7, 75.9, 76.5, 77.4, 78.3, 78.8, 79.7, 97.6, 98.0, 99.1, 99.8, 
100.0, 100.4, 101.7, 126.0 (x 2), 126.2 (x 2), 127.9 (x 2), 128.0 (x 2), 128.1(x 2), 128.4 (x 
10), 128.5 (x 6), 128.6 (x 4), 128.7 (x 4), 129.2 (x 2), 127.1, 137.3, 137.8, 138.0, 138.2, 
138.3 ppm; HR-ESI MS [M+K]
+








galactopyranoside (5.37).  Water (2 mL), triethylamine (1.0 mL, 7.1 mmol) and 1,3-
propanedithiol (0.63 mL, 6.29 mmol) were added to a solution of hexasaccharide 5.33 
(86 mg, 0.05 mmol) in pyridine (10.0 mL) and the resulting mixture was kept for 24 h at 
60 
o
C. After that, the reaction mixture was concentrated and dried in vacuo. The crude 
residue was dissolved in pyridine (5.0 mL), Ac2O (0.12 mL, 1.26 mmol) was added, and 
the resulting suspension was stirred under argon for 16 h at rt. Then, the reaction mixture 
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was concentrated in vacuo and dried. The residue crude was dissolved in THF (5 mL), 
zinc dust (100 mg), acetic acid (2 mL) and acetic anhydride (2 mL) were added. The 
reaction was stirred for 6 hr. After that, the solid was filtered-off and rinsed successively 
with CH2Cl2. The solvent was removed in vacuo. The residue was purified by column 
chromatography on silica gel (methanol - dichloromethane gradient elution) to afford the 
title compound as a white amorphous solid (58 mg, 64%). Analytical data for 5.37: Rf = 
0.29 (methanol/dichloromethane, 1/9, v/v); []D
22
 -22.2 (c = 1, CHCl3); 
1
H NMR (300 
MHz, CDCl3): δ, 1.15-1.32 (m, 12H, H-6, 6’, 6’”, 6””), 1.94, 1.97, 1.98 (3s, 9H, 3 x 
COCH3), 2.04 (s, 6H, 2 x COCH3), 2.15 (s, 3H, COCH3), 3.16 (m, 1H, J5’””,6a’”” = 5.0 Hz, 
J5’””,6b’”” = 4.7 Hz, H-5’””), 3.35-3.40 (m, 5H, J5”,6b” = 4.6 Hz, OCH3, H-3’””, 5”), 3.47 (s, 
3H, OCH3), 3.52-3.73 (m, 9H, H-3”, 4, 4’, 4”, 4’”, 4””, 4’””, 6a”, 6a’”), 3.75-3.85 (m, 
4H, H-3’”, 3””, 5’, 5””), 3.89-4.00 (m, 3H, H-3, 3’, 5) 4.04 (dd, 1H, J6a’””,6b’”” = 10.32 Hz,  
H-6b’””), 4.16 (dd, 1H, J6a”,6b” = 10.0 Hz, H-6b”), 4.42-4.89 (m, 21H, 4 x CH2Ph, H-1, 
1”, 1’”, 1””, 1’””, 2, 2’, 2”, 2’”, 2””, 2’””, 5’”), 5.49 (s, 1H, CHPh), 5.54 (s, 1H, CHPh), 
5.80 (d, 1H, J = 9.6 Hz, NH), 5.98-5.06 (m, 3H, 3 x NH), 6.20 (d, 1H, J = 9.6 Hz, NH), 
6.27 (d, 1H, J = 8.8 Hz, NH), 7.26-7.49 (m, 30H, aromatic)  ppm; 
13
C NMR (75 MHz, 
CDCl3): δ, 16.9 (x 2), 17.0, 17.1, 22.4, 23.3 (x 2), 23.8, 24.0, 24.1, 47.7, 47.8, 49.0, 49.4, 
50.5, 55.3, 58.4, 66.7, 67.0, 67.1, 67.7, 67.8, 68.4, 68.7, 74.8, 75.2, 75.4, 75.5, 76.3, 76.4, 
77.0, 77.4, 78.6 (x 2), 79.5, 80.4 (x 2), 98.1, 99.1, 99.8, 100.4, 101.6, 101.9, 102.6, 126.3 
(x 6), 127.2 (x 2), 127.3 (x 2), 127.7, 127.8, 128.0 (x 2), 128.1 (x 2), 128.2 (x 2), 128.4 (x 
6), 128.5 (x 2), 128.7 (x 6), 128.8 (x 2), 129.2, 130.0, 136.7, 137.3, 138.4, 138.7 (x 2), 
138.8, 171.0, 171.4 (x 2), 171.5, 172.0, 172.1 ppm; HR-ESI MS [M+Na]
+
 calcd for 
C92H116N6O27Na 1759.7786, found 1759.7833. 








galactopyranoside (5.38).  Hexasaccharide 5.37 (50 mg, 0.03 mmol) was dissolved in 
acetic acid (4.0 mL) and water (1.0 mL) and the resulting mixture was stirred for 16 h at 
90 
o
C. After that, the reaction mixture was concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (methanol - dichloromethane gradient 
elution) to afford the title compound as a white amorphous solid (34 mg, 76%). 
Analytical data for 5.38: Rf = 0.57 (methanol/CH2Cl2, 3/7, v/v); []D
22
 -33.4 (c = 1, 
CH3OH); 
1
H NMR (300 MHz, CD3OD): δ, 1.13-1.24 (m, 12H, H-6, 6’, 6’”, 6””), 1.92 (s, 
6H, 2 x COCH3), 1.94 (s, 6H, 2 x COCH3), 2.04 (s, 6H, 2 x COCH3), 3.13-3.18 (m, 2H, 
H-5”, 5’””), 3.22 (dd, 1H, J2”,3” = 4.2 Hz, J3”,4” = 9.6 Hz, H-3”), 3.32-3.34 (m, 4H, 
OCH3), 3.42 (s, 3H, OCH3), 3.50 (dd, 1H, H-4’””), 3.61-3.82 (m, 9H), 3.91-4.03 (m, 7H), 
4.34-4.44 (m, 3H), 4.50-4.55 (m, 3H), 4.58-4.68 (m, 3H), 4.71-4.81 (m, 2H), 4.81 (d, 
1H), 4.87 (d, 1H), 4.89-4.90 (m, 4H), 5.00-5.01 (m, 2H), 5.03-5.07 (m, 2H) 7.25-7.47 (m, 
20H, aromatic) ppm; 
13
C NMR (75 MHz, CD3OD): δ, 17.2, 17.3, 17.4, 17.5, 22.8, 22.9, 
23.0, 23.3, 23.5 (x 2), 49.9, 50.7, 51.1, 54.6, 55.7, 58.0, 61.3, 61.4, 66.7, 67.5, 68.2, 68.8, 
68.9, 69.0, 74.7, 75.3, 76.3 (x 2), 76.4, 76.6, 77.6, 78.0, 78.2, 78.4, 78.6, 80.9, 81.6, 83.7, 
99.2, 99.7, 100.0, 100.4, 100.6, 102.7, 128.7, 128.8, 128.9 (x 2), 129.0 (x 2), 129.1 (x 2), 
129.3 (x 4), 129.5 (x 4), 129.6 (x 6), 129.7 (x 2), 140.2, 140.4 (x 3), 173.7 (x 2), 173.8, 
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173.9 (x3) ppm; HR-FAB MS [M+Na]
+









galactopyranoside (5.40).  Borax buffer (1 mL) and 2,2,6,6-tetramethylpiperidine-1-oxyl 
(TEMPO, 3.0 mg, 0.02 mmol) were added to a solution of hexasaccharide 5.38 (32 mg, 
0.021 mmol) in acetonitrile (1 mL). After that, a solution of sodium chlorite (NaClO2, 9 
mg, 0.09 mmol) in water 1 mL was added dropwise at 0 
o
C. Then, the solution of bleach 
(0.6 mL), saturated sodium bicarbonate (0.13 mL) and brine (0.27 mL) was added 
dropwise. The resulting mixture was stirred for 24 h at rt.  After that, the reaction mixture 
was concentrated in vacuo, and dried. The crude residue was dissolved in DMF (3 mL), 
benzyl bromide (0.05 mL, 0.42 mmol) and NaHCO3 (21 mg, 0.25 mmol) were added. 
The resulting suspension was stirred under argon for 16 h at rt. After that, the reaction 
was the solvent was removed in vacuo. The crude residue was dissolved in pyridine (3.0 
mL), Ac2O (1.0 mL, 10.60 mmol) was added, and the resulting mixture was stirred under 
argon for 24 hr at rt. Then, MeOH (~5 mL) was added and the volatiles were removed in 
vacuo. The residue was purified by column chromatography on silica gel (methanol - 
dichloromethane gradient elution) to afford the title compound as a white amorphous 
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solid (11 mg, 31%). Analytical data for 5.40: Rf = 0.54 (methanol/dichloromethane, 1/9, 
v/v); []D
22
 -17.6 (c = 1, CHCl3);
 1
H NMR (600 MHz, CDCl3): δ, 1.25-1.29 (m, 12H, H-
6, 6’, 6’”, 6””), 1.79, 1.95, 1.99 (3s, 9H, 3 x COCH3), 2.02 (br. s, 6H, 2 x COCH3), 2.06, 
2.10, 2.11 (3s, 9H, 3 x COCH3), 3.34, 3.36 (2s, 6H, 2 x OCH3), 3.43 (dd, 1H), 3.46 (dd, 
1H), 3.55 (dd, 1H), 3.58 (s, 3H, OCH3), 3.65 (dd, 1H), 3.73-3.80 (m, 5H), 3.84 (dd, 1H), 
3.54 (s, 3H, OCH3), 3.87-3.89 (m, 4H), 4.04 (dd, 1H), 4.38 (dd, 1H), 4.44 (d, 1H), 4.57-
4.64 (m, 7H), 4.68-4.77 (m, 4H), 4.81-4.86 (m, 5H), 4.89-4.91 (m, 1H), 4.97 (d, 1H), 
5.04 (d, 1H), 5.22 (dd, 1H), 5.44 (dd, 1H), 5.66-5.69 (m, 2H, 2 x NH), 5.98 (d, 1H, NH), 
6.08 (d, 1H, NH), 6.15 (d, 1H, NH),  6.42 (d, 1H, NH), 7.26-7.38 (m, 20H, aromatic) 
ppm; 
13
C NMR (150 MHz, CDCl3): δ, 17.0, 17.1, 17.2, 17.5, 21.0, 21.2, 22.9, 23.2, 23.4, 
23.5, 23.6, 23.8, 29.9 (x 2), 46.0, 47.8 (x 2), 48.6, 48.8, 52.6 (x 2), 53.3, 55.3, 58.9, 67.1, 
67.5, 67.7, 68.2, 68.4, 69.0, 71.4, 72.4, 74.4, 74.6 (x 2), 74.7, 75.3 (x 3), 76.1, 76.7, 79.3, 
79.6, 80.5, 98.3, 99.2 (x 2), 99.4, 100.5, 100.7, 127.3 (x 2), 127.4 (x 2), 127.6, 127.7, 
127.8 (x 2), 127.9 (x 2), 128.0, 128.4 (x 2), 128.5 (x 4), 128.6 (x 3), 138.2, 138.4, 138.8, 





 calcd for C84H112N6O31 1700.7372, found 1700.7274. 
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H NMR spectrum of 2-Azido-4-O-benzoyl-2,6-dideoxy-3-O-methyl-α-D-
galactopyranosyl trichloroacetimidate (4.7) 
 
 




C NMR spectrum of 2-Azido-4-O-benzoyl-2,6-dideoxy-3-O-methyl-α-D-
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Figure A-63: 2-D NMR COSY spectrum of 2-Azido-4-O-benzoyl-2,6-dideoxy-3-O-
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H NMR spectrum of 4-O-Benzoyl-2,6-dideoxy-3-O-methyl-2-
phthalimido-D-galactopyranosyl trichloroacetimidate (4.14) 
 
 




C NMR spectrum of 4-O-Benzoyl-2,6-dideoxy-3-O-methyl-2-
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Figure A-69: 2-D NMR COSY spectrum of 4-O-Benzoyl-2,6-dideoxy-3-O-methyl-2-
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H NMR spectrum of Methyl O-(2-acetamido-2,6-dideoxy-3-O-methyl-α-
D-galactopyranosyl)-(13)-(2-acetamido-4-O-acetyl-2-deoxy-β-D-
mannopyranosid)uronic acid (D1) 
 
 




C NMR spectrum of Methyl O-(2-acetamido-2,6-dideoxy-3-O-methyl-α-
D-galactopyranosyl)-(13)-(2-acetamido-4-O-acetyl-2-deoxy-β-D-
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CD3OD 300 MHz 
 
Figure A-81: 2-D NMR COSY spectrum of Methyl O-(2-acetamido-2,6-dideoxy-3-O-
methyl-α-D-galactopyranosyl)-(13)-(2-acetamido-4-O-acetyl-2-deoxy-β-D-
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H NMR spectrum of Methyl O-(2-acetamido-2,6-dideoxy-3-O-methyl-β-
D-fucopyranosyl)-(14)-(2-acetamido-2-deoxy-β-D-mannopyranosid)uronic acid (D2) 
 
 




C NMR spectrum of Methyl O-(2-acetamido-2,6-dideoxy-3-O-methyl-β-
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CDCl3 600 MHz 
 
Figure A-117: 2-D NMR COSY spectrum of Methyl O-(methyl-2-acetamido-4-O-acetyl-
2-deoxy-3-O-methyl-β-D-mannopyranosyl uronate)-(13)-O-(2-acetamido-4-O-benzyl-
2,6-dideoxy-α-L-galactopyranosyl)-(13)-O-(2-azido-4-O-benzyl-2,6-dideoxy-α-D-
galactopyranosyl)-(13)-O-(methyl-2-acetamido-4-O-acetyl-3-O-benzoyl-2-deoxy-β-D-
mannopyranosyluronate)-(13)-O-(2-acetamido-4-O-benzyl-2,6-dideoxy-α-L-
galactopyranosyl)-(13)-2-acetamido-4-O-benzyl-2,6-dideoxy-α-D-galactopyranoside 
(5.40) 
